

CITATION REPORT

List of articles citing

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1

DOI: 10.1126/science.7545954
Science, 1994, 266, 66-71.

Source: <https://exaly.com/paper-pdf/25289084/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2230	Indication for a Possible Third Breast Cancer Predisposing Gene, BRCA3, in the Chromosome 8p12?p22 Region. 1996 , 19-26		
2229	Abstract.		
2228	BRCA1 overexpression sensitizes cancer cells to lovastatin via regulation of cyclin D1-CDK4-p21WAF1/CIP1 pathway: analyses using a breast cancer cell line and tumoral xenograft model. 1992 , 33, 555		1
2227	NIH in danger of losing out on BRCA1 patent. <i>Science</i> , 1994 , 266, 209	33.3	2
2226	Oncogenes reach a milestone. <i>Science</i> , 1994 , 266, 1942-4	33.3	17
2225	Susceptibility genes for breast cancer. 1994 , 331, 1523-4		15
2224	Editorial overview: genetics, genomics and drug discovery. 1994 , 5, 637-638		
2223	p53 and the Li-Fraumeni syndrome. 1994 , 1198, 197-213		28
2222	Breaking down BRCA1. 1994 , 8, 310		4
2221	Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer. 1994 , 8, 387-91		350
2220	Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. 1994 , 8, 392-8		285
2219	Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. 1994 , 8, 399-404		538
2218	Alu alert. 1994 , 371, 752		36
2217	Damage report for BRCA1. 1994 , 372, 574-574		2
2216	Regulation of BRCA1. 1994 , 372, 733		23
2215	Familial breast cancer. BRCA1 down, BRCA2 to go. 1994 , 4, 1023-4		4
2214	Selection of families for predictive testing for breast cancer. 1994 , 344, 1151		1

2213	Screening for cancer predisposition. 1994 , 30A, 2015-29	9
2212	Genetic counselling in the cancer family clinic. 1994 , 30A, 2012-5	18
2211	BRCA1, BRCA2, BRCA3 ... a myriad of breast cancer genes. 1994 , 30A, 1738-9	20
2210	BRCA1 mutations in primary breast and ovarian carcinomas. <i>Science</i> , 1994 , 266, 120-2	33-3 1014
2209	The human plakoglobin gene localizes on chromosome 17q21 and is subjected to loss of heterozygosity in breast and ovarian cancers. 1995 , 92, 6384-8	98
2208	Physical mapping, cloning, and identification of genes within a 500-kb region containing BRCA1. 1995 , 92, 4362-6	23
2207	Applications and limitations of polymerase chain reaction amplification. 1995 , 108, 1393-404	15
2206	Biochemie und Molekulargenetik 1994. 1995 , 43, 173-192	1
2205	Designer contraceptive pills. 1995 , 10, 1997-2000	4
2204	Chromosome 18: a possible site for a tumour suppressor gene deletion in squamous cell carcinoma of the head and neck. 1995 , 20, 266-71	20
2203	The genetic analysis of ovarian cancer. 1995 , 72, 521-7	70
2202	Association of a RING finger protein with the cytoplasmic domain of the human type-2 tumour necrosis factor receptor. 1995 , 309 (Pt 3), 825-9	42
2201	Familial Ovarian Cancer: Counselling, Genetic Testing, Prophylactic Surgery. Issues, Questions, Recommendations. 1995 , 17, 325-332	
2200	Risk assessment from automated feature analysis of digitized mammograms. 1995 ,	
2199	Contribution of genetic epidemiologic research to psychiatry. 1995 , 28 Suppl 1, 41-50	4
2198	Chromosome 17q-linkage seems to be infrequent in Icelandic families at risk of breast cancer. 1995 , 34, 657-62	15
2197	[Detection of genetic alterations in sporadic breast tumors]. 1995 , 35 Suppl 1, 63-7	2
2196	Frequent loss of heterozygosity on chromosome 17 at 17q11.2-q12 in Barrett's adenocarcinoma. 1995 , 71, 995-8	24

2195	Increased risk of second primary malignancies in patients with gynecological cancer. A Swedish record-linkage study. 1995 , 34, 771-7	40
2194	Public health methods--attributable risk as a link between causality and public health action. 1995 , 85, 1202-4	150
2193	Women's receptivity to testing for a genetic susceptibility to breast cancer. 1995 , 85, 1133-5	106
2192	Breast cancer susceptibility: a complex disease unravels. 1995 , 11, 3-5	27
2191	Structural integrity of the cyclin-dependent kinase inhibitor genes, p15, p16 and p18 in myeloid leukaemias. 1995 , 91, 139-49	55
2190	"Phototyping" for HLA: the beginning of the end of HLA typing as we know it. 1995 , 46, 353-4	11
2189	Ovarian cancer. 1995 , 45, 69-70	3
2188	The woman at increased risk for breast cancer: evaluation and management strategies. 1995 , 45, 263-78	70
2187	Interest in genetic testing among first-degree relatives of breast cancer patients. 1995 , 57, 385-92	272
2186	Frontiers in prostate cancer. Telomeres and chaos. 1995 , 75, 2027-2035	10
2185	The molecular basis of ovarian cancer. 1995 , 76, 1992-7	45
2184	Familial ovarian cancer. Update and clinical applications. 1995 , 76, 1998-2003	24
2183	Ovarian cancer screening. The role of ultrasound in early detection. 1995 , 76, 2011-5	29
2182	Gene and genome scanning by two-dimensional DNA typing. 1995 , 16, 186-96	6
2181	Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer. 1995 , 62, 266-70	185
2180	Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. 1995 , 64, 280-5	704
2179	Risk modifiers in carriers of BRCA1 mutations. 1995 , 64, 394-8	142
2178	Genetic alterations distinguish different types of ovarian tumors. 1995 , 64, 434-40	68

2177	High allele loss rates at 17q12-q21 in breast and ovarian tumors from BRCA1-linked families. The Breast Cancer Linkage Consortium. 1995 , 13, 203-10	105
2176	Loss of chromosome 17 loci in prostate cancer detected by polymerase chain reaction quantitation of allelic markers. 1995 , 13, 278-84	29
2175	Patterns of loss of heterozygosity at loci from chromosome arm 13q suggests a possible involvement of BRCA2 in sporadic breast tumors. 1995 , 13, 291-4	33
2174	Genetic alterations in breast cancer. 1995 , 14, 227-51	229
2173	Segregation analysis of breast cancer in a population-based sample of postmenopausal probands: The Iowa Women's Health Study. 1995 , 12, 401-15	11
2172	Epidemiologic and genetic follow-up study of 544 Minnesota breast cancer families: design and methods. 1995 , 12, 417-29	27
2171	Analysis of familial breast cancer in genetic analysis workshop 9: summary of findings. 1995 , 12, 833-6	5
2170	The GAW9 breast cancer linkage data set. 1995 , 12, 837-40	3
2169	Analysis of breast cancer pedigrees using affected sibship methods. 1995 , 12, 847-51	
2168	Development of the WPC approach and application to linkage analysis of breast cancer. 1995 , 12, 853-7	2
2167	Biomarkers in the ovary. 1995 , 59, 223-226	18
2166	Early detection and screening for ovarian cancer. 1995 , 23, 233-7	10
2165	Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer"--20 years as a target for the treatment and prevention of cancer. 1995 , 36, 267-85	131
2164	Breast cancer and importance of zygosity determination in triplet sisters. 1995 , 36, 315-7	
2163	A 100-kb physical and transcriptional map around the EDH1B2 gene: identification of three novel genes and a pseudogene of a human homologue of the rat PRL-1 tyrosine phosphatase. 1995 , 96, 532-8	25
2162	Age at diagnosis as an indicator of eligibility for BRCA1 DNA testing in familial breast cancer. 1995 , 95, 539-44	18
2161	Monitoring the efficacy of hybrid selection during positional cloning: the search for BRCA1. 1995 , 6, 873-9	6
2160	Assignment of three loci: tumor suppressor protein-53 (TP53), retinoic acid receptor A (RARA), collagen 1A1 (COL1A1) to Syrian hamster chromosome 9. Evidence that this chromosome is homologous with human chromosome 17, mouse chromosome 11, and rat chromosome 10. 1995 , 6, 882-4	1

2159	Psychological distress in women with a familial risk of breast cancer. 1995 , 4, 133-141	99
2158	The pathology of ductal carcinoma in situ of the breast. 1995 , 7, 232-5	10
2157	Introduction to positional cloning. 1995 , 25 Suppl 2, 116-8	1
2156	Fine-structure mapping of genes providing susceptibility to asthma on chromosome 5q31-q33. 1995 , 25 Suppl 2, 119-23	7
2155	Tumor suppressor genes: prospects for cancer therapies. 1995 , 13, 127-31	3
2154	BRCA1: more than a hereditary breast cancer gene?. 1995 , 9, 335-6	28
2153	A somatic BRCA1 mutation in an ovarian tumour. 1995 , 9, 343-4	120
2152	Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. 1995 , 9, 439-43	347
2151	Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. 1995 , 9, 444-50	509
2150	Rapid detection of BRCA1 mutations by the protein truncation test. 1995 , 10, 208-12	283
2149	The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues. 1995 , 11, 17-26	305
2148	Hypertension caused by a truncated epithelial sodium channel gamma subunit: genetic heterogeneity of Liddle syndrome. 1995 , 11, 76-82	648
2147	The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. 1995 , 11, 198-200	554
2146	Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. 1995 , 11, 428-33	439
2145	Genetics and environment in Hodgkin's disease. 1995 , 1, 298-300	4
2144	Molecular foundations of cancer: new targets for intervention. 1995 , 1, 309-20	93
2143	A human BRCA1 gene knockout. 1995 , 375, 541-2	82
2142	Chromosome engineering in mice. 1995 , 378, 720-4	437

2141	Breast cancer genes. Further enigmatic variations. 1995 , 378, 762-3	8
2140	The genetics of breast and ovarian cancer. 1995 , 72, 805-12	193
2139	Loss of heterozygosity in sporadic breast tumours at the BRCA2 locus on chromosome 13q12-q13. 1995 , 72, 1241-4	79
2138	Breast Cancer: A Template for Progress Through Multidisciplinary Cancer Research. 1995 , 1, 128-154	1
2137	Family History Status as a Prognostic Factor for Breast Cancer Patients Treated with Conservative Surgery and Irradiation. 1995 , 1, 202-209	10
2136	Potential Use of Biomarkers in Breast Cancer Risk Assessment and Chemoprevention Trials. 1995 , 1, 236-242	10
2135	Racial Differences in Breast Cancer Survival in Iowa. 1995 , 1, 350-355	4
2134	Pharmaceutical biotechnology. 1995 , 6, 719-75	
2133	Impact of the human genome project on medical practice. 1995 , 2, 14-25	2
2132	The aetiology and pathogenesis of human breast cancer. 1995 , 333, 29-35	44
2131	Risk assessment issues in breast cancer. 1995 , 333, 51-8	2
2130	Mechanisms for species differences in receptor-mediated carcinogenesis. 1995 , 333, 189-202	16
2129	Progress against cancer. 1995 , 121, 633-47	8
2128	Tumor suppressor genes and their alterations in breast cancer. 1995 , 6, 119-25	11
2127	Introduction: basic science aspects of breast cancer. 1995 , 6, 117-8	2
2126	Recessive oncogenes: current status. 1995 , 1, 7-22	7
2125	Risk factors and preventive strategies for breast cancer. 1995 , 163, 435-440	10
2124	Breast Cancer Genetics: Relevance to Oncology Practice. 1995 , 2, 107327489500200	2

2123	Differences in cancer incidence, mortality, and survival between African Americans and whites. 1995 , 103 Suppl 8, 275-81	47
2122	Identification and management of inherited cancer susceptibility. 1995 , 103 Suppl 8, 297-300	14
2121	In vitro assembly of a functional human CDK7-cyclin H complex requires MAT1, a novel 36 kDa RING finger protein.. 1995 , 14, 5608-5617	136
2120	Five distinct deleted regions on chromosome 17 defining different subsets of human primary breast tumors. 1995 , 52, 448-53	23
2119	Novel topology of a zinc-binding domain from a protein involved in regulating early Xenopus development.. 1995 , 14, 5947-5956	51
2118	Construction of human embryonic cDNA libraries: HD, PKD1 and BRCA1 are transcribed widely during embryogenesis. 1995 , 71, 197-202	14
2117	Selected Papers from Oncology Practice 1995: A Focus on Breast Cancer. 1995 , 8, 41-43	
2116	Strategies and Logistical Requirements for Efficient Testing in Genetic Disease. 1995 , 15, 839-855	2
2115	Genetics of Colorectal and Breast Cancer. 1995 , 15, 957-971	4
2114	Update on the Human Genome Project. 1995 , 15, 973-988	1
2113	Epidemiologic Features of Wilms Tumor. 1995 , 9, 1157-1178	37
2112	The solution structure of the RING finger domain from the acute promyelocytic leukaemia proto-oncoprotein PML.. 1995 , 14, 1532-1541	243
2111	The practice of prophylactic mastectomy: a survey of Maryland surgeons. 1995 , 85, 801-5	37
2110	Proportion of breast cancer cases in the United States explained by well-established risk factors. 1995 , 87, 1681-5	466
2109	Regulation of oestrogen action: role of 17 beta-hydroxysteroid dehydrogenases. 1995 , 27, 675-82	15
2108	Identification of a new subclass of Alu DNA repeats which can function as estrogen receptor-dependent transcriptional enhancers. 1995 , 270, 22777-82	178
2107	Molecular genetics of familial breast-ovarian cancer. 1995 , 48, 789-95	3
2106	Expression of Brca1 is associated with terminal differentiation of ectodermally and mesodermally derived tissues in mice. 1995 , 9, 2712-22	152

2105	52-kD SS-A/Ro: genomic structure and identification of an alternatively spliced transcript encoding a novel leucine zipper-minus autoantigen expressed in fetal and adult heart. 1995 , 182, 983-92	74
2104	Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. 1995 , 333, 975-7	257
2103	Presence of a new conserved domain in CART1, a novel member of the tumor necrosis factor receptor-associated protein family, which is expressed in breast carcinoma. 1995 , 270, 25715-21	182
2102	{BLR 2017} BRCA1 - Breast Cancer - CRADAs - Eli Lilly - Myriad Genetics - NIH - Reasonable Price Clause - University of Utah. 1995 , 14, 418-419	
2101	Genetic testing for cancer predisposition: need and demand. 1995 , 32, 161	3
2100	Molecular cloning, structure, and expression of mouse estrogen-responsive finger protein Efp. Co-localization with estrogen receptor mRNA in target organs. 1995 , 270, 24406-13	58
2099	Oncology and Hematology. 1995 , 273, 1702	
2098	An infrared fluorescent dATP for labeling DNA. 1995 , 5, 393-9	17
2097	A large multisite cancer family is linked to BRCA2. 1995 , 32, 982-4	48
2096	Mechanisms of Toxicity and Carcinogenesis. 1995 , 23, 775-827	
2095	Is there an inherited general susceptibility to cancer?. 1995 , 333, 1633-5	7
2094	NIH gets a share of BRCA1 patent. <i>Science</i> , 1995 , 267, 1086	33-3 3
2093	Cancer Predisposition, Radiosensitivity and the Risk of Radiation-Induced Cancers. I. Background. 1995 , 143, 121	39
2092	Acute stroke--on the threshold of a therapy?. 1995 , 333, 1632-3	51
2091	To stay or not to stay? That is the question. 1995 , 333, 1635-7	34
2090	What does it mean to be a cancer gene carrier? Problems in establishing causality from the molecular genetics of cancer. 1995 , 87, 1126-30	19
2089	Growth factors in breast cancer. 1995 , 16, 559-89	309
2088	Genetic services for familial cancer patients: a survey of National Cancer Institute cancer centers. 1995 , 87, 1446-55	32

2087	Murine Brca1: sequence and significance for human missense mutations. 1995 , 4, 2275-8	48
2086	Studies of Cancer and Radiation Dose Among Atomic Bomb Survivors. 1995 , 274, 402	69
2085	Should a Family History Be Taken From Every Woman With Ovarian Cancer?. 1995 , 155, 893	2
2084	Effects of individualized breast cancer risk counseling: a randomized trial. 1995 , 87, 286-92	389
2083	Detection of BRCA1 mutations by the protein truncation test. 1995 , 4, 1989-91	43
2082	Identification of women at high genetic risk of breast cancer through the National Health Service Breast Screening Programme (NHSBSP). 1995 , 32, 862-6	6
2081	Mutation analysis of the BRCA1 gene in 76 Japanese ovarian cancer patients: four germline mutations, but no evidence of somatic mutation. 1995 , 4, 1953-6	78
2080	A Collaborative Survey of 80 Mutations in the BRCA1 Breast and Ovarian Cancer Susceptibility Gene. 1995 , 273, 535	217
2079	Human chromosome-specific cDNA libraries: new tools for gene identification and genome annotation. 1995 , 5, 185-94	15
2078	Molecular biology techniques. 1995 , 67, 449R-454R	24
2077	Novel approaches to linkage mapping. 1995 , 5, 335-41	53
2076	Finding genes involved in human developmental disorders. 1995 , 5, 354-61	10
2075	Contents. 1995 , 5, 399	
2074	[Genetic predisposition to cancer]. 1995 , 16, 500-17	
2073	Loss of heterozygosity at 9p and 17q in human laryngeal tumors. 1995 , 97, 129-34	22
2072	The use of anthracyclines in the adjuvant treatment of breast cancer. 1995 , 21, 199-214	3
2071	Gene diagnostics provide new insights into breast cancer prognosis and therapy. 1995 , 159, 3-7	22
2070	Regions of evolutionary conservation between the rat and human prohibitin-encoding genes. 1995 , 158, 291-4	19

2069	CNS Young Investigator Award Lecture: molecular analysis of the neurofibromatosis 2 tumor suppressor. 1995 , 17, 231-8	4
2068	Construction of a transcription map surrounding the BRCA1 locus of human chromosome 17. 1995 , 25, 238-47	58
2067	Direct selection of expressed sequences within a 1-Mb region flanking BRCA1 on human chromosome 17q21. 1995 , 25, 248-55	21
2066	22 genes from chromosome 17q21: cloning, sequencing, and characterization of mutations in breast cancer families and tumors. 1995 , 25, 256-63	45
2065	A YAC-, P1-, and cosmid-based physical map of the BRCA1 region on chromosome 17q21. 1995 , 25, 264-73	15
2064	Tumor suppressor genes and the practice of surgical pathology. 1995 , 26, 359-61	7
2063	Long-range interaction between two promoters: activation of the leu-500 promoter by a distant upstream promoter. 1995 , 82, 445-51	46
2062	Genetic epidemiology of breast cancer: interest of survival analysis methods. 1995 , 59, 271-82	7
2061	Transcriptional Regulation by Tumor Suppressor Genes. 1995 , 8, 215-224	1
2060	Psychosocial and ethical implications of defining genetic risk for cancers. 1995 , 768, 41-52	17
2059	Ovarian cancer. A model system to study cancer genetics. 1995 , 768, 253-6	
2058	Two forms of Xenopus nuclear factor 7 have overlapping spatial but different temporal patterns of expression during development. 1995 , 52, 305-18	9
2057	Distinct transcription start sites generate two forms of BRCA1 mRNA. 1995 , 4, 2259-64	91
2056	Aberrant subcellular localization of BRCA1 in breast cancer. <i>Science</i> , 1995 , 270, 789-91	33.3 280
2055	.	
2054	Presymptomatic testing for genetic diseases of later life. Pharmacoepidemiological considerations. 1995 , 7, 117-30	3
2053	Tumour suppressor genes in disease and therapy. 1995 , 345, 902-6	35
2052	Genetic testing in breast/ovarian cancer (BRCA1) families. 1995 , 346, 583	29

2051	Breast cancer: cause and prevention. 1995 , 346, 883-7	181
2050	Genetic testing, common diseases, and health service provision. 1995 , 346, 1645-6	20
2049	Breast cancer: questions for future trials. 1995 , 21, 237-9	2
2048	Genetic susceptibility to asthma--bronchial hyperresponsiveness coinherited with a major gene for atopy. 1995 , 333, 894-900	654
2047	Localization of the human homolog of the yeast cell division control 27 gene (CDC27) proximal to ITGB3 on human chromosome 17q21.3. 1995 , 21, 351-5	1
2046	Mutations in breast cancer. 1995 , 90, 51-6	5
2045	Comparative pathology of mammary tumorigenesis in transgenic mice. 1995 , 90, 13-9	26
2044	Identification and Management of Inherited Cancer Susceptibility. 1995 , 103, 297	4
2043	Inherited breast cancer. 1996 , 76, 205-20	21
2042	Commentary on Tumor Suppressor Gene, Distal to BRCA-1, in Prostate Cancer. 1996 , 155, 430-431	4
2041	Differential Chromosome Allelic Imbalance in the Progression of Human Prostate Cancer. 1996 , 156, 2079-2083	24
2040	Evidence for a Tumor Suppressor Gene Distal to BRCA1 in Prostate Cancer. 1996 , 155, 720-725	57
2039	Chapter 4 Tumor-associated carbohydrate antigens and modified blood group antigens. 1996 , 30, 243-276	8
2038	Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. 1996 , 334, 143-9	359
2037	Tumor suppressor gene mutations in mice. 1996 , 30, 603-36	93
2036	KAP-1, a novel corepressor for the highly conserved KRAB repression domain. 1996 , 10, 2067-78	502
2035	Ovarian surface epithelium, ovulation and carcinogenesis. 1996 , 71, 529-43	50
2034	Longitudinal analysis of mortality from breast cancer in Japan, 1950-1993: fitting Gompertz and Weibull functions. 1996 , 88, 169-83	3

2033	Cancer genetics clinics: target population and consultees' expectations. 1996 , 32A, 398-403	39
2032	Cancer genetics clinics. 1996 , 32A, 391-2	20
2031	Early detection of familial ovarian cancer. 1996 , 32A, 1645-51	40
2030	The Human Genome Project and the breast-ovarian cancer gene. 1996 , 3, 2-5	
2029	CYP2D6 genotypes in Spanish women with breast cancer. 1996 , 99, 23-8	22
2028	Attitudes of obstetrician-gynecologists toward DNA testing for a genetic susceptibility to breast cancer. 1996 , 88, 611-5	21
2027	The relationship between borderline ovarian tumors and epithelial ovarian carcinoma: epidemiologic, pathologic, and molecular aspects. 1996 , 60, 347-54	49
2026	Cloning Expressed cDNAs from Defined Chromosomal Regions Using Interspecific Microcell Hybrids and Subtractive Hybridization. 1996 , 9, 47-55	
2025	The murine homolog of the human breast and ovarian cancer susceptibility gene Brca1 maps to mouse chromosome 11D. 1996 , 97, 256-9	13
2024	Antisense oncogene and tumor suppressor gene therapy of cancer. 1996 , 74, 191-204	18
2023	Fictitious breast cancer family history. 1996 , 348, 1034	15
2022	Association of BRCA1 expression with gonadotropin-responsive cells. 1996 , 348, 192-3	1
2021	Genetic analysis of synchronous mucinous tumors of the ovary and appendix. 1996 , 27, 165-71	75
2020	Interphase cytogenetic analysis of solid tumors by non-isotopic DNA in situ hybridization. 1996 , 31, 1-133	7
2019	The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. 1996 , 85, 1009-23	574
2018	TCFL4: a gene at 17q21.1 encoding a putative basic helix-loop-helix leucine-zipper transcription factor. 1996 , 181, 7-11	3
2017	Cloning and sequencing of a copper-containing, topa quinone-containing monoamine oxidase from human placenta. 1996 , 179, 279-86	66
2016	Genes responsible for familial breast cancer. 1996 , 192, 684-93	21

2015	Genetic tests: evolving policy questions. 1996 , 15, 4-10		
2014	Hereditary predisposition to breast cancer. 1996 , 6, 93-7		32
2013	The RING finger domain: a recent example of a sequence-structure family. 1996 , 6, 395-401		417
2012	Sequences and topology. 1996 , 6, 416-27		
2011	BRCA1 and BRCA2 genes: new risk factors in hereditary forms of breast cancer and ovarian carcinoma. 1996 , 1, 53-55		1
2010	Abstracts. 1996 , 14, 1-73		
2009	The galvanization of biology: a growing appreciation for the roles of zinc. <i>Science</i> , 1996 , 271, 1081-5	33.3	1612
2008	Location of BRCA1 in human breast and ovarian cancer cells. <i>Science</i> , 1996 , 272, 123-6	33.3	204
2007	The current role of prophylactic mastectomy. 1996 , 76, 231-42		40
2006	The MDM2 Oncoprotein Binds Specifically to RNA through its RING Finger Domain. 1996 , 2, 439-451		138
2005	Risk Assessment and Presymptomatic Molecular Diagnosis in Hereditary Breast Cancer. 1996 , 16, 139-167		1
2004	Hepatocarcinogenesis: A Polygenic Model of Inherited Predisposition to Cancer. 1996 , 82, 1-5		12
2003	Histoprognostic Grade in Hereditary Breast Cancer: Is Inheritance Linked to BRCA1 a Bad Prognostic Factor?. 1996 , 11-18		1
2002	Molecular Genetics of Deafness. 1996 , 29, 421-435		15
2001	Identification of BRCA1 Gene Carriers by Genetic Linkage Analysis. 1996 , 2-5		
2000	The Potential Role of Common Polymorphisms in Predisposition to Breast and Ovarian Cancer. 1996 , 27-34		
1999	Identifying the genes for human hypertension. 1996 ,		
1998	Breast cancer susceptibility genes: current challenges and future promises. 1996 , 124, 1088-90		14

1997	Graphs to estimate an individualized risk of breast cancer. 1996 , 14, 103-10	74
1996	Genetic predisposition to breast cancer. 1996 , 35, 1-8	18
1995	Inhibition of gap junctional intercellular communication in normal human breast epithelial cells after treatment with pesticides, PCBs, and PBBs, alone or in mixtures. 1996 , 104, 192-200	73
1994	Identifying the genes for human hypertension. 1996 , 11, 575-86	4
1993	Screening for breast cancer: the end of the beginning?. 1996 , 89, 239-42	
1992	Recent advances in understanding of genetic susceptibility to breast cancer. 1996 , 5 Spec No, 1515-9	51
1991	Glad and terrified: on the ethics of BRACA1 and 2 testing. 1996 , 14, 405-11	14
1990	From genes to public health: the applications of genetic technology in disease prevention. Genetics Working Group. 1996 , 86, 1717-22	81
1989	Finely tuned regulation of cytoplasmic retention of Xenopus nuclear factor 7 by phosphorylation of individual threonine residues. 1996 , 16, 990-7	23
1988	Mammary gland neoplasia in long-term rodent studies. 1996 , 104, 938-67	312
1987	In vivo and in vitro characterization of the B1 and B2 zinc-binding domains from the acute promyelocytic leukemia protooncprotein PML. 1996 , 93, 1601-6	95
1986	Genetic heterogeneity in breast cancer susceptibility. 1996 , 35, 407-10	25
1985	A novel member of the RING finger family, KRIP-1, associates with the KRAB-A transcriptional repressor domain of zinc finger proteins. 1996 , 93, 15299-304	243
1984	Allele loss from large regions of chromosome 17 is common only in certain histological subtypes of ovarian carcinomas. 1996 , 74, 1592-7	24
1983	[10]Isolating and mapping coding regions from complex genomes: Direct cDNA selection. 1996 , 8, 189-206	1
1982	Quantitative correlation of breast tissue parameters using magnetic resonance and X-ray mammography. 1996 , 73, 162-8	65
1981	Cancer incidence in the first-degree relatives of ovarian cancer patients. 1996 , 74, 280-4	46
1980	High levels of loss at the 17p telomere suggest the close proximity of a tumour suppressor. 1996 , 74, 863-70	20

1979	Screening for Ovarian Cancer. 1996 , 3, 120-129	11
1978	Brca2 is coordinately regulated with Brca1 during proliferation and differentiation in mammary epithelial cells. 1996 , 93, 13078-83	187
1977	Evidence for a transcriptional activation function of BRCA1 C-terminal region. 1996 , 93, 13595-9	391
1976	Inherited breast carcinoma--prospective findings in 1,194 women at risk. 1996 , 35 Suppl 8, 7-11	9
1975	Detection of genetic alterations in micrometastatic cells in bone marrow of cancer patients by fluorescence in situ hybridization. 1996 , 88, 8-16	64
1974	Informatics for ubiquitous sequencing. 1996 , 14, 286-9	3
1973	Gene patents--a time to balance access and incentives. 1996 , 14, 298-302	5
1972	Mutation and mutagenesis in inherited and acquired human disease. The first EEMS Frits Sobels Prize Lecture, Noordwijkerhout, The Netherlands, June 1995. 1996 , 351, 89-103	11
1971	BRCA1, a gene involved in inherited predisposition to breast and ovarian cancer. 1996 , 1242, 177-80	5
1970	A commentary on the 1996 American Association for Cancer Research Meeting--Cancer susceptibility genes and molecular carcinogenesis. 1996 , 1288, R5-8	
1969	Male breast cancer in patients with a familial history of breast cancer. 1996 , 26, 975-9	14
1968	BRCA1 mutation update and analysis. 1996 , 122, 702-6	7
1967	Lessons from the p53 mutant mouse. 1996 , 122, 319-27	29
1966	Mutations of the BRCA1 gene in human cancer. 1996 , 7, 33-40	44
1965	Manipulation of the mouse germline in the study of Min-induced neoplasia. 1996 , 7, 249-60	24
1964	Psychosocial sequelae of breast cancer and its treatment. 1996 , 18, 110-25	106
1963	Family History of Breast Cancer and Breast Cancer Risk in Japan. 1996 , 3, 161-165	1
1962	Low Frequency Loss of Heterozygosity in the BRCA1 Region in Japanese Sporadic Breast Cancer. 1996 , 3, 167-172	4

1961	Confirmation of susceptibility locus on chromosome 13 in Australian breast cancer families. 1996 , 98, 80-5	8
1960	Heteroduplex and protein truncation analysis of the BRCA1 185delAG mutation. 1996 , 98, 310-2	30
1959	Gene isolation in Arabidopsis thaliana by conditional overexpression of cDNAs toxic to Saccharomyces cerevisiae: identification of a novel early response zinc-finger gene. 1996 , 252, 587-96	23
1958	MMTV-induced mutations in mouse mammary tumors: their potential relevance to human breast cancer. 1996 , 39, 33-44	57
1957	Proliferation of the breast epithelium in relation to menstrual cycle phase, hormonal use, and reproductive factors. 1996 , 40, 187-96	76
1956	Cytogenetic abnormalities in an in situ ductal carcinoma and five prophylactically removed breasts from members of a family with hereditary breast cancer. 1996 , 38, 177-82	26
1955	Age at diagnosis and multiple primary cancers of the breast and ovary. 1996 , 41, 21-9	14
1954	Gail model breast cancer risk components are poor predictors of risk perception and screening behavior. 1996 , 41, 59-70	67
1953	Addressing women's breast cancer risk and perceptions of control in medical settings. 1996 , 3, 185-99	8
1952	Family history in ovarian cancer referral population. 1996 , 5, 27-38	
1951	Genetic mapping of the Brca1 gene on mouse chromosome 11. 1996 , 7, 242	1
1950	Molecular dissection of a cosmid from a gene-rich region in 17q21 and characterization of a candidate gene for alpha-N-acetylglucosaminidase with two cDNA isoforms. 1996 , 7, 686-90	4
1949	Role of BRCA1 mutation screening in the management of familial ovarian cancer. 1996 , 175, 738-46	35
1948	Genetic markers for breast cancer. 1996 , 5, 374-376	1
1947	Does this have a familiar RING?. 1996 , 21, 208-214	553
1946	Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. Breast Cancer Information Core. 1996 , 8, 8-18	240
1945	Notification of a family history of breast cancer: issues of privacy and confidentiality. 1996 , 66, 1-6	17
1944	How do we apply genetic testing for breast cancer susceptibility to clinical practice?. 1996 , 62, 155-7	1

1943	DNA methylation, molecular genetic, and linkage studies in prostate cancer. 1996 , 29, 36-44	22
1942	Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. 1996 , 77, 697-709	355
1941	Benefits versus risks from mammography: A critical reassessment. 1996 , 77, 903-909	73
1940	Molecular genetic evidence of the occurrence of breast cancer as an integral tumor in patients with the hereditary nonpolyposis colorectal carcinoma syndrome. 1996 , 77, 1836-43	99
1939	Analysis of numerical aberrations of specific chromosomes by fluorescent in situ hybridization as a diagnostic tool in breast cancer. 1996 , 77, 2064-9	62
1938	The genetic attributable risk of breast and ovarian cancer. 1996 , 77, 2318-24	506
1937	Participation in a women's breast cancer risk counseling trial. Who participates? Who declines? High Risk Breast Cancer Consortium. 1996 , 77, 2348-55	67
1936	Psychosocial impact of testing (by linkage) for the BRCA1 breast cancer gene: An investigation of two families in the research setting. 1996 , 5, 233-239	36
1935	Mouse ret finger protein (rfp) proto-oncogene is expressed at specific stages of mouse spermatogenesis. 1996 , 19, 309-20	37
1934	Family history and survival of young women with invasive breast carcinoma. 1996 , 78, 1417-25	56
1933	Cancer mortality in relatives of women with breast cancer: the OPCS Study. Office of Population Censuses and Surveys. 1996 , 65, 275-83	78
1932	Cancer mortality in relatives of women with ovarian cancer: the OPCS Study. Office of Population Censuses and Surveys. 1996 , 65, 284-94	56
1931	The pattern of hormonal circadian time structure (acrophase) as an assessor of breast-cancer risk. 1996 , 65, 591-3	15
1930	BRCA1 mutations in German breast-cancer families. 1996 , 68, 188-92	14
1929	Identification of a chemoprevention cohort from a population of women at high risk for breast cancer. 1996 , 63, 112-122	30
1928	Ethical and scientific considerations for chemoprevention research in cohorts at genetic risk for breast cancer. 1996 , 63, 123-130	2
1927	Mutations in the BRCA1 gene in Japanese breast cancer patients. 1996 , 7, 334-9	42
1926	A novel mutation in the BRCA1 gene in a German early-onset breast cancer family. 1996 , 8, 393-393	2

1925	Retinoic acid regulatory pathways, chromosomal translocations, and acute promyelocytic leukemia. 1996 , 15, 147-56	40
1924	Allele loss on chromosome arm 6q and fine mapping of the region at 6q27 in epithelial ovarian cancer. 1996 , 15, 223-33	66
1923	Detection of numerical chromosome anomalies in interphase cells of ovarian carcinomas using fluorescence in situ hybridization. 1996 , 16, 120-9	7
1922	Chromosome aberrations in prophylactic mastectomies from women belonging to breast cancer families. 1996 , 16, 185-8	22
1921	Detailed deletion analysis of sporadic breast tumors defines an interstitial region of allelic loss on 17q25. 1996 , 17, 64-8	24
1920	Familial clustering of obesity and breast cancer. 1996 , 13, 61-78	3
1919	Validation of family history of breast cancer and identification of the BRCA1 and other syndromes using a population-based cancer registry. 1996 , 13, 193-205	39
1918	Association between family history of cancer and breast cancer defined by estrogen and progesterone receptor status. 1996 , 13, 207-21	17
1917	Estimating disease risks for individuals with a given family history in different populations with an application to breast cancer. 1996 , 13, 229-42	7
1916	Segregation analysis of breast cancer: a comparison of type-dependent age-at-onset versus type-dependent susceptibility models. 1996 , 13, 317-28	4
1915	BRCA1 R841W: a strong candidate for a common mutation with moderate phenotype. 1996 , 13, 595-604	17
1914	Microsatellite instability and loss of heterozygosity on chromosome 10 in rat mammary tumors induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. 1996 , 15, 176-82	28
1913	Prophylactic mastectomy for genetic predisposition to breast cancer: the proband's story. 1996 , 8, 222-5	16
1912	Breast cancer genetics: family history, heterogeneity, molecular genetic diagnosis, and genetic counselling. 1996 , 20, 329-65	4
1911	Risk of second tumors in a cohort of patients with ovarian carcinoma. 1996 , 6, 313-317	3
1910	The molecular genetics of sporadic and familial epithelial ovarian cancer. 1996 , 6, 337-355	13
1909	Tumor suppressor genes and medulloblastoma. 1996 , 29, 103-12	67
1908	Norms for patents concerning human and other life forms. 1996 , 17, 279-314	10

1907	Breast Cancer Cytogenetics: Clues to Genetic Complexity of the Disease. 1996 , 2, 27-30	1
1906	Breast Cancer Cytogenetics: Clues to Genetic Complexity of the Disease. 1996 , 2, 124-140	
1905	Significance of Family History in Breast Cancer Treated with Breast Conservation Therapy. 1996 , 2, 238-245	11
1904	Ninety-one Cases of Breast Cancer and Chronic Lymphoproliferative Neoplasm: A Retrospective Review of a Population at High Risk for Multiple Malignancies. 1996 , 2, 312-319	1
1903	Genetics: changing health care in the 21st century. 1996 , 25, 777-83	4
1902	Hereditary breast cancer. 1996 , 5, 13-20	4
1901	Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. 1996 , 12, 191-4	388
1900	Granin expectations in breast cancer?. 1996 , 12, 223-5	13
1899	Growth retardation and tumour inhibition by BRCA1. 1996 , 12, 298-302	338
1898	BRCA1 is secreted and exhibits properties of a granin. 1996 , 12, 303-8	176
1897	The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. 1996 , 12, 333-7	695
1896	Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. 1996 , 13, 120-2	226
1895	Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. 1996 , 13, 126-8	252
1894	Internal repeats in the BRCA2 protein sequence. 1996 , 13, 22-3	173
1893	Mutation analysis in the BRCA2 gene in primary breast cancers. 1996 , 13, 245-7	246
1892	BRCA1 protein products ... Functional motifs. 1996 , 13, 266-8	343
1891	Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. 1996 , 14, 185-7	630
1890	The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. 1996 , 14, 188-90	337

1889	Identification of a RING protein that can interact in vivo with the BRCA1 gene product. 1996 , 14, 430-40	595
1888	Detection of heterozygous mutations in BRCA1 using high density oligonucleotide arrays and two-colour fluorescence analysis. 1996 , 14, 441-7	474
1887	Are we any closer to genetic testing for common malignancies?. 1996 , 2, 156-8	11
1886	The advent of the "unpatients". 1996 , 2, 622-4	57
1885	H-cadherin, a novel cadherin with growth inhibitory functions and diminished expression in human breast cancer. 1996 , 2, 776-82	186
1884	Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. 1996 , 2, 1179-83	253
1883	Breast cancer. What's mice got to do with it?. 1996 , 382, 672	10
1882	Transcriptional activation by BRCA1. 1996 , 382, 678-9	410
1881	Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer. 1996 , 73, 1220-6	98
1880	Microsatellite instability in early sporadic breast cancer. 1996 , 73, 1393-7	61
1879	Familial breast cancer: a controlled study of risk perception, psychological morbidity and health beliefs in women attending for genetic counselling. 1996 , 74, 482-7	181
1878	Allelic loss at chromosome 13q12-q13 is associated with poor prognosis in familial and sporadic breast cancer. 1996 , 74, 1615-9	45
1877	Some public health issues in the current state of genetic testing for breast cancer in Australia. 1996 , 20, 467-72	8
1876	A model protocol for evaluating the behavioral and psychosocial effects of BRCA1 testing. 1996 , 88, 872-82	84
1875	PCR-SSCP-HDX analysis of pooled DNA for more rapid detection of germline mutations in large genes. The BRCA1 example. 1996 , 24, 1177-8	7
1874	German family study on hereditary breast-ovarian cancer. 1996 , 33, 633-5	6
1873	Molecular epidemiology: insights into cancer susceptibility, risk assessment, and prevention. 1996 , 88, 496-509	213
1872	Ascertainment of familial ovarian cancer in the Aberdeen Genetic Clinic. 1996 , 33, 187-92	1

1871	Brk, a breast tumor-derived non-receptor protein-tyrosine kinase, sensitizes mammary epithelial cells to epidermal growth factor. 1996 , 271, 30956-63	95
1870	Mutational scanning of large genes by extensive PCR multiplexing and two-dimensional electrophoresis: application to the RB1 gene. 1996 , 5, 755-61	25
1869	Cancer families: what risks are they given and do the risks affect management?. 1996 , 33, 977-80	5
1868	BRCA1 mutations in a selected series of breast/ovarian cancer patients. 1996 , 33, 721-5	4
1867	Attitudes towards cancer predictive testing and transmission of information to the family. 1996 , 33, 731-6	78
1866	Atopy, airway responsiveness, and genes. 1996 , 51 Suppl 2, S55-9	5
1865	Complete genomic sequence and analysis of 117 kb of human DNA containing the gene BRCA1. 1996 , 6, 1029-49	200
1864	The nuclear localization sequences of the BRCA1 protein interact with the importin-alpha subunit of the nuclear transport signal receptor. 1996 , 271, 32863-8	162
1863	p53 and Breast Cancer. 1996 , 4, 93-110	5
1862	High Frequency of BRCA1 185delAG Mutation in Ovarian Cancer in Israel. 1996 , 276, 1823	39
1861	A gene transcribed from the bidirectional ATM promoter coding for a serine rich protein: amino acid sequence, structure and expression studies. 1996 , 5, 1785-91	39
1860	BRCA1 Testing in Families With Hereditary Breast-Ovarian Cancer. 1996 , 275, 1885	437
1859	Technologies for Detection of DNA Damage and Mutations. 1996 ,	17
1858	Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. 1996 , 88, 1810-20	225
1857	Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. 1996 , 88, 1456-66	599
1856	The geneticist's approach to complex disease. 1996 , 47, 333-53	55
1855	Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations. 1996 , 5, 835-42	81
1854	Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. 1996 , 335, 1413-6	360

1853	Subcellular localization and analysis of apparent 180-kDa and 220-kDa proteins of the breast cancer susceptibility gene, BRCA1. 1996 , 271, 28630-5	40
1852	Inactivation of the mouse Brca1 gene leads to failure in the morphogenesis of the egg cylinder in early postimplantation development. 1996 , 10, 1835-43	256
1851	Genetic susceptibility and the common cancers. 1996 , 1, 174-7	4
1850	BRCA1 mutations in a population-based sample of young women with breast cancer. 1996 , 334, 137-42	258
1849	Mutation analysis of the BRCA1 gene in 23 families with cases of cancer of the breast, ovary, and multiple other sites. 1996 , 33, 814-9	30
1848	Detection of BRCA1 mutations in women with early-onset ovarian cancer by use of the protein truncation test. 1996 , 88, 552-4	13
1847	Allele loss of tumour suppressor genes on chromosome 17 in human testicular germ cell tumours. 1996 , 9, 1087-90	3
1846	A deletion map of chromosome 17q in sporadic human mammary carcinomas. 1996 , 8, 1003-10	
1845	Second malignancies. 1996 , 9, 763-76	2
1844	Tribulations and rewards of academic medicine--where does teaching fit?. 1996 , 334, 184-5	25
1843	BRCA1--lots of mutations, lots of dilemmas. 1996 , 334, 186-8	161
1842	Improving the fecal occult-blood test. 1996 , 334, 189-90	24
1841	Genetics in clinical cancer care--the future is now. 1996 , 335, 1455-6	8
1840	The timing of surgery for severe mitral regurgitation. 1996 , 335, 1456-8	35
1839	Contribution of BRCA1 mutations to ovarian cancer. 1997 , 336, 1125-30	208
1838	BRCA genes--bookmaking, fortunetelling, and medical care. 1997 , 336, 1448-9	74
1837	Localization of BRCA1 and a splice variant identifies the nuclear localization signal. 1997 , 17, 444-52	200
1836	Who should provide genetic education prior to gene testing? Computers and other methods for improving patient understanding. 1997 , 1, 131-6	23

1835	Localization of BRCA1 gene expression in adult cynomolgus monkey tissues. 1997 , 45, 1173-88	8
1834	Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1 gene testing. 1997 , 89, 148-57	302
1833	High throughput parallel analysis of hundreds of patient samples for more than 100 mutations in multiple disease genes. 1997 , 6, 337-47	61
1832	The hepatitis B virus X-associated protein, XAP3, is a protein kinase C-binding protein. 1997 , 272, 16482-9	53
1831	Predisposition Genetic Testing for Late-Onset Disorders in Adults. 1997 , 278, 1217	69
1830	Psychological distress in applicants for predictive DNA testing for autosomal dominant, heritable, late onset disorders. The Rotterdam/Leiden Genetics Workgroup. 1997 , 34, 382-90	60
1829	Single-nucleotide polymorphism identification assays using a thermostable DNA polymerase and delayed extraction MALDI-TOF mass spectrometry. 1997 , 7, 378-88	231
1828	Low frequency of BRCA1 germline mutations in 45 German breast/ovarian cancer families. 1997 , 34, 884-8	13
1827	BRCA1 and BRCA2 mutation analysis in 86 early onset breast/ovarian cancer patients. 1997 , 34, 990-5	7
1826	Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. 1997 , 11, 1226-41	419
1825	Brca2 is required for embryonic cellular proliferation in the mouse. 1997 , 11, 1242-52	222
1824	Isolation and characterization of the Schizosaccharomyces pombe rhp9 gene: a gene required for the DNA damage checkpoint but not the replication checkpoint. 1997 , 25, 2138-46	87
1823	Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population. 1997 , 6, 285-9	102
1822	Genetic Testing for Susceptibility to Adult-Onset Cancer. 1997 , 277, 1467	102
1821	The progestin ORG2058 but not retinoic acid stimulates BRCA1 mRNA expression in MCF-7 human breast cancer cells. 1997 , 10, 253-6	
1820	Clinical and ethical issues in the diagnosis of hereditary breast cancer (review). 1997 , 10, 323-8	
1819	Prognostic implications of loss of heterozygosity in the 17q21 region in breast cancer. 1997 , 10, 659-63	
1818	BRCA1-p53 relationship in hereditary breast cancer. 1997 , 10, 349-53	4

1817	Molecular epidemiology in cancer research (review). 1997 , 11, 1053-69	2
1816	Genetic epidemiology and the future of disease prevention and public health. 1997 , 19, 175-80	44
1815	Impact of the Human Genome Project on epidemiologic research. 1997 , 19, 3-13	18
1814	BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and ovarian cancer. 1997 , 1, 41-6	27
1813	Multiplex genotyping of PCR products with MassTag-labeled primers. 1997 , 25, 3749-50	87
1812	Monte Carlo Markov chain methods and model selection in Genetic analysis. 1997 , 8, 129-144	
1811	RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2. 1997 , 272, 31941-4	394
1810	Mutation testing of early-onset breast cancer genes BRCA1 and BRCA2. 1997 , 1, 75-83	9
1809	BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. 1997 , 336, 1409-15	587
1808	Importance of heritable and nonheritable variation in cancer susceptibility: evidence from a twin study. 1997 , 89, 270-2	7
1807	Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. 1997 , 6, 2309-15	106
1806	Cloning, chromosomal mapping and expression pattern of the mouse Brca2 gene. 1997 , 6, 291-300	55
1805	Control of differentiation, transformation, and apoptosis in granulosa cells by oncogenes, oncoviruses, and tumor suppressor genes. 1997 , 18, 435-61	100
1804	Cloning, expression and mapping of a novel RING-finger gene (RNF5), a human homologue of a putative zinc-finger gene from <i>Caenorhabditis elegans</i> . 1997 , 79, 114-7	15
1803	BRCA1 is a cell cycle-regulated nuclear phosphoprotein. 1997 , 94, 7138-43	168
1802	Convenient, nonradioactive, heteroduplex-based methods for identifying recurrent mutations in the BRCA1 and BRCA2 genes. 1997 , 6, 229-37	5
1801	Genetic Testing Helps Patients and Researchers Predict the Future: Tests May Raise as Many Questions as They Answer. 1997 , 28, 316-322	
1800	A method to monitor mRNA levels in human breast tumor cells obtained by fine-needle aspiration. 1997 , 6, 353-60	8

1799	Decision-making about genetic testing among women at familial risk for breast cancer. 1997 , 59, 459-66	110
1798	DNA banking in epidemiologic studies. 1997 , 19, 156-62	45
1797	Genetic epidemiology of breast and ovarian cancers. 1997 , 19, 69-79	41
1796	Evolving methods in genetic epidemiology. II. Genetic linkage from an epidemiologic perspective. 1997 , 19, 24-32	26
1795	Evolving methods in genetic epidemiology. III. Gene-environment interaction in epidemiologic research. 1997 , 19, 33-43	160
1794	Psychological responses to BRCA1 mutation testing: Preliminary findings.. 1997 , 16, 63-72	288
1793	Stress and genetic testing for disease risk.. 1997 , 16, 8-19	124
1792	Overview of Genetic Diagnosis in Cancer. 1997 , 13, 10.1.1	
1791	Complex regulation of the BRCA1 gene. 1997 , 272, 20994-7	108
1790	The canine genome. 1997 , 40, 191-216	6
1789	Expression genetics in cancer: shifting the focus from DNA to RNA. 1997 , 94, 952-5	191
1788	Genes involved in oncogenesis. 1997 , 40, 51-102	1
1787	Strategies for approaching retinoblastoma tumor suppressor gene therapy. 1997 , 40, 369-97	8
1786	Screening for TP53 mutations in patients and tumours from 109 Swedish breast cancer families. 1997 , 75, 1201-4	13
1785	BRCA1 5382insC mutation in sporadic and familial breast and ovarian carcinoma in Scotland. 1997 , 75, 1377-80	9
1784	Germline BRCA2 mutations in men with breast cancer. 1997 , 76, 1428-31	38
1783	Tumor suppressor genes and human cancer. 1997 , 36, 45-135	24
1782	The status of ultrasound and color Doppler imaging for the early detection of ovarian carcinoma. 1997 , 15, 265-9	20

- 1781 Genetic testing for breast cancer susceptibility: frequency of BRCA1 and BRCA2 mutations. **1997**, 1, 85-90 14
- 1780 Strategies to identify genes for complex diseases. **1997**, 29, 493-8 12
- 1779 The government's role in public trust of biomedical science. **1997**, 5, 205-223
- 1778 Genetic susceptibility testing. **1997**, 11, 411-2
- 1777 The Oncorned approach to genetic testing. **1997**, 1, 137-44 2
- 1776 Semiparametric Estimation of Major Gene and Family-Specific Random Effects for Age of Onset. **1997**, 53, 282 29
- 1775 Increased prevalence and earlier onset of mood disorders among relatives of prepubertal versus adult probands. **1997**, 36, 466-73 89
- 1774 Fully automated DNA reaction and analysis in a fluidic capillary instrument. **1997**, 69, 848-55 81
- 1773 Sequential metal binding by the RING finger domain of BRCA1. **1997**, 36, 10240-5 54
- 1772 Genetics of sarcoidosis. **1997**, 18, 707-17 32
- 1771 Genetics of breast cancer. **1997**, 72, 54-65 77
- 1770 Ethnic Differences in Cancer Incidence: A Marker for Inherited Susceptibility?. **1997**, 105, 897 2
- 1769 Polymorphisms of H-ras-1 and p53 in Breast Cancer and Lung Cancer: A Meta-Analysis. **1997**, 105, 919 17
- 1768 Medical Hypothesis: Bifunctional Genetic-Hormonal Pathways to Breast Cancer. **1997**, 105, 571 2
- 1767 Human ovarian cancer of the surface epithelium. **1997**, 54, 541-4 73
- 1766 Genetics of common disease: implications for therapy, screening and redefinition of disease. **1997**, 352, 1051-5 5
- 1765 Management of Early Stage Breast Cancer. **1997**, 2, 270-280
- 1764 Automated detection of prevalent mutations in BRCA1 and BRCA2 genes, using a fluorogenic PCR allelic discrimination assay. **1997**, 1, 171-80 10

1763	Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. 1997 , 336, 1416-21	172
1762	Recommendations for Follow-up Care of Individuals With an Inherited Predisposition to Cancer. 1997 , 277, 997	499
1761	Changes in BRCA2 expression during progression of the cell cycle. 1997 , 234, 247-51	23
1760	Multiple regulatory elements and binding proteins of the 5'-flanking region of the human estrogen-responsive finger protein (efp) gene. 1997 , 236, 765-71	17
1759	A novel RING finger protein, BFP, predominantly expressed in the brain. 1997 , 240, 8-14	14
1758	Developmental expression of Brca2 colocalizes with Brca1 and is associated with proliferation and differentiation in multiple tissues. 1997 , 184, 385-401	139
1757	Novel genes mapping to the critical region of the 5q- syndrome. 1997 , 45, 88-96	20
1756	Isolation of two novel WNT genes, WNT14 and WNT15, one of which (WNT15) is closely linked to WNT3 on human chromosome 17q21. 1997 , 46, 450-8	46
1755	Hereditary ovarian cancer: molecular genetics and clinical implications. 1997 , 64, 196-206	103
1754	Translational behavioral research in cancer genetics. 1997 , 26, S65-9	12
1753	A review of hereditary breast cancer: from screening to risk factor modification. 1997 , 102, 407-15	13
1752	Advances in molecular genetics. 1997 , 173, 37-41; discussion 42-3	15
1751	Tracking the MEN1 gene. 1997 , 174, 266-70	3
1750	The Human Genome Project and breast cancer. 1997 , 7, 209-14	6
1749	Implications of genetic screening. 1997 , 7, 180-181	
1748	BRCA1 mutations found in archived early onset breast tumours. 1997 , 33, 683-6	3
1747	A BRCA1 founder mutation, identified with haplotype analysis, allowing genotype/phenotype determination and predictive testing. 1997 , 33, 2390-2	21
1746	Predisposition testing for breast and ovarian cancer susceptibility. 1997 , 13, 82-90	4

1745	Assessing individual risk for breast cancer: risky business. 1997 , 50, 547-56	31
1744	Mouse models for breast cancer susceptibility. 1997 , 4, 283-8	
1743	Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. 1997 , 90, 425-35	802
1742	Association of BRCA1 with Rad51 in mitotic and meiotic cells. 1997 , 88, 265-75	1284
1741	The TSG101 tumor susceptibility gene is located in chromosome 11 band p15 and is mutated in human breast cancer. 1997 , 88, 143-54	109
1740	Genetic linkage studies of stuttering: Ready for prime time?. 1997 , 22, 237-240	3
1739	Establishment and characterization of cell lines derived from uterine malignant mixed Müllerian tumor. 1997 , 66, 464-74	12
1738	Differences in phenotypic expression of a new BRCA1 mutation in identical twins. 1997 , 350, 713	10
1737	Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. 1997 , 349, 1505-1510	479
1736	Radiation and genetic factors in the risk of second malignant neoplasms after a first cancer in childhood. 1997 , 350, 91-5	121
1735	The role of MMAC1 mutations in early-onset breast cancer: causative in association with Cowden syndrome and excluded in BRCA1-negative cases. 1997 , 61, 1036-43	117
1734	Interactions between genetic and reproductive factors in breast cancer risk in a French family sample. 1997 , 61, 678-90	21
1733	Common BRCA1 variants and transcriptional activation. 1997 , 61, 761-2	32
1732	Clinical applications of tumor suppressor genes and oncogenes in cancer. 1997 , 257, 157-80	8
1731	Inherited breast and ovarian cancer: the role of the gynecologist. 1997 , 75, 95-6	1
1730	New protein and PCR markers RAK for diagnosis, prognosis and surgery guidance for breast cancer. 1997 , 112, 93-101	6
1729	The role of genetic testing in breast cancer by the year 2000. 1997 , 23 Suppl 1, S13-22	3
1728	Breast cancer risk and environmental exposures. 1997 , 105 Suppl 4, 891-6	78

- 1727 Polymorphisms of H-ras-1 and p53 in breast cancer and lung cancer: a meta-analysis. **1997**, 105 Suppl 4, 919-26 62
- 1726 Genetic factors in the pathogenesis of breast cancer: their role and relative importance. **1997**, 127, 929S-932S 15
- 1725 QTL mapping to QTL cloning: mice to the rescue. **1997**, 7, 663-5 13
- 1724 Preinvasive and Invasive Breast and Cervical Cancer Prior to or During Pregnancy. **1997**, 24, 369-389 30
- 1723 BRCA1, BRCA2. **1997**, 412-418
- 1722 Humbug breast cancer follies: odds ratios for the relative risk of truth: unsolicited reportage from a board certified non-epidemiologist. **1997**, 40, 536-42
- 1721 Radiological Screening in Hereditary Tumour Prone Conditions. **1997**, 5, 4-8
- 1720 Molecular Interactions of Aging and Cancer. **1997**, 13, 69-77 4
- 1719 RAB22 and RAB163/mouse BRCA2: proteins that specifically interact with the RAD51 protein. **1997**, 94, 6927-32 209
- 1718 Cell cycle-dependent colocalization of BARD1 and BRCA1 proteins in discrete nuclear domains. **1997**, 94, 12075-80 138
- 1717 Ethnic differences in cancer incidence: a marker for inherited susceptibility?. **1997**, 105 Suppl 4, 897-900 22
- 1716 Human BRCA1 inhibits growth in yeast: potential use in diagnostic testing. **1997**, 94, 5820-5 99
- 1715 Detection of heterozygous truncating mutations in the BRCA1 and APC genes by using a rapid screening assay in yeast. **1997**, 94, 2449-53 48
- 1714 From bench to bedside... but when?. **1997**, 7, 669-72 4
- 1713 BRCA1 is a component of the RNA polymerase II holoenzyme. **1997**, 94, 5605-10 398
- 1712 Medical hypothesis: bifunctional genetic-hormonal pathways to breast cancer. **1997**, 105 Suppl 3, 571-6 32
- 1711 Direct detection of mutations in the breast and ovarian cancer susceptibility gene BRCA1 by PCR-mediated site-directed mutagenesis. **1997**, 43, 24-29 64
- 1710 Aberrations of the B-Cell Receptor B29 (CD79b) Gene in Chronic Lymphocytic Leukemia. **1997**, 90, 1387-1394 71

1709	BRCA1 Mutation Testing: Controversies and Challenges. 1997 , 43, 6-8	10
1708	Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer. 1997 , 1, 47-51	38
1707	Impact of family history on the risk of breast cancer among the Japanese. 1997 , 88, 1130-6	6
1706	Mutational analysis of BRCA1 gene in ovarian and breast-ovarian cancer families in Japan. 1997 , 88, 407-13	22
1705	Hereditary breast cancer. 1997 , 84, 1334-1339	1
1704	Breast Cancer Genes. 1997 , 3, 1-6	7
1703	Hereditary Breast Cancer: Psychological Aspects of Counseling, Surveillance, and Management. 1997 , 3, 7-14	10
1702	Cancer genetics in the new era of molecular biology. 1997 , 833, 1-28	16
1701	Breast cancer genes: therapeutic strategies. 1997 , 833, 34-41	11
1700	Predictive genetic tests: problems and pitfalls. 1997 , 833, 42-6	10
1699	BRCA1 expression is not directly responsive to estrogen. 1997 , 14, 115-21	99
1698	Strong indication for a breast cancer susceptibility gene on chromosome 8p12-p22: linkage analysis in German breast cancer families. 1997 , 14, 741-3	98
1697	Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-delta11b. 1997 , 14, 1-16	178
1696	Comprehensive allelotyping of human hepatocellular carcinoma. 1997 , 14, 2927-33	256
1695	Relationship of p215BRCA1 to tyrosine kinase signaling pathways and the cell cycle in normal and transformed cells. 1997 , 14, 2863-9	24
1694	BRCA1 proteins are transported to the nucleus in the absence of serum and splice variants BRCA1a, BRCA1b are tyrosine phosphoproteins that associate with E2F, cyclins and cyclin dependent kinases. 1997 , 15, 143-57	123
1693	Novel BRCA1 mutations and more frequent intron-20 alteration found among 236 women from Western Poland. 1997 , 15, 1773-9	24
1692	Genetic testing: the problems and the promise. 1997 , 15, 422-6	81

1691	Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. 1997 , 15, 103-5	377
1690	A breast/ovarian cancer patient with germline mutations in both BRCA1 and BRCA2. 1997 , 15, 14-5	60
1689	BRCA1 is localized in cytoplasmic tube-like invaginations in the nucleus. 1997 , 16, 122-4	44
1688	No stranger to controversy. 1997 , 17, 247-8	4
1687	Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation. 1997 , 17, 423-30	353
1686	Double indemnity: p53, BRCA and cancer. p53 mutation partially rescues developmental arrest in Brca1 and Brca2 null mice, suggesting a role for familial breast cancer genes in DNA damage repair. 1997 , 3, 721-2	94
1685	Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1. 1997 , 389, 187-90	473
1684	A case-control study of breast cancer in Taiwan--a low-incidence area. 1997 , 75, 752-6	56
1683	Prognostic value of loss of heterozygosity at BRCA2 in human breast carcinoma. 1997 , 76, 1416-8	13
1682	Renal cysts, renal cancer and von Hippel-Lindau disease. 1997 , 51, 16-26	70
1681	Fundamental differences of excitation spectrum between malignant and benign breast tissues. 1997 , 66, 518-22	54
1680	Working from the inside out: implications of breast cancer activism for biomedical policies and practices. 1997 , 44, 1403-15	51
1679	Allelic imbalance in three distinct regions on chromosome 17q in sporadic breast cancer correlates with prognostic parameters. 1997 , 6, 1-5	2
1678	Does the evidence justify national funding of breast cancer family history clinics?. 1997 , 6, 388-393	
1677	Induced mouse chromosomal rearrangements as tools for identifying critical developmental genes and pathways. 1997 , 11, 345-51	7
1676	Mutations of the BRCA1 and BRCA2 genes and the possibilities for predictive testing. 1997 , 3, 168-74	24
1675	Molecular genetic events in the development and progression of ovarian cancer in humans. 1997 , 3, 207-13	4
1674	Genetic changes in lung cancer: potential biomarkers for early detection and prevention. 1997 , 130, 550-7	8

1673	Association of hereditary angioedema and hereditary breast cancer. 1997 , 95, 159-62	4
1672	BRCA1 Testing: Genetic Counseling Protocol Development and Counseling Issues. 1997 , 6, 223-44	47
1671	Toward a model informed consent process for BRCA1 testing: a qualitative assessment of women's attitudes. 1997 , 6, 207-22	30
1670	Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. 1997 , 25, 3389-402	53786
1669	The problem of skipped generation and subclinical disease in familial breast-ovarian cancer. 1997 , 76, 166-8	4
1668	Establishment and characterization of human ovarian carcinoma cell lines. 1997 , 66, 378-87	29
1667	Mutational analysis of the BRCA1 tumor suppressor gene in endometrial carcinoma. 1997 , 66, 449-53	10
1666	High frequency of BRCA1 and BRCA2 germline mutations in Ashkenazi Jewish ovarian cancer patients, regardless of family history. 1997 , 67, 123-6	72
1665	Establishment of long-term in vitro cultures of human ovarian cystadenomas and LMP tumors and examination of their spectrum of expression of matrix-degrading proteinases. 1997 , 67, 277-84	19
1664	Diet and premenopausal bilateral breast cancer: a case-control study. 1997 , 42, 243-51	111
1663	Gene therapy strategies for carcinoma of the breast. 1997 , 44, 93-114	14
1662	[Evaluation of cancer risk through genetic analysis?]. 1997 , 173, 444-56	1
1661	Human genetics: past, present, and future, with special reference to major trends in Japan. 1997 , 42, 265-316	13
1660	Possibilities of a viral etiology for human breast cancer. A review. 1997 , 56, 131-42	51
1659	Psychological distress in women seeking genetic counseling for breast-ovarian cancer risk: the contributions of personality and appraisal. 1997 , 19, 370-7	114
1658	Clinicopathological Features of Hereditary Breast Cancer. 1997 , 4, 239-242	12
1657	Alterations and Polymorphisms of the Estrogen Receptor Gene in Breast Cancer. 1997 , 4, 57-66	6
1656	Detailed analysis of a 17q21 microdissection library by sequence bioinformatics and isolation of region-specific clones. 1997 , 23, 353-65	1

1655	Cloning of rat Brca2 and linkage mapping to chromosome 12. 1997 , 8, 850-1	4
1654	Multistep carcinogenesis of breast cancer and tumour heterogeneity. 1997 , 75, 429-39	190
1653	Modifying effect of reproductive risk factors on the age at onset of breast cancer for German BRCA1 mutation carriers. 1997 , 123, 272-9	35
1652	BRCA1 mutations and phenotype. 1997 , 123, 69-70	9
1651	Estrogen action in human ovarian cancer. 1997 , 25, 1-9	67
1650	Facts in cancer genetics. 1997 , 32, 9-17	3
1649	Psychological issues in cancer genetics: current research and future priorities. 1997 , 32, 19-31	43
1648	Ethnic differences in knowledge and attitudes about BRCA1 testing in women at increased risk. 1997 , 32, 51-62	170
1647	Genetic counseling for hereditary cancer: a pilot study on experiences of patients and family members. 1997 , 32, 107-16	66
1646	Fallopian tube carcinoma: an under-recognized primary neoplasm. 1997 , 7, 284-288	18
1645	Molecular genetic analysis in the pathologic evaluation of solid tumors: theory and practice. 1997 , 11, 10-6	2
1644	Genetic testing for breast cancer susceptibility: Awareness and interest among women in the general population. 1997 , 68, 43-49	91
1643	BRCA1 in the family: a case description of the psychological implications. 1997 , 71, 63-71	77
1642	Patients' attitudes about autonomy and confidentiality in genetic testing for breast-ovarian cancer susceptibility. 1997 , 73, 296-303	74
1641	Vitamin D3 analogs and their 24-Oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects. 1997 , 66, 413-425	75
1640	Gene rearrangements in the molecular pathogenesis of acute promyelocytic leukemia. 1997 , 173, 288-96	35
1639	New nonsense mutation in the breast cancer-1 gene in a French site-specific breast cancer family. 1997 , 9, 474-5	
1638	Screening for ESR mutations in breast and ovarian cancer patients. 1997 , 9, 531-6	21

1637	Mutations and alternative splicing of the BRCA1 gene in UK breast/ovarian cancer families. 1997 , 18, 102-110	43
1636	German family study on hereditary breast and/or ovarian cancer: Germline mutation analysis of the BRCA1 gene. 1997 , 18, 126-132	19
1635	Patterns of allelic loss on chromosome 17 in sporadic breast carcinomas detected by fluorescent-labeled microsatellite analysis. 1997 , 18, 181-92	60
1634	Deletion of the short arm of chromosome 3 in breast tumors. 1997 , 18, 241-245	38
1633	Analysis of the BRCA1 and BRCA2 genes in sporadic meningiomas. 1997 , 20, 53-59	16
1632	Comparative genomic hybridization detects frequent overrepresentation of chromosomal material from 3q26, 8q24, and 20q13 in human ovarian carcinomas. 1997 , 20, 320-328	147
1631	Allelic loss at BRCA1, BRCA2, and adjacent loci in relation to TP53 abnormality in breast cancer. 1997 , 20, 377-382	16
1630	Use of twins in search for tumor suppressor genes. 1997 , 30, 231-9	3
1629	Positional cloning: A review and perspective. 1997 , 41, 129-141	2
1628	Dideoxy fingerprinting assay for BRCA1 mutation analysis. 1997 , 19, 176-179	11
1627	Gene expression changes associated with chemically induced rat mammary carcinogenesis. 1997 , 20, 204-15	75
1626	Genetic susceptibility testing. A therapeutic illusion. 1997 , 79, 2063-5; discussion 2066	12
1625	Immunohistochemically detected p53 and HER-2/neu expression and nuclear DNA content in familial epithelial ovarian carcinomas. 1997 , 79, 2147-53	12
1624	A descriptive study of BRCA1 testing and reactions to disclosure of test results. 1997 , 79, 2219-28	176
1623	Clear cell adenocarcinoma of the vagina and cervix. An update of the central Netherlands registry showing twin age incidence peaks. 1997 , 79, 2229-36	89
1622	BRCA1 and BRCA2 hereditary breast carcinoma phenotypes. 1997 , 80, 543-556	40
1621	BRCA2 germline mutations in Japanese breast cancer families. 1997 , 74, 199-204	20
1620	Family history and the risk of breast cancer: a systematic review and meta-analysis. 1997 , 71, 800-9	406

1619	Genomic deletions in the BRCA1, BRCA2 and TP53 regions associate with low expression of the estrogen receptor in sporadic breast carcinoma. 1997 , 74, 322-5	19
1618	Chemopreventive efficacy of anethole trithione, N-acetyl-L-cysteine, miconazole and phenethylisothiocyanate in the DMBA-induced rat mammary cancer model. 1997 , 72, 95-101	51
1617	Family history of cancer and risk of breast cancer. 1997 , 72, 735-8	36
1616	Abundance of BRCA1 transcripts in human cancer and lymphoblastoid cell lines carrying BRCA1 germ-line alterations. 1997 , 73, 715-8	15
1615	BRCA1 tumor suppressor gene product shares immunoreactive epitopes with a protein present in seminal plasma. 1997 , 30, 425-32	6
1614	Screening and clinical implications for BRCA1 and BRCA2 mutation carriers. 1998 , 3, 377-87	
1613	The genetics of inherited breast cancer. 1998 , 3, 365-76	26
1612	Expression of BRCA1 and BRCA2 in normal and neoplastic cells. 1998 , 3, 389-402	26
1611	Developmental studies of Brca1 and Brca2 knock-out mice. 1998 , 3, 431-45	64
1610	Inherited BRCA2 mutation associated with high grade breast cancer. 1998 , 47, 121-7	77
1609	Genomic organization of the canine p53 gene and its mutational status in canine mammary neoplasia. 1998 , 50, 11-25	42
1608	Molecular prognostic markers in breast cancer. 1998 , 52, 185-200	24
1607	Breast cancer in Australian women under the age of 40. 1998 , 9, 189-98	89
1606	Book Review Breakthrough: The Race to Find the Breast Cancer Gene. By Kevin Davies and Michael White. John Wiley and Sons, Inc., New York, New York, 1996, 310 pp., \$24.95 (hardback). 1998 , 7, 375-378	
1605	Cancer Risk Assessment and Genetic Counseling in an Academic Medical Center: Consultants' Satisfaction, Knowledge, and Behavior in the First Year. 1998 , 7, 279-97	26
1604	The Effect of Genetic Counseling on Knowledge and Perceptions Regarding Risks for Breast Cancer. 1998 , 7, 417-34	23
1603	The budding yeast Rad9 checkpoint protein is subjected to Mec1/Tel1-dependent hyperphosphorylation and interacts with Rad53 after DNA damage. 1998 , 17, 5679-88	220
1602	Structure of an XRCC1 BRCT domain: a new protein-protein interaction module. 1998 , 17, 6404-11	196

1601	Analysis of allelic imbalance on chromosome 17p13 in stage I and stage II epithelial ovarian cancers. 1998 , 71, 77-82	12
1600	A systematic review and meta-analysis of family history and risk of ovarian cancer. 1998 , 105, 493-9	173
1599	Multiplex mutation screening of the BRCA1 gene in 1000 Japanese breast cancers. 1998 , 89, 12-6	20
1598	Nonsense mutation at codon 63 of the BRCA1 gene in Japanese breast cancer patients. 1998 , 89, 837-41	9
1597	BRCA2 germline mutations in Swedish breast cancer families. 1998 , 6, 134-9	20
1596	Comparison of conformation-sensitive gel electrophoresis and single-strand conformation polymorphism analysis for detection of mutations in the BRCA1 gene using optimized conformation analysis protocols. 1998 , 6, 145-50	55
1595	Brca1 and Brca2 expression patterns in mitotic and meiotic cells of mice. 1998 , 16, 61-8	76
1594	Breast cancer genome anatomy: correlation of morphological changes in breast carcinomas with expression of the novel gene product Di12. 1998 , 16, 327-33	28
1593	Identification of a human homolog of the Drosophila neuralized gene within the 10q25.1 malignant astrocytoma deletion region. 1998 , 16, 1009-19	56
1592	Identification of a BRCA1-associated kinase with potential biological relevance. 1998 , 16, 1031-40	11
1591	CpG methylation within the 5' regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site. 1998 , 16, 1161-9	159
1590	Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. 1998 , 16, 1391-7	375
1589	Recombinant PML adenovirus suppresses growth and tumorigenicity of human breast cancer cells by inducing G1 cell cycle arrest and apoptosis. 1998 , 16, 1839-49	87
1588	Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA-damaging agents. 1998 , 16, 2229-41	71
1587	BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. 1998 , 16, 1097-112	545
1586	BRCA1 physically associates with p53 and stimulates its transcriptional activity. 1998 , 16, 1713-21	372
1585	DOC-2/hDab2, a candidate tumor suppressor gene involved in the development of gestational trophoblastic diseases. 1998 , 17, 419-24	79
1584	The BRCA2 is a histone acetyltransferase. 1998 , 16, 2283-5	59

1583	Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells. 1998 , 17, 1807-12	194
1582	p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours. 1998 , 17, 1681-9	145
1581	BRCA1 as a potential human prostate tumor suppressor: modulation of proliferation, damage responses and expression of cell regulatory proteins. 1998 , 16, 3069-82	88
1580	Conservation of function and primary structure in the BRCA1-associated RING domain (BARD1) protein. 1998 , 17, 2143-8	33
1579	Characterization of a carboxy-terminal BRCA1 interacting protein. 1998 , 17, 2279-85	140
1578	A targeted disruption of the murine Brca1 gene causes gamma-irradiation hypersensitivity and genetic instability. 1998 , 17, 3115-24	291
1577	Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region. 1998 , 17, 3169-76	114
1576	BRCA1 binds c-Myc and inhibits its transcriptional and transforming activity in cells. 1998 , 17, 1939-48	180
1575	Mouse models in tumor suppression. 1998 , 17, 3385-400	71
1574	Evolutionary sequence comparisons using high-density oligonucleotide arrays. 1998 , 18, 155-8	86
1573	Predicting functions from protein sequences--where are the bottlenecks?. 1998 , 18, 313-8	277
1572	BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A. 1998 , 19, 254-6	339
1571	Segregation analysis of epithelial ovarian cancer in Finland. 1998 , 77, 1537-41	5
1570	An identical novel mutation in BRCA1 and a common haplotype in familial ovarian cancer in non-Ashkenazi Jews. 1998 , 77, 1880-3	10
1569	BRCA1 mutations in southern England. 1998 , 77, 2199-203	27
1568	Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer. 1998 , 78, 771-3	43
1567	BRCA1 gene expression in reproductive and endocrine tissues in adult cynomolgus monkey. 1998 , 839, 444-6	
1566	Clinical and genetic evaluation of thirty ovarian cancer families. 1998 , 178, 85-90	40

1565	Murine tumor suppressor models. 1998 , 400, 391-407	10
1564	[Genetic risk of breast and ovarian cancer]. 1998 , 123, 399-403; discussion 403-4	
1563	Loss of nuclear BRCA1 expression in breast cancers is associated with a highly proliferative tumor phenotype. 1998 , 101, 109-15	48
1562	Search for TSG101 germ-line mutations in BRCA1/BRCA2-negative breast/ovarian cancer families. 1998 , 102, 86-7	1
1561	Molecular genetics of renal cell carcinoma. 1998 , 104, 1-18	20
1560	Loss of heterozygosity in the region including the BRCA1 gene on 17q in colon cancer. 1998 , 104, 119-23	31
1559	An alternative splice site junction in exon 1a of the BRCA1 gene. 1998 , 105, 90-2	7
1558	Mutations in BRCA1 from fixed, paraffin-embedded tissue can be artifacts of preservation. 1998 , 107, 21-7	45
1557	Expression genetics: a different approach to cancer diagnosis and prognosis. 1998 , 16, 66-71	24
1556	Breast cancer and genetic instability: the molecules behind the scenes. 1998 , 4, 263-7	18
1555	Prospective findings in breast cancer kindreds: annual incidence rates according to age, stage at diagnosis, mean sojourn time, and incidence rates for contralateral cancer. 1998 , 7, 55-59	20
1554	Do BRCA1 mutations affect the ability to breast-feed? Significantly shorter length of breast-feeding among BRCA1 mutation carriers compared with their unaffected relatives. 1998 , 7, 320-324	19
1553	Novel 5 bp germline deletion in exon 11 of the BRCA1 gene. 1998 , Suppl 1, S187-8	2
1552	Identification of a novel splice-site mutation of the BRCA1 gene in two breast cancer families: screening reveals low frequency in Icelandic breast cancer patients. 1998 , Suppl 1, S195-7	28
1551	Novel deletion at codon 1254 of the BRCA1 gene in an Italian breast cancer kindred. 1998 , Suppl 1, S237-9	4
1550	Unique features of gastric carcinoma in the young: a population-based analysis. 1998 , 83, 25-33	53
1549	Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. 1998 , 83, 310-319	152
1548	Breast carcinoma in carriers of BRCA1 or BRCA2 mutations: implications of proposed distinct histologic phenotypes. 1998 , 83, 2251-4	7

1547	Preferential allelic expression can lead to reduced expression of BRCA1 in sporadic breast cancers. 1998, 77, 1-6	41
1546	BRCA1-related breast cancer in Austrian breast and ovarian cancer families: specific BRCA1 mutations and pathological characteristics. 1998, 77, 354-60	63
1545	Down-regulation of BRCA1 and BRCA2 in human ovarian cancer cells exposed to adriamycin and ultraviolet radiation. 1998, 77, 600-9	40
1544	An important role for BRCA1 in breast cancer progression is indicated by its loss in a large proportion of non-familial breast cancers. 1998, 79, 334-42	89
1543	BRCA1 is localized in ductal secretions of normal breast tissues: Detection by antibodies raised against the amino terminus of BRCA1 (K-18). 1998, 77, 803-6	10
1542	Low incidence of BRCA1 mutations among Italian families with breast and ovarian cancer. 1998, 78, 581-6	22
1541	Allelic loss of the BRCA1 and BRCA2 genes and other regions on 17q and 13q in breast cancer among women from Taiwan (area of low incidence but early onset). 1998, 79, 580-7	40
1540	Psychosocial implications of progress in breast cancer genetics: uncertainties and challenges. 1998, 5, 109-123	2
1539	'You don't want to lose your ovaries because you think 'I might become a man". Women's perceptions of prophylactic surgery as a cancer risk management option. 1998, 7, 263-75	48
1538	Psychological support needs for women at high genetic risk of breast cancer: some preliminary indicators. 1998, 7, 402-12	89
1537	Distress in individuals facing predictive DNA testing for autosomal dominant late-onset disorders: comparing questionnaire results with in-depth interviews. Rotterdam/Leiden Genetics Workgroup. 1998, 75, 62-74	48
1536	Analysis of BRCA1 mutations in a Pakistani family with hereditary breast and ovarian cancer syndrome. 1998, 78, 386-387	3
1535	Marker segregation information in breast/ovarian cancer genetic counseling: is it still useful? Groupe Gène et Cancer de la Fédération Nationale des Centres de Lutte Contre le Cancer. 1998, 79, 175-83	4
1534	Implications of a novel cryptic splice site in the BRCA1 gene. 1998, 80, 140-144	20
1533	Breast cancer genes and the surgeon. 1998, 67, 267-74	16
1532	Generalized affine gap costs for protein sequence alignment. 1998, 32, 88-96	52
1531	Mammalian protein homologous to VAT-1 of <i>Torpedo californica</i> : Isolation from Ehrlich ascites tumor cells, biochemical characterization, and organization of its gene. 1998, 69, 304-315	14
1530	Constant denaturant gel electrophoresis (CDGE) in BRCA1 mutation screening. 1998, 11, 166-74	10

1529	Multiple possible sites of BRAC2 interacting with DNA repair protein RAD51. 1998 , 21, 217-222	33
1528	Identification of missense and truncating mutations in the BRCA1 gene in sporadic and familial breast and ovarian cancer. 1998 , 21, 244-249	25
1527	Deletion mapping of endocrine tumors localizes a second tumor suppressor gene on chromosome band 11q13. 1998 , 22, 130-7	56
1526	National database of familial cancer in Sweden. 1998 , 15, 225-36	57
1525	Future prospects for the staging of breast cancer. 1996 , 12, 3-11	1
1524	Involvement of tyrosine phosphorylation of p185c-erbB2/neu in tumorigenicity induced by x-rays and the neu oncogene in human breast epithelial cells. 1998 , 21, 225-233	34
1523	Estrogen upregulation of BRCA1 expression with no effect on localization. 1998 , 22, 102-9	52
1522	Evidence for the upregulation of osteogenic protein-1 mRNA expression in musculoskeletal neoplasms. 1998 , 16, 8-14	20
1521	Breast cancer risk assessment: use of complete pedigree information and the effect of misspecified ages at diagnosis of affected relatives. 1998 , 102, 348-56	17
1520	High throughput fluorescence-based conformation-sensitive gel electrophoresis (F-CSGE) identifies six unique BRCA2 mutations and an overall low incidence of BRCA2 mutations in high-risk BRCA1-negative breast cancer families. 1998 , 102, 549-56	47
1519	Identification, localization and characterization of the human gamma-synuclein gene. 1998 , 103, 106-12	148
1518	A high proportion of mutations in the BRCA1 gene in German breast/ovarian cancer families with clustering of mutations in the 3' third of the gene. 1998 , 103, 154-61	14
1517	New mechanism of BRCA-1 mutation by deletion/insertion at the same nucleotide position in three unrelated French breast/ovarian cancer families. 1998 , 103, 334-9	16
1516	Identification of the 185delAG BRCA1 mutation in a Spanish Gypsy population. 1998 , 103, 707-8	21
1515	High proportion of missense mutations of the BRCA1 and BRCA2 genes in Japanese breast cancer families. 1998 , 43, 42-8	30
1514	Molekularbiologie maligner Tumorerkrankungen. 1998 , 4, 671-681	1
1513	Genetische Prädisposition beim Mammakarzinom. 1998 , 4, 868-877	2
1512	Awareness and attitudes concerning BRCA gene testing. 1998 , 5, 607-12	44

1511	A mutation (IVS8+0.6kdelTC) creating a new donor splice site activates a cryptic exon in an Alu-element in intron 8 of the human beta-glucuronidase gene. 1998 , 103, 686-93	36
1510	Neural networks approach to early breast cancer detection. 1998 , 44, 617-633	28
1509	Allelic Loss on Chromosome 8p in BRCA-1 Mutation Positive Breast/Ovarian Cancers. 1998 , 4, 9-12	4
1508	Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence. 1998 , 49, 695-707	138
1507	Psycho-social aspects of breast cancer susceptibility testing: a literature review. 1998 , 7, 174-80	19
1506	Genetic susceptibility to cancer: ICRP Publication 79. 1998 , 28, 1-157	26
1505	Chromosomal assignment and expression pattern of the murine Lasp-1 gene. 1998 , 207, 171-5	29
1504	Diverse modes of alternative splicing of human splicing factor SF1 deduced from the exon-intron structure of the gene. 1998 , 211, 29-37	15
1503	Promoter analysis of mouse estrogen-responsive finger protein (efp) gene: mouse efp promoter contains an E-box that is also conserved in human. 1998 , 216, 155-62	7
1502	Génétique des cancers: la quadrature du test. 1998 , 1998, 20-23	1
1501	Molecular analysis of the six most recurrent mutations in the BRCA1 gene in 87 Spanish breast/ovarian cancer families. 1998 , 123, 153-8	19
1500	Prostate, breast and gynecological cancer markers RAK with homology to HIV-1. 1998 , 124, 213-23	9
1499	BRCA1 and BRCA2: penetrating the clinical arena. 1998 , 352, 1325-6	5
1498	Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. 1998 , 351, 316-21	380
1497	Population-based study of risk of breast cancer in carriers of BRCA2 mutation. 1998 , 352, 1337-9	287
1496	The promise of cancer genetics. 1998 , 351 Suppl 2, S11-8	47
1495	Functions of the BRCA1 and BRCA2 genes. 1998 , 8, 14-20	79
1494	Screening women aged less than 50 years with a family history of breast cancer. 1998 , 34, 878-83	58

1493	BRCA1-positive patients are small for gestational age compared with their unaffected relatives. 1998 , 34, 368-71	19
1492	Truncated TSG101 transcripts are present in peripheral blood from both familial breast cancer patients and controls. 1998 , 34, 1077-80	4
1491	Predicted anti-oestrogen resistance in BRCA-associated familial breast cancers. 1998 , 34, 1683-6	58
1490	Loss of heterozygosity of BRCA1, TP53 and TCRD markers analysed in sporadic endometrial cancer. 1998 , 34, 1770-6	18
1489	Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. European Familial Breast Cancer Collaborative Group. 1998 , 34, 1922-6	98
1488	FAMILIAL BREAST AND OVARIAN CANCER: THE ROLE OF THE BRCA GENES. 1998 , 5, 140-143	0
1487	Histopathology and molecular biology of ovarian epithelial tumors. 1998 , 2, 195-207	17
1486	Involvement of Brca2 in DNA repair. 1998 , 1, 347-57	504
1485	Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. 1998 , 2, 317-28	498
1484	A review of breast cancer chemoprevention. 1998 , 52, 133-6	14
1483	Pathobiologic characteristics of hereditary breast cancer. 1998 , 29, 1140-4	67
1482	Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. 1998 , 62, 676-89	2347
1481	A BRCA1 nonsense mutation causes exon skipping. 1998 , 62, 713-5	88
1480	Evidence of founder mutations in Finnish BRCA1 and BRCA2 families. 1998 , 62, 1544-8	68
1479	Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. 1998 , 62, 1381-8	138
1478	Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. 1998 , 63, 1341-51	136
1477	Ovarian cancer gene therapy. 1998 , 12, 539-52	12
1476	Epithelial ovarian cancer, infertility and induction of ovulation: possible pathogenesis and updated concepts. 1998 , 12, 581-91	8

1475	Breast disease. 1998 , 82, 203-22	6
1474	Deleterious mutations of both BRCA1 and BRCA2 in three siblings. 1998 , 2, 75-7	12
1473	Applying genomics tools to identify therapeutic targets for asthma. 1998 , 7, 1301-12	
1472	Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors. 1998 , 245, 75-80	69
1471	Molecular cloning of a novel RING finger-B box-coiled coil (RBCC) protein, terf, expressed in the testis. 1998 , 251, 515-9	27
1470	Ionizing radiation and genetic risks IX. Estimates of the frequencies of mendelian diseases and spontaneous mutation rates in human populations: a 1998 perspective. 1998 , 411, 129-78	33
1469	Identification of a third EXT-like gene (EXTL3) belonging to the EXT gene family. 1998 , 47, 230-7	113
1468	Cloning, genomic structure, and expression of mouse ring finger protein gene Znf179. 1998 , 49, 394-400	15
1467	Transcript mapping of the human chromosome 11q12-q13.1 gene-rich region identifies several newly described conserved genes. 1998 , 49, 419-29	15
1466	A transcriptional Map of the FMF region. 1998 , 50, 147-60	12
1465	Molecular cloning, localization, and developmental expression of mouse brain finger protein (Bfp)/ZNF179: distribution of bfp mRNA partially coincides with the affected areas of Smith-Magenis syndrome. 1998 , 54, 59-69	17
1464	Optimization of PCR and electrophoresis conditions enhances mutation analysis of the BRCA1 gene. 1998 , 64, 173-6	8
1463	A genomic approach to understanding Heliiothis and Helicoverpa resistance to chemical and biological insecticides. 1998 , 353, 1713-1722	32
1462	Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. 1998 , 62, 145-58	581
1461	Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations. 1998 , 47, 129-36	96
1460	Hereditary breast cancer. 1998 , 49, 425-36	54
1459	Cancer chemoprevention. A new way to treat cancer before it happens. 1998 , 25, 361-79	11
1458	Testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes: a decision analysis. 1998 , 18, 365-75	26

1457	The genetics of breast cancer susceptibility. 1998 , 32, 95-121	221
1456	Current Guidelines for the Diagnosis and Treatment of Breast Cancer. 1998 , 3, 239-250	8
1455	Management of Advanced Breast Cancer: Defining the Role of Toremifene. 1998 , 3, 143-152	1
1454	Rad9 comes of age. <i>Science</i> , 1998 , 281, 185-6	33-3 5
1453	BRCA1 required for transcription-coupled repair of oxidative DNA damage. <i>Science</i> , 1998 , 281, 1009-12	33-3 371
1452	The anti-BRCA1 peptide antibody C-20 recognizes smooth muscle cells. 1998 , 78, 396-7	
1451	Family history of breast cancer: what do women understand and recall about their genetic risk?. 1998 , 35, 731-8	101
1450	Estrogen-responsive RING finger mRNA induction in gastrointestinal carcinoma cells following bile acid treatment. 1998 , 19, 1901-6	7
1449	Diagnostic drift in the reporting of cancer incidence. 1998 , 90, 863-4	6
1448	In vitro repression of Brca1-associated RING domain gene, Bard1, induces phenotypic changes in mammary epithelial cells. 1998 , 143, 1329-39	83
1447	Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history. 1998 , 90, 1824-9	91
1446	The Progression of Neoplasia, Cell Replication, and Electromagnetic Fields. 1998 , 17, 59-108	0
1445	An evaluation of common breast cancer gene mutations in a population of Ashkenazi Jews. 1998 , 35, 10-2	6
1444	Predicting adaptation to presymptomatic DNA testing for late onset disorders: who will experience distress? Rotterdam Leiden Genetics Workgroup. 1998 , 35, 745-54	55
1443	Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors. 1998 , 90, 995-1000	44
1442	Physical map of the human chromosome 8p12-p21 encompassing tumor suppressor and Werner's syndrome gene loci. 1998 , 5, 103-13	2
1441	Using gene carrier probability to select high risk families for identifying germline mutations in breast cancer susceptibility genes. 1998 , 35, 116-21	11
1440	Men in breast cancer families: a preliminary qualitative study of awareness and experience. 1998 , 35, 739-44	53

1439	BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history. 1998 , 279, 922-9	171
1438	Germline PTEN mutations in Cowden syndrome-like families. 1998 , 35, 881-5	115
1437	Accurate, high-throughput "snapshot" detection of hMLH1 mutations by two-dimensional DNA electrophoresis. 1998 , 2, 43-53	10
1436	Genetic testing for breast-ovarian cancer susceptibility: a regional trial. 1998 , 2, 305-13	14
1435	Genetic testing for BRCA1 and BRCA2: recommendations of the Stanford Program in Genomics, Ethics, and Society. Breast Cancer Working Group. 1998 , 7, 531-45	25
1434	A practical guide to orient yourself in the labyrinth of genome databases. 1998 , 7, 1641-8	15
1433	The C-terminal (BRCT) domains of BRCA1 interact in vivo with CtIP, a protein implicated in the CtBP pathway of transcriptional repression. 1998 , 273, 25388-92	299
1432	The cancer-predisposing mutation C61G disrupts homodimer formation in the NH2-terminal BRCA1 RING finger domain. 1998 , 273, 7795-9	67
1431	BRCA1 is associated with the centrosome during mitosis. 1998 , 95, 12983-8	265
1430	Mutation detection using a novel plant endonuclease. 1998 , 26, 4597-602	306
1429	Genetic testing for cancer risk: how to reconcile the conflicts. 1998 , 279, 179-81	23
1428	hMLH1 and hMSH2 expression and BAX frameshift mutations in ovarian cancer cell lines and tumors. 1998 , 19, 691-4	13
1427	A population study of mutations and LOH at breast cancer gene loci in tumours from sister pairs: two recurrent mutations seem to account for all BRCA1/BRCA2 linked breast cancer in Iceland. 1998 , 35, 446-9	28
1426	Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. 1998 , 279, 915-21	259
1425	The mammalian numb phosphotyrosine-binding domain. Characterization of binding specificity and identification of a novel PDZ domain-containing numb binding protein, LNX. 1998 , 273, 9179-87	93
1424	Effects of monounsaturated and polyunsaturated fatty acids (omega-3 and omega-6) on Brca1 protein expression in breast cell lines. 1998 , 90, 1234-5	4
1423	Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. 1998 , 90, 1138-45	565
1422	Influence of genistein and daidzein on Brca1 protein levels in human breast cell lines. 1998 , 90, 862-3	13

1421	Breast cancer susceptibility genes. BRCA1 and BRCA2. 1998 , 77, 208-26	101
1420	Why do we need randomised controlled trials to assess behavioural interventions?. 1998 , 316, 611-3	110
1419	Hereditary and sporadic ovarian cancer: genetic testing and clinical implications (review). 1998 , 12, 1029-34	3
1418	Pathology of sporadic breast tumors with LOH at the BRCA1 locus: correlation with histopathological features specific to familial BRCA1 tumors and absence of microsatellite instability. 1998 , 12, 1373-8	
1417	Nucleolar localization of BRCA1 protein in human breast cancer.. 1998 , 13, 513	
1416	Loss of heterozygosity of BRCA1, BRCA2 and ATM genes in sporadic invasive ductal breast carcinoma. 1998 , 13, 849-53	12
1415	Frequent microsatellite instability and loss of heterozygosity in the region including BRCA1 (17q21) in young patients with gastric cancer. 1998 , 12, 1245-51	15
1414	The role of retinoblastoma and p53 tumor suppressor pathways in human mammary epithelial cell immortalization. 1998 , 12, 499-507	7
1413	Detection of BRCA1 gene mutations in families with breast cancer patients and their healthy relatives. 1998 , 13, 275-9	1
1412	The genetic passport. 1998 , 147, 513-5	3
1411	Family history score as a predictor of breast cancer mortality: prospective data from the Cancer Prevention Study II, United States, 1982-1991. 1998 , 147, 652-9	33
1410	A missense mutation in the BRCA2 gene in three siblings with ovarian cancer. 1998 , 77, 1199-202	9
1409	BRCA1 regulates p53-dependent gene expression. 1998 , 95, 2302-6	317
1408	Motivations, perceptions and interpersonal differences associated with interest in genetic testing for breast cancer susceptibility among women at high and average risk. 1998 , 13, 1071-1086	34
1407	Genetic testing for cancer risk: a population survey on attitudes and intention. 1998 , 1, 213-22	35
1406	BRCA1 and BRCA2 proteins: roles in health and disease. 1998 , 51, 237-47	40
1405	Perspective on BRCA1. 1998 , 10, 3-10	11
1404	Frequent loss of heterozygosity at chromosome 13q12-13 with BRCA2 markers in sporadic male breast cancer. 1998 , 7, 57-62	9

1403	A new BRCA1 mutation in a Filipino woman with a family history of breast and ovarian cancer. 1998 , 7, 164-7	5
1402	BRCA1 splice variants BRCA1a and BRCA1b associate with CBP co-activator. 1998 , 5, 591-5	15
1401	Coactivator TIF1beta interacts with transcription factor C/EBPbeta and glucocorticoid receptor to induce alpha1-acid glycoprotein gene expression. 1998 , 18, 5880-7	68
1400	Screening for breast and ovarian cancer: the relevance of family history. 1998 , 54, 823-38	24
1399	Course of distress experienced by persons at risk for an autosomal dominant inheritable disorder participating in a predictive testing program: an explorative study. Rotterdam/Leiden Genetics Workgroup. 1998 , 60, 543-9	28
1398	Linkage analysis and the tracking of susceptibility genes. 1998 , 112, 323-30	5
1397	Ethical aspects of genetic screening in Israel. 1998 , 11, 419-29	11
1396	The BRCA2 gene product functionally interacts with p53 and RAD51. 1998 , 95, 13869-74	213
1395	Yeast-based assays for detection and characterization of mutations in BRCA1. 1998 , 10, 61-70	15
1394	Identification of a novel cytoplasmic protein that specifically binds to nuclear localization signal motifs. 1998 , 273, 6183-9	97
1393	Genetic Disorders. 1998 , 409-426	
1392	Predictive diagnosis and genetic screening: manipulation of fate?. 1998 , 41, 282-9	6
1391	Allelic loss and microsatellite instability in prostate cancers in Japan. 1998 , 55, 569-74	21
1390	Genetic testing for the BRCA1 gene and the need for protection from discrimination: an evolving legislative and social issue. 1998 , 10, 127-35	7
1389	Gene therapy for breast and ovarian cancer with BRCA1. 1998 , 10, 89-98	5
1388	Biological functions of the BRCA1 protein. 1998 , 10, 11-22	4
1387	What you don't know can hurt you: adverse psychologic effects in members of BRCA1-linked and BRCA2-linked families who decline genetic testing. 1998 , 16, 1650-4	219
1386	Germ-line BRCA1 mutations in women with sporadic breast cancer: clinical correlations. 1998 , 16, 115-20	30

1385	Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. 1998 , 16, 397-404	224
1384	Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. 1998 , 16, 979-85	177
1383	Prophylactic mastectomy: deliverance or delusion? We don't know, so we need to start registering all cases now. 1998 , 317, 1402-3	7
1382	Rapid sequencing of the p53 gene with a new automated DNA sequencer. 1998 , 44, 1397-1403	15
1381	Ovarian Cancer. 1998 , 7, 317-333	12
1380	Clinical Application of Tissue and Serum Markers in Breast Cancer. 1998 , 61-91	2
1379	Critical factors in the performance and cost of two-dimensional gene scanning: RB1 as a model. 1998 , 25, 664-8, 670, 672-5	10
1378	Protein partners of the BRCA1 tumor suppressor. 1998 , 10, 23-32	4
1377	Informed consent for BRCA1 and BRCA2 testing. 1998 , 10, 99-114	11
1376	The Role of Specialized Genetic Counseling for the Patient at Risk for Breast Cancer. 1998 , 5, 19-20	17
1375	Characterization of Brca1 deficient mice. 1998 , 10, 33-44	4
1374	Commentary from the patient's perspective. 1998 , 10, 137-40	4
1373	Accumulation of genetic alterations in brain metastases of sporadic breast carcinomas is associated with reduced survival after metastasis. 1998 , 18, 81-95	11
1372	Cell cycle control, checkpoint mechanisms, and genotoxic stress. 1999 , 107 Suppl 1, 5-24	180
1371	Allele frequency of D17S855 microsatellite locus in Japanese people. 1999 , 49, 61-2	4
1370	Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2. 1999 , 17, 1040-6	114
1369	Moral concerns of different types of patients in clinical BRCA1/2 gene mutation testing. 1999 , 17, 1595-600	25
1368	Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: are they prognostically different?. 1999 , 17, 3653-63	82

1367	Cancer control in susceptible groups: opportunities and challenges. 1999 , 17, 719-25	10
1366	Breast cancer in carriers of BRCA1 and BRCA2 mutations: tackling a molecular and clinical conundrum. 1999 , 17, 3367-70	11
1365	BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations. 1999 , 17, 3017-24	106
1364	Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2. 1999 , 17, 494-500	64
1363	Psychological and Behavioral Implications of Screening for Breast or Ovarian Cancer Predisposition Genes BRCA1 and BRCA2. 1999 , 12, 87-92	
1362	Cancer genetics services in Europe. 1999 , 15, 3-13	12
1361	Four years analysis of cancer genetic clinics activity in France from 1994 to 1997: a survey on 801 patients. French Cooperative Network/Groupe GÉnétique et Cancer de la Fédération Nationale des Centres de Lutte Contre le Cancer. 1999 , 15, 15-29	13
1360	Molecular cancer genetics in eastern and central Europe. 1999 , 15, 75-7	7
1359	Risk estimation as a decision-making tool for genetic analysis of the breast cancer susceptibility genes. EC Demonstration Project on Familial Breast Cancer. 1999 , 15, 53-65	7
1358	Denaturing Gradient Gel Electrophoresis-based Analysis of Loss of Heterozygosity Distinguishes Nonobvious, Deleterious BRCA1 Variants from Nonpathogenic Polymorphisms. 1999 , 45, 2028-2030	12
1357	Citrate-Theophylline-Adenine-Dipyridamol Buffer Is Preferable to Citrate Buffer as an Anticoagulant for Flow Cytometric Measurement of Platelet Activation. 1999 , 45, 2030-2033	23
1356	BRCA1 Gene Mutations in Sporadic Ovarian Carcinomas: Detection by PCR and Reverse Allele-specific Oligonucleotide Hybridization. 1999 , 45, 976-981	30
1355	Structure and expression of variant BRCA2a lacking the transactivation domain.. 1999 , 6, 437	0
1354	Prevalence of mutations in the BRCA1 gene among Chinese patients with breast cancer. 1999 , 91, 882-5	42
1353	Methylation, gene expression and the chromatin connection in cancer (review). 1999 , 4, 333-50	20
1352	Systematic sequencing of the BRCA-1 coding region for germ-line mutation detection in 70 French high-risk families. 1999 , 14, 971-7	1
1351	Identification of a 5-cM region of common allelic loss on 8p12-p21 in human breast cancer and genomic analysis of the hEXT1L/EXTR1/EXTL3 gene in this locus. 1999 , 15, 443-51	1
1350	Subcellular localization of BRCA1 protein in sporadic breast carcinoma with or without allelic loss of BRCA1 gene. 1999 , 14, 653-61	4

1349	Cancer genetic consultation and anxiety in healthy consultees. 1999 , 14, 379-390	20
1348	Tamoxifen, raloxifene, and the prevention of breast cancer. 1999 , 20, 253-78	173
1347	Introduction of a German genetic counseling program for hereditary breast and ovarian cancer. 1999 , 29, 234-6	
1346	Resistance to mammary tumorigenesis in Copenhagen rats is associated with the loss of preneoplastic lesions. 1999 , 20, 221-7	26
1345	Mammographic densities and risk of breast cancer among subjects with a family history of this disease. 1999 , 91, 1404-8	68
1344	The psychological impact of a negative BRCA1 test: a wolf in sheep's clothing?. 1999 , 1, 69-70	
1343	The assessment of genetic risk of breast cancer: a set of GP guidelines. 1999 , 16, 71-7	27
1342	Loss of heterozygosity at D14S62 and metastatic potential of breast cancer. 1999 , 91, 1391-7	22
1341	Activation of transcription in vitro by the BRCA1 carboxyl-terminal domain. 1999 , 274, 2113-7	72
1340	Hereditary cancer. 1999 , 38, 439-47	10
1339	Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. 1999 , 91, 2112-7	149
1338	Genome Scanning Detects Amplification of the Cathepsin B Gene (CtsB) in Transformed Rat Ovarian Surface Epithelial Cells. 1999 , 6, 32-40	5
1337	Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations. 1999 , 91, 469-73	85
1336	Hunting with traps: genome-wide strategies for gene discovery and functional analysis. 1999 , 9, 1019-25	27
1335	Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer. 1999 , 91, 339-46	93
1334	Synchronous inflammatory breast cancer and advanced ovarian carcinoma: a case with prolonged disease-free survival. 1999 , 10, 585-8	1
1333	Mapping the functional domains of BRCA1. Interaction of the ring finger domains of BRCA1 and BARD1. 1999 , 274, 5659-65	109
1332	NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. 1999 , 96, 214-9	262

1331	Cytogenetic Approaches to Breast Cancer. 1999 , 373-388	
1330	Cryptic intron activation within the large exon of the mouse polymeric immunoglobulin receptor gene: cryptic splice sites correspond to protein domain boundaries. 1999 , 27, 3446-54	13
1329	Gynaecological cancer. 1999 , 75, 332-8	4
1328	A highly accurate, low cost test for BRCA1 mutations. 1999 , 36, 747-53	33
1327	RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. 1999 , 96, 11364-9	945
1326	The functions of breast cancer susceptibility gene 1 (BRCA1) product and its associated proteins. 1999 , 380, 117-28	35
1325	Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations. 1999 , 52, 372-5	35
1324	Molecular biology in radiation oncology. Radiation oncology perspective of BRCA1 and BRCA2. 1999 , 38 Suppl 13, 55-9	13
1323	Genetic factors in septic shock. 1999 , 282, 579-81	20
1322	Laparoscopic Surgery. 1999 ,	1
1321	CT of epithelial ovarian tumors. 1999 , 19 Spec No, S85-102; quiz S263-4	88
1320	Cancer risks in BRCA2 mutation carriers. 1999 , 91, 1310-6	1270
1319	Bad news/good news: information about breast cancer risk following prophylactic oophorectomy. 1999 , 91, 1442-3	5
1318	A role for the GSG domain in localizing Sam68 to novel nuclear structures in cancer cell lines. 1999 , 10, 3015-33	122
1317	BRCA1 and BRCA2 and breast cancer incidence: A review. 1999 , 10, S113-S120	14
1316	Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with the androgen receptor. 1999 , 274, 8570-6	170
1315	Is there a genetic basis for lung cancer susceptibility?. 1999 , 151, 3-12	81
1314	Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. 1999 , 91, 1847-56	347

1313	Psychological issues in genetic testing for breast cancer. 1999 , 28, 73-91	9
1312	BRCA1 interacts with components of the histone deacetylase complex. 1999 , 96, 4983-8	278
1311	Heregulin induces phosphorylation of BRCA1 through phosphatidylinositol 3-Kinase/AKT in breast cancer cells. 1999 , 274, 32274-8	93
1310	BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair. 1999 , 274, 18808-12	177
1309	Transcription of BRCA1 is dependent on the formation of a specific protein-DNA complex on the minimal BRCA1 Bi-directional promoter. 1999 , 274, 31297-304	31
1308	Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. 1999 , 91, 943-9	654
1307	Underdeveloped uterus and reduced estrogen responsiveness in mice with disruption of the estrogen-responsive finger protein gene, which is a direct target of estrogen receptor alpha. 1999 , 96, 12027-32	53
1306	Evaluation of a shared decision making program for women suspected to have a genetic predisposition to breast cancer: preliminary results. 1999 , 19, 230-41	30
1305	Biological basis of genetic predisposition to breast cancer. 1999 , 2, 137-158	1
1304	Tumor suppressor genes in breast cancer. 1999 , 6, 405-19	26
1303	Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history. 1999 , 55, 318-24	45
1302	Psychological and social determinants of women's decisions to undergo genetic counseling and testing for breast cancer. 1999 , 55, 419-30	80
1301	Isolation, purification and quantification of BRCA1 protein from tumour cells by affinity perfusion chromatography. 1999 , 721, 163-70	9
1300	Dealing with the uncertainty of developing a cancer. 1999 , 8, 233-7	6
1299	The genetic basis of breast cancer and its clinical implications. 1999 , 69, 95-105	21
1298	Immunolocalization of BRCA1 protein in normal breast tissue and sporadic invasive ductal carcinomas: a correlation with other biological parameters. 1999 , 34, 106-12	50
1297	Expression and function of BRCA1 and BRCA2 in familial and sporadic breast cancer. 1999 , 34, 170-4	5
1296	Atypical lobular hyperplasia and lobular carcinoma in situ: surgical and molecular pathology. 1999 , 35, 195-200	37

1295	A mirage of genes. 1999 , 21, 228-241	46
1294	Doing the right thing: genetic risk and responsibility. 1999 , 21, 597-621	213
1293	Laboratory identification of hereditary risk of breast and ovarian cancer. 1999 , 10, 289-94	4
1292	Hormonal prevention of breast cancer: proposal for a change in paradigm. 1999 , 106, 1006-18	15
1291	The human genome project and the future of medicine. 1999 , 882, 42-55; discussion 56-65	39
1290	BRCA 1/2 gene mutation testing-based cancer prevention and the moral concerns of different types of patients. 1999 , 889, 240-3	3
1289	Oncogenetic information in the hands of physicians and the preventive options of persons who are not their patients. 1999 , 889, 256-61	
1288	Mutational analysis of beta-catenin gene in Japanese ovarian carcinomas: frequent mutations in endometrioid carcinomas. 1999 , 90, 510-5	65
1287	Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. 1999 , 21, 236-40	348
1286	Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. 1999 , 22, 37-43	640
1285	The second BRCT domain of BRCA1 proteins interacts with p53 and stimulates transcription from the p21WAF1/CIP1 promoter. 1999 , 18, 263-8	149
1284	Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. 1999 , 18, 1957-65	286
1283	Refined mapping of the region of loss of heterozygosity on the long arm of chromosome 7 in human breast cancer defines the location of a second tumor suppressor gene at 7q22 in the region of the CUTL1 gene. 1999 , 18, 2015-21	46
1282	Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions. 1999 , 18, 2451-9	83
1281	Disabled-2 inactivation is an early step in ovarian tumorigenicity. 1999 , 18, 3104-13	117
1280	Identification of a 3 kb Alu-mediated BRCA1 gene rearrangement in two breast/ovarian cancer families. 1999 , 18, 4160-5	85
1279	Overexpression of the Tpl-2/Cot oncogene in human breast cancer. 1999 , 18, 4968-73	71
1278	Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. 1999 , 18, 5221-31	129

1277	Overexpression of BRCA2 gene in sporadic breast tumours. 1999 , 18, 5232-8	58
1276	Conserved BRCT regions of TopBP1 and of the tumor suppressor BRCA1 bind strand breaks and termini of DNA. 1999 , 18, 5194-203	71
1275	The Brn-3b POU family transcription factor represses expression of the BRCA-1 anti-oncogene in breast cancer cells. 1999 , 18, 6684-91	62
1274	Gamma-rays-induced death of human cells carrying mutations of BRCA1 or BRCA2. 1999 , 18, 7334-42	122
1273	BRCA1 signals ARF-dependent stabilization and coactivation of p53. 1999 , 18, 6605-14	62
1272	BRCA1 deficient embryonic stem cells display a decreased homologous recombination frequency and an increased frequency of non-homologous recombination that is corrected by expression of a brca1 transgene. 1999 , 18, 7900-7	168
1271	BRCA1 mutations and other sequence variants in a population-based sample of Australian women with breast cancer. 1999 , 79, 34-9	69
1270	Allelotype influence at glutathione S-transferase M1 locus on breast cancer susceptibility. 1999 , 79, 346-53	37
1269	Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas. 1999 , 79, 754-8	60
1268	Identification of a C/G polymorphism in the promoter region of the BRCA1 gene and its use as a marker for rapid detection of promoter deletions. 1999 , 79, 759-63	7
1267	The impact of genetic counselling on risk perception and mental health in women with a family history of breast cancer. 1999 , 79, 868-74	204
1266	Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2. 1999 , 79, 1475-8	44
1265	Loss of heterozygosity and microsatellite instability in hepatocellular carcinoma in Taiwan. 1999 , 80, 468-76	59
1264	Frequent allelic losses at 11q24.1-q25 in young women with breast cancer: association with poor survival. 1999 , 80, 843-9	25
1263	A polymorphism in the CYP17 gene is associated with male breast cancer. 1999 , 81, 141-3	68
1262	BRCA1, BRCA2 and their possible function in DNA damage response. 1999 , 81, 1099-102	18
1261	Genetic alterations on chromosome 16 and 17 are important features of ductal carcinoma in situ of the breast and are associated with histologic type. 1999 , 81, 1410-8	88
1260	Frequency of BRCA1 mutation 5382insC in German breast cancer patients. 1999 , 72, 402-6	53

1259	BRCA1-related and sporadic ovarian cancer in the same family: implications for genetic testing. 1999 , 75, 468-72	5
1258	Molecular genetics of breast cancer progression. 1999 , 9, 277-88	73
1257	Comparison of alterations of chromosome 17 in carcinoma of the ovary and of the breast. 1999 , 434, 517-22	7
1256	Sperm artificially exposed to antisperm antibodies show altered deoxyribonucleic acid. 1999 , 16, 443-9	1
1255	BRCA1 and BRCA2 in breast cancer. 1999 , 54, 1-10	55
1254	Antiestrogens--tamoxifen, SERMs and beyond. 1999 , 17, 285-311	91
1253	Reproductive factors in hereditary breast cancer. 1999 , 58, 295-301	13
1252	Sequence analysis of the rat Brca1 homolog and its promoter region. 1999 , 10, 19-25	19
1251	P. Meera Khan (1935-1998). 1999 , 78, 63-70	
1250	Die genetischen Grundlagen erblicher Tumorkrankheiten des Menschen. 1999 , 5, 855-866	3
1249	The 1999 James Ewing Lecture: in pursuit of molecules of oncogenesis and neoplastic therapy. 1999 , 6, 528-41	2
1248	Molecular characterization of germline mutations in the BRCA1 and BRCA2 genes from breast cancer families in Taiwan. 1999 , 104, 201-4	53
1247	BRCA1 mutations in African Americans. 1999 , 105, 28-31	19
1246	BRCA1 mutations in African Americans. 1999 , 105, 28-31	49
1245	A comparison of BRCA1 mutation analysis by direct sequencing, SSCP and DHPLC. 1999 , 105, 72-8	157
1244	Mutation analysis of the BRCA1 gene in Japanese patients with sporadic ovarian cancer. 1999 , 4, 348-352	
1243	Germ-line TP53 mutations in Finnish cancer families exhibiting features of the Li-Fraumeni syndrome and negative for BRCA1 and BRCA2. 1999 , 112, 9-14	18
1242	Mutation analysis of BRCA1, TP53, and KRAS2 in ovarian and related pelvic tumors. 1999 , 112, 105-18	22

1241	Classification of IVS1-10T-->C as a polymorphism of BRCA1. 1999 , 113, 58-64	7
1240	Isolation and characterization of a novel human gene (HFB30) which encodes a protein with a RING finger motif. 1999 , 1445, 232-6	7
1239	Cloning and expression profile of mouse and human genes, Rnf11/RNF11, encoding a novel RING-H2 finger protein. 1999 , 1489, 421-7	20
1238	Knowledge discovery in gene-expression-microarray data: mining the information output of the genome. 1999 , 17, 429-36	61
1237	BRCA-associated cancer risk: molecular biology and clinical practice. 1999 , 134, 11-8	4
1236	A note on the relevance of human population genetic variation and molecular epidemiology to assessing radiation health risk for space travellers. 1999 , 430, 293-8	3
1235	Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening. 1999 , 180, 917-28	105
1234	Hereditary endocrinopathies. 1999 , 36, 653-762	17
1233	Epithelial ovarian cancer. 1999 , 36, 1-53	11
1232	Molecular diagnostics of cancer predisposition: hereditary non-polyposis colorectal carcinoma and mismatch repair defects. 1999 , 1423, O1-O10	20
1231	Familial associations between cancer sites. 1999 , 32, 517-29	20
1230	Emerging roles of BRCA1 in transcriptional regulation and DNA repair. 1999 , 181, 385-92	56
1229	A new L771L polymorphism in the BRCA1 gene frequently found in southern Italy. 1999 , 13, 85-85	
1228	Mutation analysis of the BRCA1 and BRCA2 genes results in the identification of novel and recurrent mutations in 6/16 Flemish families with breast and/or ovarian cancer but not in 12 sporadic patients with early-onset disease. Mutations in brief no. 224. Online. 1999 , 13, 256	12
1227	Mutation in the coding region of the BRCA1 gene leads to aberrant splicing of the transcript. 1999 , 14, 540-1	11
1226	A somatic BRCA2 mutation in RER+ endometrial carcinomas that specifically deletes the amino-terminal transactivation domain. 1999 , 24, 207-12	20
1225	Loss of markers linked to BRCA1 precedes loss at important cell cycle regulatory genes in epithelial ovarian cancer. 1999 , 25, 65-9	5
1224	Linkage analysis and loss of heterozygosity for chromosome arm 1p in familial breast cancer. 1999 , 25, 354-361	10

1223	Allelic loss at 1p34, 13q12, 17p13.3, and 17q21.1 correlates with poor postoperative prognosis in breast cancer. 1999 , 26, 134-141	21
1222	Inclusion of risk factor covariates in a segregation analysis of a population-based sample of 426 breast cancer families. 1999 , 16, 150-64	2
1221	Increased cancer risk among relatives of nonsmoking lung cancer cases. 1999 , 17, 1-15	27
1220	Inhibition of BRCA-1 expression by benzo[a]pyrene and its diol epoxide. 1999 , 26, 100-18	29
1219	Clinicopathologic analysis of BRCA1- or BRCA2-associated hereditary breast carcinoma in Japanese women. 1999 , 85, 2200-2205	61
1218	Inherited genetic predisposition in breast cancer. A population-based perspective. 1999 , 86, 2493-501	41
1217	Managing hereditary ovarian cancer risk. 1999 , 86, 2517-24	28
1216	BRCA1 gene mutation and loss of heterozygosity on chromosome 17q21 in primary prostate cancer. 1999 , 84, 19-23	20
1215	Quantification of BRCA1 protein in sporadic breast carcinoma with or without loss of heterozygosity of the BRCA1 gene. 1999 , 80, 823-6	41
1214	BRCA1 and BRCA2 proteins are expressed in milk fat globules. 1999 , 81, 839-43	6
1213	BRCA1 expression levels predict distant metastasis of sporadic breast cancers. 1999 , 84, 258-62	51
1212	Germline brca2 sequence variants in patients with ocular melanoma. 1999 , 82, 325-8	40
1211	BRCA1 and BRCA2 genes: role in hereditary breast and ovarian cancer in Italy. 1999 , 83, 5-9	38
1210	BRCA1 mutation analysis in 83 Spanish breast and breast/ovarian cancer families. 1999 , 83, 465-9	22
1209	BRCA1 IVS16+6T->C is a deleterious mutation that creates an aberrant transcript by activating a cryptic splice donor site. 1999 , 85, 113-116	16
1208	No evidence for a role of BRCA1 or BRCA2 mutations in Ashkenazi Jewish families with hereditary prostate cancer. 1999 , 39, 280-4	42
1207	Coordinate alterations in the expression of BRCA1, BRCA2, p300, and Rad51 in response to genotoxic and other stresses in human prostate cancer cells. 1999 , 40, 37-49	29
1206	The pathology of familial breast cancer: Clinical and genetic counselling implications of breast cancer pathology. 1999 , 1, 48-51	8

1205	The pathology of familial breast cancer: How do the functions of BRCA1 and BRCA2 relate to breast tumour pathology?. 1999 , 1, 41-7		13
1204	The pathology of familial breast cancer: Morphological aspects. 1999 , 1, 31-5		58
1203	BRCA1 partially reverses the transforming activity of the ras oncogene. 1999 , 1, 417-23		
1202	Shattuck lecture--medical and societal consequences of the Human Genome Project. 1999 , 341, 28-37		578
1201	Genetic testing for breast cancer predisposition. 1999 , 79, 1171-87, xxi		5
1200	BRCA1 inhibition of estrogen receptor signaling in transfected cells. <i>Science</i> , 1999 , 284, 1354-6	33.3	394
1199	Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. <i>Science</i> , 1999 , 285, 747-50	33.3	531
1198	BRCA1 screening in patients with a family history of breast or ovarian cancer. 1999 , 3, 223-6		7
1197	Primary carcinoma of the peritoneum masquerading as ovarian malignancy. 1999 , 19, 675		
1196	The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. 1999 , 64, 963-70		181
1195	Evidence for effective suppression of recombination in the chromosome 17q21 segment spanning RNU2-BRCA1. 1999 , 64, 1427-39		33
1194	A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington disease. 1999 , 64, 1293-304		214
1193	Evidence for a BRCA1 founder mutation in families of West African ancestry. 1999 , 65, 575-8		45
1192	Transmitting genetic risk information in families: attitudes about disclosing the identity of relatives. 1999 , 65, 902-9		24
1191	The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes. 1999 , 65, 1021-9		109
1190	A critical evaluation of the process of cancer genetic counselling: From research-based investigation to clinical diagnosis. 1999 , 3, 96-101		1
1189	Chromosomal abnormality in hepatocellular carcinoma by comparative genomic hybridisation in Taiwan. 1999 , 35, 652-8		50
1188	Mutation analysis of BRCA1 and BRCA2 in Turkish cancer families: a novel mutation BRCA2 3414del4 found in male breast cancer. 1999 , 35, 707-10		18

1187	Loss of heterozygosity at chromosome 13q in hepatocellular carcinoma: identification of three independent regions. 1999 , 35, 1730-4	77
1186	Screening for hereditary cancer and genetic testing, epitomized by breast cancer. 1999 , 35, 1954-62	14
1185	Needle-in-a-haystack detection and identification of base substitution mutations in human tissues. 1999 , 406, 79-100	14
1184	A characterization of genetic variants in BRCA1 intron 8 identifies a mutation and a polymorphism. 1999 , 406, 101-7	4
1183	BRCA1 and BRCA2 gene mutations and risk of breast cancer. Public health perspectives. 1999 , 16, 91-8	37
1182	HRT and cancer risk: separating fact from fiction. 1999 , 33 Suppl 1, S65-72	6
1181	Differences between hereditary and sporadic ovarian cancer. 1999 , 82, 151-3	13
1180	Genetic susceptibility testing and prophylactic oophorectomy. 1999 , 82, 159-64	3
1179	Genetic testing of breast and ovarian cancer patients: clinical characteristics and hormonal risk modifiers. 1999 , 85, 75-80	10
1178	Is TP53 dysfunction required for BRCA1-associated carcinogenesis?. 1999 , 155, 143-52	48
1177	Two contiguously located germline BRCA1 mutations in a Spanish early-onset breast cancer family. 1999 , 142, 71-3	1
1176	Defining biochemical functions for the BRCA1 tumor suppressor protein: analysis of the BRCA1 binding protein BAP1. 1999 , 143 Suppl 1, S13-7	30
1175	The Molecular and Cellular Basis of Radiosensitivity: Implications for Understanding How Normal Tissues and Tumors Respond to Therapeutic Radiation. 1999 , 17, 56-72	84
1174	Genetic analysis of familial and multiple malignancies of endometrial cancer. 1999 , 66, 149-53	
1173	Characterization of the BRCA1-like immunoreactivity of human seminal plasma. 1999 , 54, 753-62	1
1172	Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. 1999 , 97, 575-86	493
1171	Phenotypic characteristics of early-onset autosomal-dominant type 2 diabetes unlinked to known maturity-onset diabetes of the young (MODY) genes. 1999 , 22, 253-61	44
1170	Widespread B29 (CD79b) gene defects and loss of expression in chronic lymphocytic leukemia. 1999 , 32, 561-9	17

1169	A rapid and sensitive approach to mutation detection using real-time polymerase chain reaction and melting curve analyses, using BRCA1 as an example. 1999 , 4, 241-6	23
1168	Session 1: Summary of clinical issues. 1999 , 6, S267-S277	
1167	An alternative medicine study of herbal effects on the penetration of zona-free hamster oocytes and the integrity of sperm deoxyribonucleic acid. 1999 , 71, 517-22	55
1166	Substrate specificities and identification of putative substrates of ATM kinase family members. 1999 , 274, 37538-43	575
1165	Positive regulation of the BRCA1 promoter. 1999 , 274, 8837-43	39
1164	Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21. 1999 , 59, 59-65	626
1163	Construction of a detailed physical and transcript map of the FTDP-17 candidate region on chromosome 17q21. 1999 , 60, 129-36	7
1162	Human aiolos, an ikaros-related zinc finger DNA binding protein: cDNA cloning, tissue expression pattern, and chromosomal mapping. 1999 , 61, 326-9	19
1161	Identification and validation of tumor suppressor genes. 1999 , 2, 1-10	11
1160	BRCA1 mutations in familial ovarian cancer. 1999 , 67, 357-63	13
1159	Prolactin-dependent up-regulation of BRCA1 expression in human breast cancer cell lines. 1999 , 258, 284-91	30
1158	Casein kinase 2 binds to and phosphorylates BRCA1. 1999 , 260, 658-64	41
1157	Promoting cancer screening among the first-degree relatives of breast and colorectal cancer patients: the design of two randomized trials. 1999 , 28, 229-42	17
1156	Bilateral prophylactic mastectomy decision making: A vignette study. 1999 , 29, 216-21	30
1155	Genetic Testing in Familial Breast Cancer: A Pandora's Box?. 1999 , 21, 787-794	
1154	Testing for Hereditary Risk of Ovarian Cancer. 1999 , 6, 327-334	12
1153	French physicians' knowledge about hereditary breast/ovarian cancer: the need for continuing vocational training in genetics. 1999 , 2, 165-72	4
1152	CHAPTER 5.4 Finding liability genes for schizophrenia. 1999 , 13, 805-819	

1151	Chapter 5 Molecular biology of prostate cancer. 1999 , 85-122	1
1150	Contrast detail detectability of a full-field digital mammography system. 1999 , 3595, 186	
1149	Familial gastric cancer in the Japanese population is frequently located at the cardiac region. 1999 , 20, 235-41	7
1148	Assessing risk of breast cancer. 1999 , 105, 49-58	5
1147	A history of cancer of the male breast. 1999 , 2, 229-243	1
1146	BRCA1 is phosphorylated at serine 1497 in vivo at a cyclin-dependent kinase 2 phosphorylation site. 1999 , 19, 4843-54	96
1145	Survival in hereditary breast cancer associated with germline mutations of BRCA2. 1999 , 17, 3396-402	153
1144	Growth retardation, DNA repair defects, and lack of spermatogenesis in BRCA1-deficient mice. 1999 , 19, 7061-75	90
1143	Investigation of single-strand conformational polymorphism of the TP53 gene in women with a family history of breast cancer. 2000 , 33, 1325-8	
1142	Benefits and Costs of Genetic Screening for Breast Cancer. 2000 , 3, 190-192	
1141	Frequency of microsatellite instability in Breast cancer determined by high-resolution fluorescent microsatellite analysis. 2000 , 59, 44-9	35
1140	Distress and psychiatric morbidity among women from high-risk breast and ovarian cancer families.. 2000 , 68, 864-874	107
1139	Indole-3-carbinol is a negative regulator of estrogen receptor-alpha signaling in human tumor cells. 2000 , 130, 2927-31	86
1138	Interactions of the Nijmegen breakage syndrome protein with ATM and BRCA1. 2000 , 65, 535-45	7
1137	Psychological adjustment of women at increased risk of developing hereditary breast cancer. 2000 , 5, 377-388	27
1136	Testing for hereditary breast and ovarian cancer in the southeastern United States. 2000 , 231, 624-34	13
1135	Recent advances in breast cancer biology. 2000 , 12, 521-5	4
1134	Evaluation and treatment of BRCA-positive patients. 2000 , 105, 714-9	6

1133	Primary care physicians' knowledge and attitudes towards genetic testing for breast-ovarian cancer predisposition. 2000 , 11, 1131-5	66
1132	Well-differentiated villoglandular adenocarcinoma of the uterine cervix: oncogene/tumor suppressor gene alterations and human papillomavirus genotyping. 2000 , 19, 110-7	44
1131	Loss of heterozygosity on chromosome 17q in epithelial ovarian tumors: association with carcinomas with serous differentiation. 2000 , 19, 152-7	21
1130	A comparison of methods currently used in clinical practice to estimate familial breast cancer risks. 2000 , 11, 451-4	13
1129	Ongoing research to identify environmental risk factors in breast carcinoma. 2000 , 88, 1224-1229	53
1128	Rnf4, a RING protein expressed in the developing nervous and reproductive systems, interacts with Gscl, a gene within the DiGeorge critical region. 2000 , 218, 102-11	28
1127	Detection of BRCA1 and BRCA2 mutations in breast cancer families by a comprehensive two-stage screening procedure. 2000 , 85, 474-81	23
1126	BRCA2 protein expression in sporadic breast carcinoma with or without allelic loss of BRCA2. 2000 , 86, 453-6	4
1125	Attitudes toward the genetic testing of children among adults in a Utah-based kindred tested for a BRCA1 mutation. 2000 , 92, 25-32	38
1124	A new BRCA1 germline mutation (E879X) in a Malaysian breast cancer patient of Chinese descent. 2000 , 15, 485	2
1123	Assessing changes in ages at onset over successive generation: an application to breast cancer. 2000 , 18, 17-32	12
1122	Human DNA sequence polymorphisms: New opportunities for drug discovery and customized patient care. 2000 , 49, 46-53	
1121	Genes implicated in hereditary breast cancer syndromes. 2000 , 18, 281-6	20
1120	Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. 2000 , 18, 287-95	114
1119	Clinical management of BRCA1- and BRCA2-associated breast cancer. 2000 , 18, 296-304	8
1118	Psychosocial aspects of cancer genetics: women at high risk for breast and ovarian cancer. 2000 , 18, 333-8	36
1117	. 2000 , 89, 2006-2017	20
1116	Ovarian and breast cancer risks to women in families with two or more cases of ovarian cancer. 2000 , 87, 110-7	54

1115	SSA/RO52 gene and expressed sequence tags in an 85 kb region of chromosome segment 11p15.5. 2000 , 87, 61-7	4
1114	Frequent loss of BRCA1 mRNA and protein expression in sporadic ovarian cancers. 2000 , 87, 317-21	77
1113	Abnormal expression of BRCA1 and BRCA1-interactive DNA-repair proteins in breast carcinomas. 2000 , 88, 28-36	82
1112	Association between loss of heterozygosity of BRCA1 and BRCA2 and morphological attributes of sporadic breast cancer. 2000 , 88, 204-208	23
1111	Differential expression and subcellular localization of murine BRCA1 and BRCA1-delta 11 isoforms in murine and human cell lines. 2000 , 88, 519-24	11
1110	Retinoids and ovarian cancer. 2000 , 185, 1-20	73
1109	Roles of BRCA1 and its interacting proteins. 2000 , 22, 728-37	225
1108	The puzzling multiple lives of PML and its role in the genesis of cancer. 2000 , 22, 827-35	46
1107	The breast cancer information core: database design, structure, and scope. 2000 , 16, 123-31	158
1106	BRCA1 mutation analysis in breast/ovarian cancer families from Greece. 2000 , 16, 272-3	26
1105	Direct genomic multiplex PCR for BRCA1 and application to mutation detection by single-strand conformation and heteroduplex analysis. 2000 , 16, 334-44	8
1104	Hierarchical mutation screening protocol for the BRCA1 gene. 2000 , 16, 422-30	2
1103	High frequency of recurrent mutations in BRCA1 and BRCA2 genes in Polish families with breast and ovarian cancer. 2000 , 16, 482-90	37
1102	Two identical triplet sisters carrying a germline BRCA1 gene mutation acquire very similar breast cancer somatic mutations at multiple other sites throughout the genome. 2000 , 28, 359-69	19
1101	Multiple copies of mutant BRCA1 and BRCA2 alleles in breast tumors from germ-line mutation carriers. 2000 , 28, 432-42	26
1100	Genetic epidemiology with a capital "E". 2000 , 19, 289-300	37
1099	Prophylactic oophorectomy: clinical considerations. 2000 , 19, 20-7	13
1098	Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines. 2000 , 28, 236-46	34

1097	A qualitative study of the information needs of high-risk women undergoing prophylactic oophorectomy. 2000 , 9, 486-95	65
1096	Uptake of hereditary breast/ovarian cancer genetic testing in a French national sample of BRCA1 families. The French Cancer Genetic Network. 2000 , 9, 504-10	44
1095	The psychological consequences of offering mutation searching in the family for those at risk of hereditary breast and ovarian cancer--a pilot study. 2000 , 9, 537-48	33
1094	Perceptions of Ashkenazi Jewish breast cancer patients on genetic testing for mutations in BRCA1 and BRCA2. 2000 , 57, 376-83	39
1093	Cancer worries, risk perceptions and associations with interest in DNA testing and clinic satisfaction in a familial colorectal cancer clinic. 2000 , 58, 460-8	53
1092	Searching high and low: a review of the genetics of bipolar disorder. 2000 , 2, 8-26	57
1091	High suicidal ideation in persons testing for Huntington's disease. 2000 , 102, 150-61	54
1090	Prevention of breast cancer. 2000 , 33, 221-38	6
1089	Monte Carlo Markov chain methods and model selection in genetic epidemiology. 2000 , 32, 349-360	1
1088	MALDI-TOF based mutation detection using tagged in vitro synthesized peptides. 2000 , 18, 95-7	20
1087	Brca1 required for T cell lineage development but not TCR loci rearrangement. 2000 , 1, 77-82	69
1086	Adaptive evolution of the tumour suppressor BRCA1 in humans and chimpanzees. Australian Breast Cancer Family Study. 2000 , 25, 410-3	98
1085	Pointing (zinc) fingers at BRCA1 targets. 2000 , 6, 1318-9	6
1084	Laminin-rich extracellular matrix association with mammary epithelial cells suppresses Brca1 expression. 2000 , 7, 360-7	11
1083	Predictive testing for hereditary breast and ovarian cancer: a psychological framework for pre-test counselling. 2000 , 8, 130-6	30
1082	Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland. 2000 , 8, 757-63	64
1081	Role of the tumor suppressor gene Brca1 in genetic stability and mammary gland tumor formation. 2000 , 19, 1059-64	128
1080	Allelotyping defines minimal imbalance at chromosomal region 17q25 in non-serous epithelial ovarian cancers. 2000 , 19, 1466-72	22

1079	Retinoblastoma susceptibility protein, Rb, possesses multiple BRCT-Ws, BRCA1 carboxyl-terminus-related W regions with DNA break-binding activity. 2000 , 19, 1982-91	10
1078	Initiation of translation from a downstream in-frame AUG codon on BRCA1 can generate the novel isoform protein DeltaBRCA1(17aa). 2000 , 19, 2767-73	20
1077	Mlx, a new Max-like bHLHZip family member: the center stage of a novel transcription factors regulatory pathway?. 2000 , 19, 3266-77	64
1076	Absence of evidence for a familial breast cancer susceptibility gene at chromosome 8p12-p22. 2000 , 19, 4170-3	32
1075	BRCA1 activation of the GADD45 promoter. 2000 , 19, 4050-7	83
1074	The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression. 2000 , 19, 5091-7	83
1073	Lessons learned from BRCA1 and BRCA2. 2000 , 19, 6159-75	134
1072	DNA polymerase stalling, sister chromatid recombination and the BRCA genes. 2000 , 19, 6176-83	65
1071	BRCA1 and cell signaling. 2000 , 19, 6152-8	69
1070	Transactivation of the p21 promoter by BRCA1 splice variants in mammary epithelial cells: evidence for both common and distinct activities of wildtype and mutant forms. 2000 , 19, 6351-60	17
1069	hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. 2000 , 404, 201-4	453
1068	The transcriptional role of PML and the nuclear body. 2000 , 2, E85-90	465
1067	In search of the tumour-suppressor functions of BRCA1 and BRCA2. 2000 , 408, 429-32	547
1066	Screening of BRCA1 mutation using immunohistochemical staining with C-terminal and N-terminal antibodies in familial ovarian cancers. 2000 , 91, 399-409	13
1065	BRCA1 expression status in relation to DNA methylation of the BRCA1 promoter region in sporadic breast cancers. 2000 , 91, 519-26	44
1064	Preferential occurrence of breast carcinomas with loss of chromosome 16q and der (16) t (1;16) / der (1;16) in middle-aged patients with hyperplasia of mammary glands. 2000 , 91, 692-9	4
1063	p53 and WAF1 polymorphisms in Jewish-Israeli women with epithelial ovarian cancer and its association with BRCA mutations. 2000 , 107, 849-54	10
1062	Breast cancer genetics and the role of tamoxifen in prevention. 2000 , 12, 21-8; quiz 29-31	1

1061	The psychological complexity of predictive testing for late onset neurogenetic diseases and hereditary cancers: implications for multidisciplinary counselling and for genetic education. 2000 , 51, 831-41	92
1060	BRCA1: exploring the links to transcription. 2000 , 25, 469-74	75
1059	Immunohistochemical detection of a germline BRCA1 mutation in a breast and ovarian cancer family. 2000 , 9, 286-91	2
1058	Management of the contralateral breast in patients with hereditary breast cancer. 2000 , 9, 301-5	2
1057	The management of familial breast cancer. 2000 , 9, 247-63	16
1056	Insights into the functions of BRCA1 and BRCA2. 2000 , 16, 69-74	260
1055	Ionizing radiation and genetic risks. XII. The concept of "potential recoverability correction factor" (PRCF) and its use for predicting the risk of radiation-inducible genetic disease in human live births. 2000 , 453, 129-81	10
1054	Role of Gadd45 in apoptosis. 2000 , 59, 43-5	159
1053	Familial aggregation of dyslexia phenotypes. 2000 , 30, 385-96	55
1052	Breast cancer screening uptake in women at increased risk of developing hereditary breast cancer. 2000 , 59, 101-11	44
1051	Survival and tumor characteristics of German hereditary breast cancer patients. 2000 , 59, 185-92	42
1050	Management of familial breast cancer risk. 2000 , 62, 19-33	10
1049	Influence of chemically modified tetracyclines on proliferation, invasion and migration properties of MDA-MB-468 human breast cancer cells. 2000 , 18, 139-46	22
1048	Patient Motivation, Satisfaction, and Coping in Genetic Counseling and Testing for BRCA1 and BRCA2. 2000 , 9, 219-35	39
1047	Immunohistochemical versus molecular detection of RAK antigens in breast cancer. 2000 , 69, 27-36	3
1046	BRCA1: what do we know? What do we think we know? What do we really need to know?. 2000 , 76, 291-3	2
1045	Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds. 2000 , 78, 278-87	51
1044	Preclinical studies of a new generation retroviral vector for ovarian cancer BRCA1 gene therapy. 2000 , 79, 471-6	16

1043	Hereditary breast cancer: a review. 2000 , 10, 271-88	40
1042	Transcriptional analysis of the 69-kb sequence centromeric to HLA-J: a dense and complex structure of five genes. 2000 , 11, 1127-31	9
1041	Simultaneous breast cancer in non-identical Ashkenazi Jewish twins: management dilemmas when genetic testing is negative. 2000 , 12, 305-8	
1040	Identification of a founder BRCA2 mutation in Sardinia. 2000 , 82, 553-9	34
1039	Molecular analysis of the BRCA1 and BRCA2 genes in 32 breast and/or ovarian cancer Spanish families. 2000 , 82, 1266-70	70
1038	Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. 2000 , 83, 1301-8	501
1037	Loss of heterozygosity in bilateral breast cancer. 2000 , 64, 241-51	32
1036	Mutation detection in the breast cancer gene BRCA1 using the protein truncation test. 2000 , 14, 89-97	3
1035	Breast cancer prevention trials. 2000 , 2, 558-65	12
1034	An epistatic interaction controls the latency of a transgene-induced mammary tumor. 2000 , 11, 883-9	46
1033	Suppression of breast cancer invasion and migration by indole-3-carbinol: associated with up-regulation of BRCA1 and E-cadherin/catenin complexes. 2000 , 78, 155-65	102
1032	Enhanced detection of mutations in BRCA1 exon 11 using restriction endonuclease fingerprinting-single-strand conformation polymorphism. 2000 , 78, 580-7	2
1031	Current national health insurance coverage policies for breast and ovarian cancer prophylactic surgery. 2000 , 7, 325-32	24
1030	BRCA1 and BRCA2--breast cancer susceptibility genes. 2000 , 126, 487-96	29
1029	Prevalence of BRCA1 and BRCA2 mutations among clinic-based African American families with breast cancer. 2000 , 107, 186-91	89
1028	cDNA cloning, expression profile, and genomic structure of human and mouse RNF10/Rnf 10 genes, encoding a novel RING finger protein. 2000 , 45, 38-42	11
1027	Identification of Rad51 alteration in patients with bilateral breast cancer. 2000 , 45, 133-7	79
1026	Inherited Genetic Susceptibility and Breast Cancer. 2000 , 884-894	

1025	CEL I enzymatic mutation detection assay. 2000 , 29, 44-6, 48	51
1024	Modified primers facilitate rapid screening of 16S rRNA gene libraries. 2000 , 29, 48-50	9
1023	Adaptation of conformation-sensitive gel electrophoresis to an ALFexpress DNA sequencer to screen BRCA1 mutations. 2000 , 28, 1019-25	10
1022	Construction of macromolecular assemblages in eukaryotic processes and their role in human disease: linking RINGs together. 2000 , 1, 49-73	30
1021	Intention to undergo prophylactic bilateral mastectomy in women at increased risk of developing hereditary breast cancer. 2000 , 18, 2250-7	104
1020	Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer. 2000 , 18, 1980-95	110
1019	Familial invasive breast cancers: worse outcome related to BRCA1 mutations. 2000 , 18, 4053-9	154
1018	Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. 2000 , 18, 3360-9	229
1017	Hereditary nonpolyposis colorectal cancer: a call for attention. 2000 , 18, 2189-92	9
1016	Genetics and the Multidisciplinary Breast Center. 2000 , 9, 367-396	1
1015	The Impact of Presymptomatic Molecular Testing in Hereditary Cancers. 2000 , 9, 221-248	
1014	Testing for Hereditary Risk of Breast and Ovarian Cancer. 2000 , 3, 193-197	
1013	Ovarian Cancer. 2000 ,	3
1012	Collaboration of signal transducer and activator of transcription 1 (STAT1) and BRCA1 in differential regulation of IFN-gamma target genes. 2000 , 97, 5208-13	185
1011	Why do women attend familial breast cancer clinics?. 2000 , 37, 197-202	84
1010	A common polymorphism associated with antibiotic-induced cardiac arrhythmia. 2000 , 97, 10613-8	411
1009	Genetic susceptibility to breast cancer: HLA DQB*03032 and HLA DRB1*11 may represent protective alleles. 2000 , 97, 11451-4	59
1008	BRCA1 physically and functionally interacts with ATF1. 2000 , 275, 36230-7	46

1007	Identification and characterization of human DNA polymerase beta 2, a DNA polymerase beta-related enzyme. 2000 , 275, 31233-8	53
1006	Mosaicism for a dup(12)(q22q13) in a patient with hypomelanosis of Ito and asymmetry. 2000 , 37, 804-7	5
1005	BRCA1 facilitates stress-induced apoptosis in breast and ovarian cancer cell lines. 2000 , 275, 33487-96	110
1004	Identification of a functional nuclear export sequence in BRCA1. 2000 , 275, 38589-96	118
1003	BRCA1 effects on the cell cycle and the DNA damage response are linked to altered gene expression. 2000 , 275, 2777-85	162
1002	Unexpected high frequency of de novo unbalanced translocations in patients with Wolf-Hirschhorn syndrome (WHS). 2000 , 37, 798-804	37
1001	Nuclear localization and cell cycle-specific expression of CtIP, a protein that associates with the BRCA1 tumor suppressor. 2000 , 275, 18541-9	123
1000	Prevalence of BRCA1 in a hospital-based population of Dutch breast cancer patients. 2000 , 83, 719-24	31
999	BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients. 2000 , 83, 737-42	40
998	An evaluation of needs of female BRCA1 and BRCA2 carriers undergoing genetic counselling. 2000 , 37, 866-74	78
997	Attitudes to genetic testing for breast cancer susceptibility in women at increased risk developing hereditary breast cancer. 2000 , 37, 472-6	31
996	The mitochondrial genome in Wolfram syndrome. 2000 , 37, 463-6	29
995	Characterization of a novel trans-activation domain of BRCA1 that functions in concert with the BRCA1 C-terminal (BRCT) domain. 2000 , 275, 40910-5	35
994	Establishment of a radiation- and estrogen-induced breast cancer model. 2000 , 21, 769-76	60
993	Randomized trial of a specialist genetic assessment service for familial breast cancer. 2000 , 92, 1345-51	81
992	Influence of menstrual and reproductive factors on ovarian cancer risk in women with and without family history of breast or ovarian cancer. 2000 , 29, 799-802	45
991	BRCA1 and E-cadherin promoter hypermethylation and gene inactivation in cancer-association or mechanism?. 2000 , 92, 515-7	30
990	Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review). 2000 , 16, 567-76	63

989	Patterns of allelic loss at the BRCA1 locus in Arabic women with breast cancer. 2000 , 6, 565-9	7
988	Familial breast and ovarian cancer: a Swedish population-based register study. 2000 , 152, 1154-63	55
987	Familial ovarian cancer. 2001 , 39, 13-24	1
986	Familiärer Brustkrebs: 2-Stufen-Gendiagnostik zum Nachweis von BRCA1- und BRCA2-Mutationen in Risikofamilien - A Two-stage Test to Identify BRCA-1 and BRCA-2 Mutations in High-risk Families -. 2000 , 60, 326-332	
985	Molecular genetics of ovarian cancer : a technical overview. 2001 , 39, 273-90	
984	Endocrine Oncology. 2000 ,	
983	Genetic Susceptibility and Survival: Application to Breast Cancer. 2000 , 95, 28-42	15
982	Interest in a Support Group Among Individuals Tested for a BRCA1 Gene Mutation. 2000 , 18, 15-37	9
981	Impact of genomics on drug discovery and clinical medicine. 2000 , 93, 391-423	100
980	NFBD1/KIAA0170 is a novel nuclear transcriptional transactivator with BRCT domain. 2000 , 19, 475-85	37
979	The founder mutations in the BRCA1, BRCA2, and ATM genes in Moroccan Jewish women with breast cancer. 2000 , 4, 403-7	6
978	Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. 2000 , 92, 1529-31	140
977	An anaphoid supernumerary marker chromosome derived from chromosome 3 ascertained in a fetus with multiple malformations. 2000 , 37, 807-10	10
976	Uncovering functionally relevant signaling pathways using microarray-based expression profiling. 2000 , 5, 501-7	42
975	Fine molecular mapping of the 4p16.3 aneuploidy syndromes in four translocation families. 2000 , 37, 449-51	1
974	The psychological impact of a cancer family history questionnaire completed in general practice. 2000 , 37, 470-2	20
973	Investigation of meiotic rearrangements in DGS/VCFS patients with a microdeletion 22q11.2. 2000 , 37, 452-4	12
972	Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. 2000 , 21, 1761-5	183

971	New MR/MCA syndrome with distinct facial appearance and general habitus, broad and webbed neck, hypoplastic inverted nipples, epilepsy, and pachygyria of the frontal lobes. 2000 , 37, 460-2	20
970	A functional comparison of BRCA1 C-terminal domains in transcription activation and chromatin remodeling. 2000 , 275, 40169-73	26
969	Attitudes of von Hippel-Lindau disease patients towards presymptomatic genetic diagnosis in children and prenatal diagnosis. 2000 , 37, 476-8	13
968	Hormonal carcinogenesis. 2000 , 21, 427-33	662
967	Pure trisomy 20p resulting from isochromosome formation and whole arm translocation. 2000 , 37, 454-8	29
966	The APC11 RING-H2 finger mediates E2-dependent ubiquitination. 2000 , 11, 2315-25	156
965	A SALL1 mutation causes a branchio-oto-renal syndrome-like phenotype. 2000 , 37, 458-60	42
964	The mutation spectrum in Holt-Oram syndrome. 2000 , 37, 785-7	49
963	Evaluation of a counselling protocol for predictive genetic testing for hereditary non-polyposis colorectal cancer. 2000 , 37, 108-13	29
962	Communicating genetic risk: pros, cons, and counsel. 2000 , 5, 152-61	3
961	BRCA2 germline mutations among early onset breast cancer patients unselected for family history of the disease. 2000 , 37, E17	10
960	Prophylactic mastectomy or screening in women suspected to have the BRCA1/2 mutation: a prospective pilot study of women's treatment choices and medical and decision-analytic recommendations. 2000 , 20, 251-62	23
959	Atypical medullary carcinoma of the breast with cartilaginous metaplasia in a patient with a BRCA1 germline mutation. 2000 , 30, 30-2	8
958	Relevance of the viral RAK alpha gene in diagnosis of malignant versus nonmalignant tumors of the ovary and uterus. 2000 , 7, 360-5	1
957	Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. 2000 , 215, 267-79	485
956	Analysis of the human tumour necrosis factor-alpha (TNFalpha) gene promoter polymorphisms in children with bone cancer. 2000 , 37, 789-92	31
955	Why patients do not attend for their appointments at a genetics clinic. 2000 , 37, 810-5	23
954	A model protocol evaluating the introduction of genetic assessment for women with a family history of breast cancer. 2000 , 37, 192-6	15

953	Report of five novel and one recurrent COL2A1 mutations with analysis of genotype-phenotype correlation in patients with a lethal type II collagen disorder. 2000 , 37, 263-71	52
952	Two further cases of Sener syndrome: frontonasal dysplasia and dilated Virchow-Robin spaces. 2000 , 37, 466-70	9
951	Mutational analysis of Sanfilippo syndrome type A (MPS IIIA): identification of 13 novel mutations. 2000 , 37, 704-7	32
950	Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells. 2000 , 97, 11256-61	120
949	Stimulation of cell invasion and migration by alcohol in breast cancer cells. 2000 , 273, 448-53	52
948	Real-time PCR quantification of full-length and exon 11 spliced BRCA1 transcripts in human breast cancer cell lines. 2000 , 274, 73-8	44
947	TGF-beta1 inhibits BRCA1 expression through a pathway that requires pRb. 2000 , 276, 686-92	11
946	The BRCT regions of tumor suppressor BRCA1 and of XRCC1 show DNA end binding activity with a multimerizing feature. 2000 , 279, 678-84	48
945	Single-strand conformation polymorphism analysis by capillary and microchip electrophoresis: a fast, simple method for detection of common mutations in BRCA1 and BRCA2. 2000 , 63, 25-34	110
944	BRCA1 suppresses insulin-like growth factor-I receptor promoter activity: potential interaction between BRCA1 and Sp1. 2000 , 69, 130-6	71
943	Regulation of the insulin-like growth factor-I receptor gene by oncogenes and antioncogenes: implications in human cancer. 2000 , 71, 315-20	44
942	Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. 2000 , 31, 75-80	224
941	The breast surgeon's role in BRCA1 and BRCA2 testing. 2000 , 180, 294-8	11
940	Molecular cloning and characterization of a human homologue of TBPIP, a BRCA1 locus-related gene. 2000 , 248, 99-107	20
939	Isolation of a functional copy of the human BRCA1 gene by transformation-associated recombination in yeast. 2000 , 250, 201-8	22
938	Implications of genetic epidemiology for the prevention of substance use disorders. 2000 , 25, 807-20	80
937	Le gène : bien privé ou bien commun ?. 2000 , 2000, 26-30	1
936	Progression of human breast cancers to the metastatic state is linked to genotypes of catechol-O-methyltransferase. 2000 , 150, 23-31	40

935	Allelic loss at the BRCA1, BRCA2 and TP53 loci in human sporadic breast carcinoma. 2000 , 150, 165-70	25
934	Impact of genome research on children and their families. 2000 , 15, 207-11	1
933	Genetic alterations in breast cancer. 2000 , 6, 271-281	4
932	Minor lesion mutational spectrum of the entire NF1 gene does not explain its high mutability but points to a functional domain upstream of the GAP-related domain. 2000 , 66, 790-818	264
931	A genome screen of multiplex sibships with prostate cancer. 2000 , 66, 933-44	131
930	Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. 2000 , 66, 1963-8	196
929	Genetics of prostate cancer: too many loci, too few genes. 2000 , 67, 1367-75	152
928	The BRCA1 C-terminal domain: structure and function. 2000 , 460, 319-32	110
927	Sequence-specific transcriptional corepressor function for BRCA1 through a novel zinc finger protein, ZBRK1. 2000 , 6, 757-68	200
926	Familial breast cancer in southern Finland: how prevalent are breast cancer families and can we trust the family history reported by patients?. 2000 , 36, 1143-8	84
925	Germ line BRCA1 and BRCA2 gene mutations in Turkish breast cancer patients. 2000 , 36, 2076-82	22
924	BRCA1 mutations and clinicopathological features in a sample of Italian women with early-onset breast cancer. 2000 , 36, 2083-9	28
923	BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer. 2000 , 102, 257-65	441
922	Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. 2000 , 355, 2015-20	250
921	Reduction of BRCA1 expression in sporadic ovarian cancer. 2000 , 76, 294-300	50
920	Role of chromosomal loss in the progression of prostate cancers. 2000 , 5, 345-354	7
919	BRCA1 and BRCA2 protein expressions in an ovotestis of a 46, XX true hermaphrodite. 2001 , 3, 61-5	2
918	Breast cancer risk perception: what do we know and understand?. 2000 , 2, 387-91	63

917	Role of BRCA gene dysfunction in breast and ovarian cancer predisposition. 2000 , 2, 324-30	61
916	Future possibilities in the prevention of breast cancer: intervention strategies in BRCA1 and BRCA2 mutation carriers. 2000 , 2, 283-90	23
915	Increased cell survival by inhibition of BRCA1 using an antisense approach in an estrogen responsive ovarian carcinoma cell line. 2000 , 2, 139-48	16
914	Founder populations and their uses for breast cancer genetics. 2000 , 2, 77-81	41
913	Assessing the risk of breast cancer. 2000 , 342, 564-71	221
912	VCP, a weak ATPase involved in multiple cellular events, interacts physically with BRCA1 in the nucleus of living cells. 2000 , 19, 253-63	63
911	Genetic and hormonal risk factors in breast cancer. 2000 , 92, 1126-35	202
910	Breast cancer genetics. Implications of clinical practice. 2000 , 14, 705-25	5
909	Chemoprevention of breast cancer in the older patient. 2000 , 14, 113-30	8
908	The predictive value of BRCA1 and BRCA2 mutation testing. 2000 , 4, 45-8	8
907	The prevalence of BRCA1 mutations in Chinese patients with early onset breast cancer and affected relatives. 2000 , 82, 538-42	44
906	Prevalence of BRCA1 and BRCA2 mutations in male breast cancer patients in Canada. 2000 , 1, 57-63; discussion 64-5	26
905	The breast cancer susceptibility gene, BRCA2: at the crossroads between DNA replication and recombination?. 2000 , 355, 191-8	19
904	Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. 2001 , 345, 159-64	768
903	Tamoxifen resistance in breast cancer: elucidating mechanisms. 2001 , 61, 1721-33	72
902	Contralateral breast cancer risk. 2001 , 60, 239-46	24
901	Genome-wide analyses on loss of heterozygosity in hepatocellular carcinoma in Southern China. 2001 , 34, 840-9	59
900	Genetic linkage methods for quantitative traits. 2001 , 10, 3-25	30

899	Nongenetic screening of ovarian malignancies. 2001 , 28, 637-51, vii	9
898	Knowledge, attitudes, and interest in breast-ovarian cancer gene testing: a survey of a large African-American kindred with a BRCA1 mutation. 2001 , 33, 543-51	80
897	Expression profiles of BRCA1 splice variants in asynchronous and in G1/S synchronized tumor cell lines. 2001 , 280, 32-8	53
896	Molecular cloning and characterization of RNF26 on human chromosome 11q23 region, encoding a novel RING finger protein with leucine zipper. 2001 , 282, 1038-44	59
895	Rb-associated protein 46 (RbAp46) inhibits transcriptional transactivation mediated by BRCA1. 2001 , 284, 507-14	25
894	Interactions between BRCA proteins and DNA structure. 2001 , 264, 67-73	12
893	Introducing defined chromosomal rearrangements into the mouse genome. 2001 , 24, 81-94	29
892	High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele loss. 2001 , 159, 119-30	122
891	Primary mammary small-cell carcinoma: a molecular analysis of 2 cases. 2001 , 32, 753-7	51
890	Evidence for a susceptibility gene, SLEV1, on chromosome 17p13 in families with vitiligo-related systemic lupus erythematosus. 2001 , 69, 1401-6	107
889	Coping with grim news from genetic tests. 2001 , 42, 100-5	17
888	Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families. 2001 , 37, 2082-90	57
887	Breast cancer: hormones and other risk factors. 2001 , 38, 103-13; discussion 113-6	146
886	Survival analysis in familial ovarian cancer, a case control study. 2001 , 98, 219-23	18
885	Germline BRCA1 mutations in Iranian women with breast cancer. 2001 , 165, 87-94	17
884	BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. 2001 , 10, 705-13	427
883	Gene-expression profiles in hereditary breast cancer. 2001 , 344, 539-48	1462
882	Screening women at high risk of breast cancer on the basis of evidence. 2001 , 39, 50-9	15

881	Chromosomal breakage syndromes and the BRCA1 genome surveillance complex. 2001 , 7, 560-5	48
880	The Cooperative Familial Registry for Breast Cancer Studies: design and first year recruitment rates in Ontario. 2001 , 54, 93-8	19
879	Germ line mutations associated with breast cancer susceptibility. 2001 , 37, 300-21	39
878	A founder mutation of the BRCA1 gene in Western Sweden associated with a high incidence of breast and ovarian cancer. 2001 , 37, 1904-9	52
877	A hypothesis about tumour development and the clinical features of hereditary breast cancers. 2001 , 37, 2023-9	7
876	Genetic epidemiology of BRCA1 mutations in Norway. 2001 , 37, 2428-34	40
875	Identification of BARD1 as mediator between proapoptotic stress and p53-dependent apoptosis. 2001 , 8, 1255-66	95
874	Constitutive activation of JAK-STAT3 signaling by BRCA1 in human prostate cancer cells. 2001 , 488, 179-84	84
873	Prevalence of breast cancer predisposition gene mutations in Chinese women and guidelines for genetic testing. 2001 , 313, 179-85	20
872	A human BRCA2 complex containing a structural DNA binding component influences cell cycle progression. 2001 , 104, 247-57	118
871	BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. 2001 , 105, 149-60	520
870	[Clinical and pathological characteristics and clinical course of patients with breast cancer and BRCA1/BRCA2 mutations]. 2001 , 117, 161-6	0
869	Contemporary management of ovarian cancer. 2001 , 28, 759-73	3
868	Pharmacogenomics: a clinician's primer on emerging technologies for improved patient care. 2001 , 76, 299-309	62
867	Psychological and social predictors of decisions about genetic testing for breast cancer in high-risk women. 2001 , 6, 321-333	14
866	The Tyr978X BRCA1 Mutation in Non-Ashkenazi Jews: Occurrence in High-Risk Families, General Population and Unselected Ovarian Cancer Patients. 2001 , 4, 50-55	21
865	IDENTIFICATION OF NOVEL GENE FAMILY MEMBERS BASED ON EFFICIENT FULL-LENGTH CDNA CLONING. 2001 , 5-19	
864	Genetic testing for cancer predisposition. 2001 , 52, 371-400	92

863	SAG/ROC/Rbx/Hrt, a zinc RING finger gene family: molecular cloning, biochemical properties, and biological functions. 2001 , 3, 635-50	74
862	Gene expression profiling can distinguish tumor subclasses of breast carcinomas. 2001 , 132-161	1
861	Progress in the application of DNA microarrays. 2001 , 109, 881-91	49
860	BRCA2 mutation analysis of 87 Spanish breast/ovarian cancer families. 2001 , 12, 1699-703	11
859	Prophylactic Breast Surgery for Women with Brca1 and BRCA2 Germline Mutations. 2001 , 87, 13-15	3
858	Surgical management of high-risk patients. 2001 , 12, 3-12	1
857	BRCA1/2 testing: complex themes in result interpretation. 2001 , 19, 2555-65	54
856	Use of Monozygotic Twins in Search for Breast Cancer Susceptibility Loci. 2001 , 4, 251-259	5
855	The Human Genome Project: an update. 2001 , 24, 287-92; quiz 292-3	4
854	Hereditary cancers in obstetrics and gynecology. 2001 , 44, 450-63	7
853	Underarm cosmetics are a cause of breast cancer. 2001 , 10, 389-93	75
852	Use of monozygotic twins in search for breast cancer susceptibility loci. 2001 , 4, 251-9	
851	Validity and efficiency of screening for history of depression by self-report.. 2001 , 13, 163-170	25
850	Role played by BRCA1 in regulating the cellular response to stress. 2001 , 31, 257	2
849	Uncovering BRCA1-regulated signalling pathways by microarray-based expression profiling. 2001 , 29, 678-683	14
848	Satellites on the terminal short arm of chromosome 12 (12ps), inherited through several generations in three families: a new variant without phenotypic effect. 2001 , 38, 723-7	12
847	Microsatellite polymorphism in intron 14 of the canine BRCA1 gene. 2001 , 63, 479-81	5
846	Absence of microsatellite instability and germline mutations of E-cadherin, APC and p53 genes in Japanese familial gastric cancer. 2001 , 22, 262-8	17

845	p38 mitogen-activated protein kinase-independent induction of gadd45 expression in nerve growth factor-induced apoptosis in medulloblastomas. 2001 , 276, 41120-7	16
844	Ovarian Gene Database. 2001 , 8, S37-S39	0
843	Apoptosis in breast cancer. 2001 , 6, 1-22	
842	Familial ovarian cancer and early ovarian cancer: biologic, pathologic, and clinical features. 2001 , 20, 48-63	33
841	Mutation analysis of a Mauritian hereditary breast cancer family reveals the BRCA2 6503delTT mutation previously found to recur in different ethnic populations. 2001 , 52, 55-8	4
840	Cancer genetics in oncology practice. 2001 , 12, 895-908	24
839	[Prevention in familial breast cancer susceptibility]. 2001 , 41, 366-70	2
838	Genetic factors in ovarian carcinoma. 2001 , 3, 27-32	29
837	Educational review: role of the surgeon in hereditary breast cancer. 2001 , 8, 368-78	5
836	Familien Mamma- und Ovarialkarzinom. 2001 , 17, 368-376	
835	Hormonale Kontrazeption, Hormonsubstitution und reproduktives Krebsrisiko. 2001 , 17, 87-99	
834	Identification of a recurrent BRCA1 mutation in German breast-cancer and/or ovarian-cancer families. 2001 , 127, 200-2	1
833	HLA-DRB 1 alleles and the susceptibility of Iranian patients with breast cancer. 2001 , 7, 39-41	20
832	Parental communication of BRCA1/2 genetic test results to children. 2001 , 42, 213-24	90
831	Psychosocial care in family cancer clinics in The Netherlands: a brief report. 2001 , 43, 205-9	7
830	Psychosocial dimensions of BRCA testing: an overshadowed issue. 2001 , 10, 96-9	5
829	Coincident PTCH and BRCA1 germline mutations in a patient with nevoid basal cell carcinoma syndrome and familial breast cancer. 2001 , 116, 472-4	11
828	From adjuvant therapy to breast cancer prevention: BCPT and STAR. 2001 , 7, 144-57	47

827	Current perspectives on BRCA1- and BRCA2-associated breast cancers. 2001 , 31, 349-56	9
826	Psychological impact of genetic counselling and testing in women previously diagnosed with breast cancer. 2001 , 31, 397-405	34
825	Breast conservation in BRCA1 or BRCA2 mutation carriers with early stage breast cancer. 2001 , 45, 200-4	
824	Information and support needs of women with primary relatives with breast cancer: development of the Information and Support Needs Questionnaire. 2001 , 35, 497-507	40
823	Radiation-induced chromatid breaks and deficient DNA repair in cancer predisposition. 2001 , 37, 87-96	38
822	Gene mutation as a target for early detection in cancer diagnosis. 2001 , 40, 195-213	11
821	Ethical implications of genetic testing for breast cancer susceptibility. 2001 , 40, 149-57	27
820	A rapid fluorescent multiplexed-PCR analysis (FMPA) for founder mutations in the BRCA1 and BRCA2 genes. 2000 , 57, 213-20	27
819	Hereditary breast/ovarian cancer--pitfalls in genetic counseling. 2001 , 60, 310-3	4
818	Founder mutations in the BRCA1 gene in west Belarusian breast-ovarian cancer families. 2001 , 60, 470-1	26
817	Cancer-specific worry interference in women attending a breast and ovarian cancer risk evaluation program: impact on emotional distress and health functioning. 2001 , 10, 349-60	60
816	Psychological issues among children of hereditary breast cancer gene (BRCA1/2) testing participants. 2001 , 10, 336-46	67
815	RB1 genetic testing as a clinical service: a follow-up study. 2001 , 37, 372-8	18
814	Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas. 2001 , 92, 54-60	72
813	The frequency of founder mutations in the BRCA1, BRCA2, and APC genes in Australian Ashkenazi Jews: implications for the generality of U.S. population data. 2001 , 92, 440-5	38
812	Loss of heterozygosity on chromosome 13q12-q14, BRCA-2 mutations and lack of BRCA-2 promoter hypermethylation in sporadic epithelial ovarian tumors. 2001 , 92, 787-95	40
811	Women's attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another: differences among English, French, and Canadian women. 2001 , 92, 959-68	83
810	Spanish family study on hereditary breast and/or ovarian cancer: analysis of the BRCA1 gene. 2001 , 91, 137-40	25

809	Frequency of BRCA1 and BRCA2 germline mutations in Japanese breast cancer families. 2001 , 91, 83-8	70
808	Deletion mapping of chromosome segment 11q24-q25, exhibiting extensive allelic loss in early onset breast cancer. 2001 , 92, 208-13	17
807	Founder BRCA1 and BRCA2 mutations in early-onset French Canadian breast cancer cases unselected for family history. 2001 , 95, 189-93	37
806	Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer. 2001 , 95, 255-9	52
805	Psychological impact of receiving a BRCA1/BRCA2 test result. 2001 , 98, 15-24	135
804	Adrenal tumors in BRCA1/BRCA2 mutation carriers. 2001 , 98, 277-9	8
803	Caucasian family with two independent mutations: 2594delC in BRCA1 and 5392delAG in BRCA2 gene. 2001 , 101, 146-52	5
802	Reflectance spectroscopy for in vivo characterization of ovarian tissue. 2001 , 28, 56-66	78
801	Detection of germline mutations in the BRCA1 gene by RNA-based sequencing. 2001 , 18, 149-56	16
800	Evidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast/ovarian cancer. 2001 , 18, 163-4	206
799	Identification of proteins that interact with BRCA1 by Far-Western library screening. 2001 , 83, 521-31	4
798	Multipoint development of the weighted pairwise correlation (WPC) linkage method for pedigrees of arbitrary size and application to the analysis of breast cancer and alcoholism familial data. 2001 , 21, 40-52	5
797	Education about genetic testing for breast cancer susceptibility: patient preferences for a computer program or genetic counselor. 2001 , 103, 24-31	56
796	Frequency of BRCA1 and BRCA2 mutations in a clinic-based series of breast and ovarian cancer families. 2001 , 17, 74	6
795	Prevalence of BRCA1 founder mutations in western Poland. 2001 , 17, 75	16
794	Involvement of BRCA1 and BRCA2 in breast cancer in a western Finnish sub-population. 2001 , 20, 239-46	7
793	Human BRCA1 gene rescues the embryonic lethality of Brca1 mutant mice. 2001 , 29, 72-7	39
792	BRCA: the breast, ovarian, and other cancer genes. 2001 , 80, 337-40	13

791	Allelotype of papillary serous peritoneal carcinomas. 2001 , 82, 69-76	19
790	Survival of BRCA1 negative ovarian cancer patients based on family history. 2001 , 83, 109-14	3
789	Genetic epidemiology of female breast cancer. 2001 , 11, 367-74	51
788	Molecular and pathological characterization of inherited breast cancer. 2001 , 11, 375-85	11
787	Knockout mouse models and mammary tumorigenesis. 2001 , 11, 387-94	38
786	Risk models used to counsel women for breast and ovarian cancer: a guide for clinicians. 2001 , 1, 197-206	27
785	Expression of pp32 gene family members in breast cancer. 2001 , 68, 65-73	25
784	How Do Geneticists and Genetic Counselors Counsel Women from High-Risk Breast Cancer Families?. 2001 , 10, 185-199	29
783	Fas ligand expression in BRCA1-associated hereditary breast carcinoma clearly differs from that in sporadic breast carcinoma. 2001 , 66, 95-100	2
782	Biophenotypes and survival of BRCA1 and TP53 deleted breast cancer in young women. 2001 , 66, 135-42	22
781	Association of family history and other risk factors with breast cancer risk among Japanese premenopausal and postmenopausal women. 2001 , 12, 349-58	36
780	Risk of cancer in BRCA1 and BRCA2 mutation-positive and -negative breast cancer families (Finland). 2001 , 12, 739-46	22
779	The contribution of epigenetic changes to abnormal centrosomes and genomic instability in breast cancer. 2001 , 6, 203-12	20
778	Double primary cancers of the breast and thyroid in women: molecular analysis and genetic implications. 2001 , 1, 17-24	13
777	A paradox: urgent BRCA genetic testing. 2001 , 1, 25-9	9
776	Clinical management of women with genomic BRCA1 and BRCA2 mutations. 2001 , 69, 101-13	22
775	Measuring women's preferences for breast cancer treatments and BRCA1/BRCA2 testing. 2001 , 10, 595-607	30
774	Search for Frequent Mutations in Genes Predisposing to Breast Cancer. 2001 , 37, 1415-1420	3

773	Differential expression of WISP-1 and WISP-2 genes in normal and transformed human breast cell lines. 2001 , 228, 99-104	29
772	Molecular genetics of ovarian cancer. 2001 , 19, 13-28	2
771	Germline TP53 alterations in Finnish breast cancer families are rare and occur at conserved mutation-prone sites. 2001 , 84, 116-9	29
770	Frequent somatic loss of BRCA1 in breast tumours from BRCA2 germ-line mutation carriers and vice versa. 2001 , 85, 1201-5	10
769	Analysis of candidate genes included in the mammary cancer susceptibility 1 (Mcs1) region. 2001 , 12, 199-206	9
768	Biochemical markers in breast cancer: which ones are clinically useful?. 2001 , 34, 347-52	66
767	Fanconi anemia and breast cancer: what's the connection?. 2001 , 27, 352-3	3
766	Breast cancer genetics: what we know and what we need. 2001 , 7, 552-6	354
765	With the ends in sight: images from the BRCA1 tumor suppressor. 2001 , 8, 822-4	9
764	A cell death-promoting kinase. 2001 , 8, 824-6	8
763	Structure of a BRCA1-BARD1 heterodimeric RING-RING complex. 2001 , 8, 833-7	381
762	Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1. 2001 , 8, 838-42	201
761	BRCA1 carries tumor suppressor activity distinct from that of p53 and p21. 2001 , 8, 759-70	16
760	Men at risk of being a mutation carrier for hereditary breast/ovarian cancer: an exploration of attitudes and psychological functioning during genetic testing. 2001 , 9, 492-500	46
759	The western Swedish BRCA1 founder mutation 3171ins5; a 3.7 cM conserved haplotype of today is a reminiscence of a 1500-year-old mutation. 2001 , 9, 787-93	45
758	Haplotype analysis in Icelandic and Finnish BRCA2 999del5 breast cancer families. 2001 , 9, 773-9	21
757	Role of direct interaction in BRCA1 inhibition of estrogen receptor activity. 2001 , 20, 77-87	212
756	Identification of a novel transcriptional repressor element located in the first intron of the human BRCA1 gene. 2001 , 20, 440-50	18

755	c-Fos oncogene regulator Elk-1 interacts with BRCA1 splice variants BRCA1a/1b and enhances BRCA1a/1b-mediated growth suppression in breast cancer cells. 2001 , 20, 1357-67	50
754	A targeted mouse Brca1 mutation removing the last BRCT repeat results in apoptosis and embryonic lethality at the headfold stage. 2001 , 20, 2544-50	48
753	p53 contains a DNA break-binding motif similar to the functional part of BRCT-related region of Rb. 2001 , 20, 2859-67	7
752	Nine novel conserved motifs in BRCA1 identified by the chicken orthologue. 2001 , 20, 4433-8	36
751	Disruption of BRCA1 LXCXE motif alters BRCA1 functional activity and regulation of RB family but not RB protein binding. 2001 , 20, 4827-41	36
750	Functional analysis of CpG methylation in the BRCA1 promoter region. 2001 , 20, 5331-40	50
749	BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. 2001 , 20, 6123-31	142
748	Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. 2001 , 20, 6597-606	166
747	A CREB site in the BRCA1 proximal promoter acts as a constitutive transcriptional element. 2001 , 20, 7110-4	40
746	Mutant BRCA1 genes antagonize phenotype of wild-type BRCA1. 2001 , 20, 8215-35	63
745	Cancer genetics: from Boveri and Mendel to microarrays. 2001 , 1, 77-82	79
744	Quantitative analysis of BRCA1 and BRCA2 mRNA expression in sporadic breast carcinomas and its relationship with clinicopathological characteristics. 2001 , 92, 624-30	23
743	A BRCA1 variant, IVS23+1G-->A, causes abnormal RNA splicing by deleting exon 23. 2001 , 127, 188-90	12
742	Exclusion of large deletions and other rearrangements in BRCA1 and BRCA2 in Finnish breast and ovarian cancer families. 2001 , 129, 120-3	40
741	Allelic imbalance and fine mapping of the 17p13.3 subregion in sporadic breast carcinomas. 2001 , 129, 145-9	14
740	BRCA1-associated tumorigenesis: what have we learned from knockout mice?. 2001 , 17, S18-22	60
739	Hereditary breast cancer. 2001 , 38, 387-480	111
738	Chromosomal instability in BRCA1- or BRCA2-defective human cancer cells detected by spontaneous micronucleus assay. 2001 , 474, 15-23	29

737	Tumorigenesis as a consequence of genetic instability in Brca1 mutant mice. 2001 , 477, 183-9	41
736	From genomics to proteomics: techniques and applications in cancer research. 2001 , 11, S60-5	34
735	From genomics to proteomics: techniques and applications in cancer research. 2001 , 11, S60-S65	21
734	Molecular pathogenesis of pancreatic ductal adenocarcinoma and clinical implications. 2001 , 10, 1-23	21
733	On the birth of breast cancer. 2001 , 1552, 1-13	17
732	Direct DNA binding by Brca1. 2001 , 98, 6086-91	213
731	Functional communication between endogenous BRCA1 and its partner, BARD1, during <i>Xenopus laevis</i> development. 2001 , 98, 12078-83	126
730	Uptake, Time Course, and Predictors of Risk-Reducing Surgeries in BRCA Carriers. 2009 , 090108090224061	1
729	The human genome project: evolving status and emerging opportunities for disease prevention. 2000 , 45-60	3
728	Genetic Concepts and Methods in Epidemiologic Research. 2006 , 89-98	3
727	The future of family-based studies in life course epidemiology: challenges and opportunities. 2009 , 325-334	2
726	A review of tumor suppressor genes in cutaneous neoplasms with emphasis on cell cycle regulators. 1998 , 20, 302-13	11
725	Multiple primary neoplasms at a single institution: differences between synchronous and metachronous neoplasms. 2000 , 23, 364-70	69
724	Overestimation of hereditary breast cancer risk. 1998 , 228, 375-84	20
723	Recent advances in breast cancer biology. 1999 , 11, 429-34	16
722	The Human Genome Project. 1997 , 20, 62-71, quiz 72-5	4
721	Current role of ultrasound in ovarian cancer screening. 1996 , 39, 259-67	7
720	Familial breast-ovarian cancer syndromes: BRCA1 and BRCA2. 1998 , 41, 157-66	13

719	Li-Fraumeni syndrome and the role of the p53 tumor suppressor gene in cancer susceptibility. 1998 , 41, 172-99	26
718	Early detection and risk reduction for familial gynecologic cancers. 1998 , 41, 200-14	7
717	The genetics of ovarian cancer: molecular biology and clinical application. 1998 , 53, 248-56	5
716	BRCA1 and BRCA2 gene mutations: decision-making dilemmas concerning testing and management. 2000 , 55, 373-84	28
715	Implications of multifactorial inheritance for identification of genetic mechanisms in major psychiatric disorders. 2002 , 12, 121-6	9
714	Convergent evolution as an indicator for selection during acute HIV-1 infection.	1
713	Novel ratio-metric features enable the identification of new driver genes across cancer types.	1
712	Familial clustering of erosive hand osteoarthritis in a large statewide cohort.	1
711	Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies new candidate susceptibility genes for breast and ovarian cancer.	0
710	Genotype-first approach to the detection of hereditary breast and ovarian cancer risk, and effects of risk disclosure to biobank participants.	1
709	Disease Spectrum of Breast Cancer Susceptibility Genes.	1
708	Accurate functional classification of thousands of BRCA1 variants with saturation genome editing.	12
707	Identification of Novel Common Breast Cancer Risk Variants in Latinas at the 6q25 Locus.	1
706	Discovery of synthetic lethal interactions from large-scale pan-cancer perturbation screens.	2
705	The RING finger/B-box factor TAM-1 and a retinoblastoma-like protein LIN-35 modulate context-dependent gene silencing in <i>Caenorhabditis elegans</i> . 1999 , 13, 2958-70	88
704	BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. 2000 , 14, 927-939	565
703	Mining SNPs From EST Databases. 1999 , 9, 167-174	112
702	Chromosomal instability and cancer predisposition: insights from studies on the breast cancer susceptibility gene, BRCA2. 2000 , 65, 567-72	2

701	DNA sequence variation of Homo sapiens. 2003 , 68, 55-63	2
700	Human immunodeficiency virus type 1-like DNA sequences and immunoreactive viral particles with unique association with breast cancer. 1998 , 5, 645-53	12
699	Giant syncytia and virus-like particles in ovarian carcinoma cells isolated from ascites fluid. 1999 , 6, 115-26	7
698	Recent advances. Medical genetics. 1996 , 312, 1021-5	6
697	Testing for the breast cancer predisposition gene, BRCA1. 1996 , 313, 572-3	17
696	The new genetics in clinical practice. 1998 , 316, 618-20	143
695	From proband to provider: is there an obligation to inform genetic relatives of actionable risks discovered through direct-to-consumer genetic testing?. 2020 ,	1
694	Secretome profiling identifies neuron-derived neurotrophic factor as a tumor-suppressive factor in lung cancer. 2019 , 4,	3
693	Pioneering geneticist Mary-Claire King receives the 2014 Lasker~Koshland Special Achievement Award in Medical Science. 2014 , 124, 4148-51	4
692	pathogenic variants in triple-negative luminal-like breast cancers: genotype-phenotype correlation in a cohort of 531 patients. 2020 , 12, 1758835920975326	19
691	Aberrations of the B-Cell Receptor B29 (CD79b) Gene in Chronic Lymphocytic Leukemia. 1997 , 90, 1387-1394	7
690	Genetic predisposition to cancer. 2004 , 3-10	2
689	BRCA-1, BRCA-2 and Hereditary Breast Cancer. 2002 , 555-624	6
688	Feature selection for data integration with mixed multiview data. 2020 , 14,	4
687	Absence of the CHEK2 c.1100delC mutation in familial breast and ovarian cancer in Colombia: a case-control study. 7, 1032	1
686	Lipoprotein genotype and conserved pathway for exceptional longevity in humans. 2006 , 4, e113	167
685	Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk. 2018 , 14, e1007111	20
684	Identification of novel high-frequency DNA methylation changes in breast cancer. 2007 , 2, e1314	83

683	Methylation of the tumor suppressor protein, BRCA1, influences its transcriptional cofactor function. 2010 , 5, e11379	56
682	Transcriptional activity and nuclear localization of Cabut, the Drosophila ortholog of vertebrate TGF- β -inducible early-response gene (TIEG) proteins. 2012 , 7, e32004	8
681	A common polymorphism near the ESR1 gene is associated with risk of breast cancer: evidence from a case-control study and a meta-analysis. 2012 , 7, e52445	15
680	Signal oscillation is another reason for variability in microarray-based gene expression quantification. 2013 , 8, e54753	1
679	Missense variants of uncertain significance (VUS) altering the phosphorylation patterns of BRCA1 and BRCA2. 2013 , 8, e62468	7
678	Similarities in the Age-Specific Incidence of Colon and Testicular Cancers. 2013 , 8, e66694	6
677	copy number variation analysis in familial BRCA1/2-negative Finnish breast and ovarian cancer. 2013 , 8, e71802	25
676	Association between 1p11-rs11249433 polymorphism and breast cancer susceptibility: evidence from 15 case-control studies. 2013 , 8, e72526	5
675	Structural and functional implication of RAP80 Glu81 mutation. 2013 , 8, e72707	7
674	Genome-wide association study of breast cancer in the Japanese population. 2013 , 8, e76463	30
673	Strong evidence for a genetic contribution to late-onset Alzheimer's disease mortality: a population-based study. 2013 , 8, e77087	12
672	Inferring gene dependency network specific to phenotypic alteration based on gene expression data and clinical information of breast cancer. 2014 , 9, e92023	7
671	Large genomic rearrangements of BRCA1 and BRCA2 among patients referred for genetic analysis in Galicia (NW Spain): delimitation and mechanism of three novel BRCA1 rearrangements. 2014 , 9, e93306	13
670	Acetylation Enhances the Promoting Role of AIB1 in Breast Cancer Cell Proliferation. 2016 , 39, 663-8	6
669	Clinical Implications of Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome in the Era of Genomic Medicine: Clinician's Perspectives. 2016 , 4, 1-9	3
668	Fertility in BRCA mutation carriers: counseling BRCA-mutated patients on reproductive issues. 2020 , ,	3
667	In silico-Based Virtual Drug Screening and Molecular Docking Analysis of Phyto Chemical Derived Compounds and FDA Approved Drugs against BRCA1 Receptor. 2017 , 8,	2
666	BRCA1 and BRCA2 mutations and treatment strategies for breast cancer. 2017 , 4,	68

665	A novel Ubc9 -dependent pathway regulates SIRT1- ER- α Axis and BRCA1-associated TNBC lung metastasis. 2017 , 4,	3
664	Screening of BRCA1 variants c.190T>C, 1307delT, g.5331G>A and c.2612C>T in breast cancer patients from North India. 2020 , 43, e20190014	1
663	Hereditary Factors in Gynecologic Cancer. 1998 , 3, 319-338	17
662	[Modern approach to breast cancer diagnostics]. 2014 , 60, 141-60	5
661	Mutations in the BRCT binding site of BRCA1 result in hyper-recombination. 2011 , 3, 515-32	34
660	The LSD1 inhibitor iadademstat (ORY-1001) targets SOX2-driven breast cancer stem cells: a potential epigenetic therapy in luminal-B and HER2-positive breast cancer subtypes. 2020 , 12, 4794-4814	21
659	germline variants in early-onset breast cancer patients from hereditary breast and ovarian cancer families. 2017 , 8, 472-483	6
658	"Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors. 2017 , 8, 23891-23904	17
657	Increased breast cancer risk with HABP1/p32/gC1qR genetic polymorphism rs2285747 and its upregulation in northern Chinese women. 2017 , 8, 13932-13941	7
656	Germline whole exome sequencing and large-scale replication identifies as a likely high grade serous ovarian cancer susceptibility gene. 2017 , 8, 50930-50940	30
655	Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting. 2017 , 8, 43653-43661	67
654	Five zinc finger protein 350 single nucleotide polymorphisms and the risks of breast cancer: a meta-analysis. 2017 , 8, 107273-107282	6
653	Cancer risk susceptibility loci in a Swedish population. 2017 , 8, 110300-110310	5
652	Genetic alterations detected by comparative genomic hybridization in BRCA1 breast and ovarian cancers of Brazilian population. 2018 , 9, 27525-27534	2
651	Elucidating the novel BRCA1 function as a non-genomic metabolic restraint in ER-positive breast cancer cell lines. 2018 , 9, 33562-33576	8
650	Analysis of clinical characteristics of breast cancer patients with the Japanese founder mutation L63X. 2019 , 10, 3276-3284	9
649	IQGAP1 control of centrosome function defines distinct variants of triple negative breast cancer. 2020 , 11, 2493-2511	3
648	Functional consequence of the MET-T1010I polymorphism in breast cancer. 2015 , 6, 2604-14	27

647	BRCA1 regulates PIG3-mediated apoptosis in a p53-dependent manner. 2015 , 6, 7608-18	32
646	Functional isogenic modeling of BRCA1 alleles reveals distinct carrier phenotypes. 2015 , 6, 25240-51	7
645	BRCA1/p220 loss triggers BRCA1-IRIS overexpression via mRNA stabilization in breast cancer cells. 2012 , 3, 299-313	12
644	First description of a sporadic breast cancer in a woman with BRCA1 germline mutation. 2015 , 6, 35616-24	7
643	A new class of small molecule estrogen receptor-alpha antagonists that overcome anti-estrogen resistance. 2015 , 6, 40388-404	2
642	Pyrosequencing quantified methylation level of BRCA1 promoter as prognostic factor for survival in breast cancer patient. 2016 , 7, 27499-510	14
641	Germline BRCA1 mutation reprograms breast epithelial cell metabolism towards mitochondrial-dependent biosynthesis: evidence for metformin-based "starvation" strategies in BRCA1 carriers. 2016 , 7, 52974-52992	24
640	A Novel Pathway that Links Caveolin-1 Down-Regulation to BRCA1 Dysfunction in Serous Epithelial Ovarian Cancer Cells. 2014 , 1,	3
639	Myriad Genetics: In the Eye of a Policy Storm.	7
638	Progress of Individualized Chemotherapy for Gastric Carcinoma Under the Guidance of Genetic Testing. 2020 , 27, 2322-2334	3
637	Targeting tumor suppressor networks for cancer therapeutics. 2014 , 15, 2-16	56
636	Functional investigation of the Val1714Gly and Asp1733Gly variants by computational tools and yeast transcription activation assay. 2019 , 8, 113-118	3
635	Olaparib for advanced breast cancer. 2020 , 16, 717-732	6
634	BRCA1 and BRCA2 genes mutation analysis in patients with a family history of breast and ovarian cancer. 2004 , 23, 271-277	3
633	The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers. 2014 , 19, 605-18	97
632	Heritability and Familiarity of MMPI Personality Dimensions in the Korean Families with Schizophrenia. 2018 , 15, 1121-1129	2
631	Differential Profile of BRCA1 vs. BRCA2 Mutated Families: A Characterization of the Main Differences and Similarities in Patients. 2019 , 20, 1655-1660	1
630	The INTRABEAM [®] Photon Radiotherapy System for the adjuvant treatment of early breast cancer: a systematic review and economic evaluation. 2015 , 19, 1-190	18

629	Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics: a dual cohort study. 2016 , 4, 1-210	48
628	Interplay between BRCA1 and GADD45A and Its Potential for Nucleotide Excision Repair in Breast Cancer Pathogenesis. 2020 , 21,	11
627	Loss of BRCA1 expression leads to worse survival in patients with gastric carcinoma. 2013 , 19, 1968-74	18
626	Exome sequencing in a breast cancer family without BRCA mutation. 2015 , 33, 149-54	14
625	Skin-sparing mastectomy. 2015 , 4, 541-53	8
624	The Correlation of Serum HER-2/neu and CA15-3 in Patients with Metastatic Breast Cancer. 2008 , 11, 18	3
623	Genomics era and complex disorders: Implications of GWAS with special reference to coronary artery disease, type 2 diabetes mellitus, and cancers. 2016 , 62, 188-98	10
622	Novel Germline Mutation of BRCA1 Gene in a 56-Year-Old Woman with Breast Cancer, Ovarian Cancer, and Diffuse Large B-Cell Lymphoma. 2015 , 47, 534-8	6
621	The cellular response to DNA damage: a focus on MDC1 and its interacting proteins. 2010 , 1, 166-78	59
620	Reasons for Prophylactic Mastectomy in Women Carrying BRCA 1/2 Mutation: A Systematic Literature Review. 2013 , 02, 97-105	1
619	Alternative splicing of breast cancer associated gene BRCA1 from breast cancer cell line. 2007 , 40, 15-21	18
618	Egr-1 regulates the transcription of the BRCA1 gene by etoposide. 2013 , 46, 92-6	14
617	Hereditary Breast Cancer in Korea. 2012 , 9, 1-10	1
616	Analysis of BRCA1/2 Mutations and Performance of Manchester Scoring System in High Risk Iranian Breast Cancer Patients: A Pilot Study. 2017 , 10,	4
615	Fusion of FNA-cytology and gene-expression data using Dempster-Shafer Theory of evidence to predict breast cancer tumors. 2006 , 1, 170-5	8
614	BRCA1, hormone, and tissue-specific tumor suppression. 2009 , 5, 20-7	24
613	Methylation of DNA repair genes and the efficacy of DNA targeted anticancer treatment. 2014 , 2, 3	12
612	Screening of 185DelAG, 1014DelGT and 3889DelAG BRCA1 mutations in breast cancer patients from North-East India. 2012 , 13, 5871-4	17

611	The CHEK2 I157T variant and breast cancer susceptibility: a systematic review and meta-analysis. 2012 , 13, 1355-60	35
610	CHEK2 1100delC variant and breast cancer risk in Caucasians: a meta-analysis based on 25 studies with 29,154 cases and 37,064 controls. 2012 , 13, 3501-5	14
609	Identification of a novel BRCA2 and CHEK2 A-C-G-C haplotype in Turkish patients affected with breast cancer. 2013 , 14, 3229-35	7
608	Identification of germline BRCA1 mutations among breast cancer families in Northeastern Iran. 2013 , 14, 4339-45	15
607	Association of +405C>G and +936C>T polymorphisms of the vascular endothelial growth factor gene with sporadic breast cancer in North Indians. 2014 , 15, 257-63	8
606	BRCA1 gene exon 11 mutations in Uighur and Han women with early-onset sporadic breast cancer in the northwest region of China. 2014 , 15, 4513-8	4
605	Current evidence on the association between rs3757318 of C6orf97 and breast cancer risk: a meta-analysis. 2014 , 15, 8051-5	2
604	Evaluation of genetic variations in miRNA-binding sites of BRCA1 and BRCA2 genes as risk factors for the development of early-onset and/or familial breast cancer. 2014 , 15, 8319-24	12
603	Clinicopathological significance of BRCA1 promoter hypermethylation in Thai breast cancer patients. 2014 , 15, 10585-9	14
602	Breast cancer in Morocco: a literature review. 2014 , 15, 1067-74	24
601	Expression of EMSY, a novel BRCA2-link protein, is associated with lymph node metastasis and increased tumor size in breast carcinomas. 2014 , 15, 1783-9	14
600	BRCA1 and BRCA2 common mutations in Iranian breast cancer patients: a meta analysis. 2015 , 16, 1219-24	11
599	The spectrum of genetic mutations in breast cancer. 2015 , 16, 2177-85	37
598	Understanding EGFR Signaling in Breast Cancer and Breast Cancer Stem Cells: Overexpression and Therapeutic Implications. 2016 , 17, 445-53	20
597	A Pilot Study on Screening of BRCA1 Mutations (185delAG, 1294del40) in Nepalese Breast Cancer Patients. 2016 , 17, 1829-32	5
596	MicroRNA-mediated repression of nonsense mRNAs. 2014 , 3, e03032	27
595	Association of three single nucleotide polymorphisms of ESR1 with breast cancer susceptibility: a meta-analysis. 2017 , 31, 213-225	13
594	The expression and clinical significance of GADD45A in breast cancer patients. 2018 , 6, e5344	5

593	Heritability and Familiality of Temperament and Character Dimensions in Korean Families with Schizophrenic Linkage Disequilibrium. 2016 , 14, 203-9	3
592	Cancer in General. 2021 , 171-198	
591	Insights into ovarian cancer care: report from the ANZGOG Ovarian Cancer Webinar Series 2020. 2021 , 32, e95	0
590	The BRCA1/BARD1 ubiquitin ligase and its substrates. 2021 , 478, 3467-3483	3
589	Clinicopathological Characterization of Double Heterozygosity for BRCA1 and BRCA2 Variants in Korean Breast Cancer Patients. 2021 ,	1
588	The fellowship of the RING: BRCA1, its partner BARD1 and their liaison in DNA repair and cancer. 2021 , 108009	1
587	GC-MS Analysis, Molecular Docking and Pharmacokinetic Properties of Phytocompounds from Solanum torvum Unripe Fruits and Its Effect on Breast Cancer Target Protein. 2021 , 194, 529	1
586	DDX17 is required for efficient DSB repair at DNA:RNA hybrid deficient loci.	
585	Genetic Differences between Physical Injury Patients With and Without Post-traumatic Syndrome: Focus on Secondary Findings and Potential Variants Revealed by Whole Exome Sequencing. 2021 , 19, 683-694	
584	Chemoprevention of Breast Cancer. 2000 , 183-207	
583	Structure and Function of BRCA Genes. 2000 , 337-351	
582	Quantitative Image Analysis for Estimation of Breast Cancer Risk. 2000 , 323-340	1
581	Public health assessment of genetic predisposition to cancer. 2000 , 151-172	
580	Historischer Abriss der molekularen Tumorforschung. 2001 , 527-532	
579	Die Bedeutung des Humangenomprojekts für die Identifizierung menschlicher Erkrankungsgene. 2001 , 43-61	
578	The Des Syndrome—A prototype of Human Teratogenesis and Tumorigenesis by Xenoestrogens?. 2001 , 81-118	3
577	Molekulare Diagnostik beim hereditären Mammakarzinom. 2001 , 131-148	
576	Genome Destabilization and Multistep Progression to Cancer. 2001 , 385-403	

- 575 Internationale und nationale Rahmenbedingungen der Molekularen Medizin. **2001**, 563-578
- 574 Hereditärer Brust- und Eierstockkrebs. **2001**, 257-281
- 573 New Directions in Epidemiologic Studies of Hormonally-related Cancers. **2001**, 44-58
- 572 Genetics of Cancer. **2001**, 1597-1618
- 571 The Human Genome Project. **2001**, 41-60
- 570 Hereditary Cancer. **2002**, 159-185
- 569 Chromosomal Radiosensitivity as an Indicator of Genetic Predisposition to Breast Cancer. **2002**, 167-176
- 568 Breast cancer susceptibility genes: Options for those carrying BRCA1 mutations. **2002**, 10, 119-122 1
- 567 Risk assessment & genetic testing. **2002**, 107, 29-59 1
- 566 Androgen Receptor Interacting Proteins: Co-Activators And Co-Repressors. **2002**, 91-138
- 565 Familienes Mammakarzinom Beratung und Betreuung betroffener Familien. **2002**, 43-59
- 564 Das Aufklärungsgespräch beim hereditären Mammakarzinom. **2002**, 61-67
- 563 Molecular Genetic Diagnosis of Inherited Cancer Predisposition. **2002**, 497-520
- 562 VNTR Mapping.
- 561 Interleukin-1 gene cluster polymorphisms: all in the family. **2002**, 30, 1168-9 1
- 560 Human Subjects Research, Ethics, Family, and Pedigree Studies.
- 559 Patents, Ethics, Human Life Forms.
- 558 Genetic Information, Ethics, Informed Consent to Testing and Screening.

557 BRCA1 and BRCA2 Mutations in Ovarian Carcinoma. **2003**, 201-208

556 IFN γ Receptor-STAT1 Signaling and Cancer Immunoediting. **2003**, 399-418

555 Animal Models for Mechanistic Cancer Research. **2003**, 271-288

554 Biostatistics. **2004**, 29-56

553 Genetic Markers in Breast Tumors with Hereditary Predisposition. **2004**, 151-179

1

552 Genetics. **2004**, 83-103

551 Prevention of Gynecologic Malignancies. **2004**, 883-919

550 Mammakarzinom. **2004**, 1011-1055

549 Disposition f \ddot{u} erbliche Krebserkrankungen. **2004**, 147-173

548 Epidemiology, Genetics, and Molecular Biology of Gestational Trophoblastic Disease. **2004**, 544-554

547 Was ist Krebs?. **2004**, 3-15

546 Genetische Grundlagen der Kanzerogenese. **2004**, 75-145

1

545 Genetic Counseling for Hereditary Cancer Predisposition Testing. **2004**, 453-471

544 Familial Cancer Syndromes. **2004**, 211-237

543 Mutation. **2004**, 57-88

542 Psychological Evaluation a Consideration in the Ethics of Genetic Testing for Breast Cancer. **2004**, 34, 118-124

541 Applications. **2004**, 237-252

540 Familial ovarian cancer. **2004**, 303-314

539 Breast Cancer: An Overview. **2004**, 1, 71-80

2

538 [Pre-symptomatic diagnosis of severe hereditary diseases with late onset in Lebanon: a choice or a necessity?]. **2005**, 17, 617-26

537 Management of Central Nervous System Metastases from Breast Carcinoma. **2005**, 404-429

536 Cancer Susceptibility Genes and Common Gene Variants That Increase Cancer Risk. **2005**, 181-204

535 Future Perspectives in Biopharmaceutical Development. **2005**, 485-492

534 Epidemiology of Breast, Prostate, and Colon Cancers. **2005**,

533 Tumor Suppressor Genes. **2005**, 131-150

532 Duchenne And Becker Muscular Dystrophies. **2005**, 126-152

531 Epidemiology, staging and clinical characteristics. **2005**, 1-37

530 Epitheliales Ovarialkarzinom. **2006**, 4344-4464

529 Genetics of Breast Cancer in Women of African Descent: An Overview. **2006**, 23-37

528 Pharmacoproteomics. **2006**, 35-50

527 Breast Diseases. **2007**, 327-357

1

526 Immunology and Molecular Oncology in Gynecologic Cancer. **2007**, 731-741

525 Reproductive Genetics. **2007**, 21-42

524 Genes and Cancer. **2007**, 637-667

523 Risk Prediction in Breast Cancer. **2007**, 35-50

522 The Genetic Epidemiology of Hereditary Breast Cancer. **2007**, 1-17

521 Risk Prediction in Breast Cancer. **2007**, 19-33

520 Genotypes That Predict Toxicity and Genotypes That Predict Efficacy of Anticancer Drugs. **2008**, 383-390

519 DNA Biomarkers for Pharmacogenomics and Personalized Medicine. **2008**, 445-471

518 TGF β Roles in DNA Damage Responses. **2008**, 321-333

517 Genetic Disposition. **2008**, 311-328

516 Genetics of Cancer. **2008**, 1901-1924

2

515 Breast cancer expression of E-cadherin does not differ between patients with positive and negative oncological history. **2008**, 53, 251-5

514 Introduction. **2008**, 1-12

1

513 Genetic Factors: Finding Cancer Susceptibility Genes. **2008**, 193-205

512 The Human Genome Project. 41-59

511 Clinical Relevance of Hereditary Ovarian Cancer. **2008**, 1-13

510 Risk assessment and management. **2009**, 327-337

509 Breast-Cancer Prevention with Antiestrogens. **2009**, 213-231

508 Inherited Breast Cancer. **2009**, 203-210

507 Molecular Biology of Ovarian Cancer. **2009**, 913-920

506 Malignant Disease. **2009**, 635-659

505 Inherited Breast Cancer. **2009**, 41-48

504 Bilateral Breast Cancer. **2009**, 1329-1337

503 The Genetics of Breast Cancer. **2009**, 39-54

502 Interrelationship of the Fanconi Anemia/BRCA Pathway. **2009**, 65-80

501 Inherited Predisposition: Familial Aggregation and High Risk Genes. **2010**, 277-299

500 Interplay of 14-3-3 Family of Proteins with DNA Damage-Regulated Molecules in Checkpoint Control. **2010**, 69-80

499 Genetics of Hereditary Breast Cancer. **2010**, 41-51

498 Basic Principles of Cancer Genetics. **2010**, 1-22

497 Gen-Werden [Gen-Wandel?]. **2010**, 53-67

496 Developing functional assays for BRCA1 unclassified variants. **2010**, 653, 281-91

495 Hereditary Breast Cancer Syndromes. **2011**, 51-104

494 The genetics and molecular biology of gynaecological cancer. **2011**, 522-538

493 Les «causes» du cancer du sein. **2011**, 43-77

492 Mammogram Interpretation. **2011**, 24-62

491 Klonierung und DNA-Analyse in der Medizin. **2011**, 223-239

490 Cancers du sein familiaux. **2011**, 43-52

489 Epidemiology of Breast Cancer. **2011**, 25-55

1

488 Diagnosis and Management of Cancer Using Serologic and Tissue Tumor Markers. **2011**, 1385-1399

487 Target-Selected ENU Mutagenesis to Develop Cancer Models in the Rat. **2012**, 113-131

1

486 Inherited Diseases. **2012**, 1239-1292

- 485 The Case against the Privatization of Knowledge: Some Thoughts on the Myriad Genetics Controversy. **2012**, 11-36 3
- 484 Tumor Markers. **2012**, 617-667 1
- 483 Molecular Genetics and Cancer Biology. **2012**, 530-567.e16
- 482 Current Issues and Tasks of Genetic Cancer Nursing in Korea. **2012**, 12, 267 3
- 481 Medizinische Grundlagen. **2012**, 19-30 1
- 480 Public Health - Pages e1-e91. **2012**, e1-e91
- 479 Breast Cancer. **2012**, 195-219
- 478 Genetics and Gynecological Cancer. **2013**, 107-122
- 477 1 0 6. **2012**, 118-118
- 476 The Role of BRCA1 and BRCA2 in Anticancer Drug Therapy. **2013**, 143-155
- 475 Early Stage Breast Cancer. **2013**, 87-102
- 474 Epidemiology of Epithelial Ovarian Carcinoma. **2013**, 3-12
- 473 Breast Diseases. **2013**, 301-334
- 472 Ovarian Cancer. **2013**, 1135-1145 1
- 471 TYPES OF DNA DAMAGE. **2013**, 115-118
- 470 Pharmacogenomics of Gynecological Disorders. **2013**, 707-741
- 469 Reproductive Genetics. **2013**, 19-38
- 468 Polymorphic repeat length in the AIB1 gene and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a meta-analysis of observational studies. **2013**, 8, e57781

- 467 and Gene Mutations Screening In Sporadic Breast Cancer Patients In Kazakhstan. **2013**, 2, 29 1
- 466 Editorial: BRCA1 and BRCA2 gene mutations screening in sporadic breast cancer patients in Kazakhstan. **2013**, 2, 41
- 465 Ductal carcinoma in situ: how should we treat it?. **2013**, 2, 245-256
- 464 BRCA1 and BRCA2 Testing in Inherited Breast Cancer. **2014**, 167-189
- 463 Genetic Factors in Breast Cancer. 35-57
- 462 Molecular Genetics of Bipolar Disorder.
- 461 Hereditary Risk for Cancer. **2014**, 123-150
- 460 Genetic Susceptibility to Female Cancers. 68-88
- 459 The DNA Damage Response Mediates Apoptosis and Tumor Suppression. **2014**, 135-165 0
- 458 BRCA Gene Testing and Clinicopathological Study of Familial Breast Cancer. **2014**, 75, 1765-1771
- 457 Genetic counseling in post-genomic era: Don't pretend to know the meaning of a gene mutation if you don't know. **2014**, 4, 1
- 456 Discovery and Characterization of Cancer Genetic Susceptibility Alleles. **2014**, 309-321.e3
- 455 Cancers Arising in the Ovary. **2014**, 1592-1613.e6 1
- 454 The genetics of breast cancer, risk-reducing surgery and prevention. **2014**, 127-145
- 453 Omics of Hereditary Breast Cancer. **2014**, 17-40
- 452 Genetic Changes in Breast Cancer. **1995**, 191-208
- 451 Clinical Application of Genetic, Oncogenic, and Differentiation Markers of Cancer. **1995**, 1-16
- 450 Oncogenes and Tumor-Suppressor Genes in Gynecological Malignancies. **1995**, 111-138 1

449 Breast cancer genetics. **1995**, 1-19

448 Molecular medicine makes its way to the bedside. **1995**, 162, 567-568

447 The Protein Truncation Test (PTT) for Rapid Detection of Translation-Terminating Mutations. **1996**, 323-341

446 Allelverlust von prädisponierenden Genen (BRCA1, BRCA2, AT, p53) bei Mammakarzinomen und deren Metastasen. **1996**, 201-204

445 Genetics of Breast Cancer. **1996**, 197-224

444 Introduction. **1996**, 88-90

443 Familial ovarian cancer. **1996**, 290-296

o

442 From chromosomes to genes: how to isolate cancer-predisposition genes. **1996**, 40-55

441 Evidence for a Tumor Suppressor Gene Distal to BRCA1 in Prostate Cancer. **1996**, 720-725

440 Commentary on Tumor Suppressor Gene, Distal to BRCA-1, in Prostate Cancer. **1996**, 430-431

439 Breast cancer-predisposing genes: Their discovery marks a turning point in deciphering a complex disease. **1996**, 16, 243-8

438 Differential Chromosome Allelic Imbalance in the Progression of Human Prostate Cancer. **1996**, 2079-2083

437 References. **1997**, 215-326

436 Breast Cancer. **1997**, 257-279

435 Genetische Screeningmöglichkeiten für das familiäre Mammakarzinom. **1997**, 189-195

434 Breast Tumor Cytogenetic Markers. **1997**, 111-149

1

433 Recent advances in understanding function and mutations of breast cancer susceptibility genes. **1998**, 59-72

432 Prohibitin: Mitochondrial Tumor Suppressor Protein. **1998**, 345-363

- 431 Molecular Diagnostic Testing. **1998**, 83-88
- 430 Molecular prognostic markers in breast cancer. **1998**, 275-290
- 429 Breast Cancer. **1998**, 135-144
- 428 Mechanismen der Entstehung genetisch bedingter Krebsformen. **1998**, 3-26
- 427 Tumor Suppressor Genes. **1998**, 51-76
- 426 Excitation Spectroscopy of Proteins in Malignant and Benign Tissues. **1998**,
- 425 Hormonal strategies for the prevention of breast cancer. **1998**, 94, 135-57
- 424 Reply to Karunaratne and Elston. **1998**, 62, 739-740
- 423 Evaluating the performance of a genetic test using information from previous studies in place of a gold standard. **1998**, 36, AS46-56
- 422 Minimally Invasive Surgery in Breast Pathology. **1999**, 297-304
- 421 Genetically Modified Mice as Tools for Cancer Research. **1999**, 471-485 1
- 420 Biological Functions of the BRCA1 and BRCA2 Proteins. **1999**, 225-246 1
- 419 Genetik des Mammacarcinoms. **1999**, 11-25
- 418 Hereditary Breast Cancer: an Overview. **1999**, 57-80
- 417 Aromatase Inhibitors and the Role of Hormonal Therapy in Breast Cancer. **1999**, 469-480
- 416 Mammacarcinom: Epidemiologie und Prävention. **1999**, 1-9
- 415 Hereditary Breast Cancer. **1999**, 239-252
- 414 Modeling Risk of Breast Cancer and Decisions about Genetic Testing. **1999**, 133-203 1

413 The Laboratory Analysis of Cancer Susceptibility Genes. **1999**, 91-102

412 Testing for Breast Cancer Risk in the Ashkenazim. **1999**, 65-80

411 Translational Research in Breast Cancer. **1999**, 345-356

410 Progress in the Molecular Medicine of Cancer. 129-152

409 Risk Factors of Malignant Neoplasms of Female Genital Organs (Review of Literature). **2014**, 21, 115-121

4

408 The Generation, Detection, and Prevention of Genomic Instability During Cancer Progression and Metastasis. **2015**, 15-38

407 Breast Cancer Susceptibility Genes.

406 BRCA1 and 2. **2015**, 1-12

405 PARP Inhibitor Resistance What Is Beyond BRCA1 or BRCA2 Restoration?. **2015**, 453-471

404 Biomarkers for PARP Inhibitors. **2015**, 553-579

403 Epigenetics of Endocrine Tumors in Women and Dietary Prevention. **2015**, 153-166

402 Tumors of the breast. 426-446

401 The necessity for functional analysis in human medical genetics. **2015**, 2,

1

400 Encyclopedia of Signaling Molecules. **2016**, 1-6

399 Inherited Breast Cancer. **2016**, 315-327

398 History and Epidemiology. **2016**, 1-16

397 Prophylactic Risk-Reducing Surgery for Breast Cancer. **2016**, 21-32

396 Genomic Analysis. **2016**, 83-106

- 395 Haplotype analysis of BRCA1 intragenic markers in Iranian patients with familial breast and ovarian cancer. **2016**, 14, 271-274
- 394 Genetics of Ovarian Carcinomas. **2017**, 13-31
- 393 Familial heterogeneity in breast cancer predisposition: a study of 22 Utah families.
- 392 Therapeutische Grundlagen in der gyn ologischen Onkologie. **2017**, 183-253
- 391 Genetics. **2017**, 51-62
- 390 Molecular Classification of Breast Cancer. **2017**, 1-22
- 389 Risikoadaptierte Diagnostik und Therapie. **2017**, 43-53
- 388 Hereditary Ovarian Cancer. **2017**, 15-35
- 387 Reparameterization of PAM50 expression identifies novel breast tumor dimensions and leads to discovery of a breast cancer susceptibility locus at 12q15.
- 386 Novel pedigree analysis implicates DNA repair and chromatin remodeling in Multiple Myeloma risk. ○
- 385 BRCA1 novel mutation V1736D and in silico analysis of SNP Q356R in Sudanese patients with breast cancer. 6, 1461
- 384 BRCA1 novel mutation V1736D and in silico analysis of SNP Q356R in Sudanese patients with breast cancer. 6, 1461
- 383 DNA Damage Repair. **2018**, 405-417
- 382 BRCA1 novel mutation V1736D and in silico analysis of SNP Q356R in Sudanese patients with breast cancer. 6, 1461
- 381 Care for BRCA1 and BRCA2 gene carriers from the gynecologist's point of view. **2017**, 11, 228-230
- 380  klu Primer T n ler-Tek Merkez Deneyimi. 339-343
- 379 Effect sizes of somatic mutations in cancer. 1
- 378 Hereditary breast and ovarian cancer genetics: Genetic testing in Serbia. **2018**, 115-140

377 Encyclopedia of Signaling Molecules. **2018**, 572-578

376 BRCA1 novel variation V1736D and in silico analysis of SNP Q356R in Sudanese patients with breast cancer. **6**, 1461

0

375 Inherited BRCA1 epimutation as a novel cause of breast and ovarian cancer.

374 Expression of breast cancer type 1 and its relation with expression of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2/neu in breast carcinoma on trucut biopsy specimens. **2018**, **61**, 31-38

1

373 Morphological and Molecular Approaches to Breast Cancer Risk Assessment. **2018**, 81-91

372 ??????????????. **2018**, **27**, 29-33

1

371 Rare, pathogenic germline variants in Fanconi Anemia genes increase risk for squamous lung cancer.

0

370 Synchronous and antecedent malignancies in patients with papillary thyroid carcinoma.

369 Inferring Disease Risk Genes from Sequencing Data in Multiplex Pedigrees Through Sharing of Rare Variants.

368 A novel role for the HLH protein Inhibitor of Differentiation 4 (ID4) in the DNA damage response in basal-like breast cancer.

367 Enabling population assignment from cancer genomes with SNP2pop.

0

366 53BP1 nuclear body-marked replication stress in a human mammary cell model of BRCA2 deficiency.

365 A Pedigree of Familial Breast Cancer with Seven Breast Cancer Patients in Four Generations. **2019**, **80**, 848-853

364 PARP Inhibiter as a Treatment for Breast Cancer. **2019**, **80**, 1802-1806

363 Hereditary Breast Cancer : The Difference between Genetic Medicines of Hereditary Cancer Syndrome and Genetic Testing as Companion Diagnostics. **2019**, **80**, 1269-1278

362 Breast Cancer With Relevance for Heavy Metals, Mycotoxines, and Pesticides. **2019**, 152-192

361 Molecular Pathway and Fluorescence In Situ Hybridization Testing of ERBB2 (HER2) Gene Amplification in Invasive Ductal Carcinoma of Breast. **2019**, 237-268

360 Hereditary Risk for Cancer. **2019**, 161-197

- 359 The Atypical Cyclin-Like Protein Spy1 Overrides p53-Mediated Tumour Suppression and Promotes Susceptibility to Breast Tumorigenesis.
- 358 Expression of and and their association with recurrent breast cancer.. **2019**, 8, 248-254 0
- 357 A Novel Mutation-BRCA1 Associated Hereditary Haplotype of Intragenic Markers of BRCA1 Gene in a Family with History of Breast Cancer. **2019**, 20, 611-614
- 356 Gene-level heritability analysis explains the polygenic architecture of cancer.
- 355 Estrogen induces mammary ductal dysplasia. 1
- 354 Incidence of Hypersensitivity Reactions to Carboplatin or Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With or Without or Mutations. **2019**, 10, 428-439 1
- 353 Case History in Humans: Mapping QTLs for Complex Traits in Humans. **2019**, 255-264
- 352 LARP7 is a BRCA1 ubiquitinase substrate and regulates genome stability and tumorigenesis.
- 351 Towards Quantifying Genetic Interactions Among Tumor Suppressor Genes in Breast Cancer. **2019**,
- 350 Population based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high grade serous ovarian cancer.
- 349 The genetics of inherited cancers. **2020**, 456-470
- 348 Novel mutations in the RING-finger domain of gene in clinically diagnosed breast cancer patients. **2020**, 10, 47
- 347 Recent Advances in the Treatment of Hereditary Breast and Ovarian Cancer in Japan - Elucidation of Clinical and Pathological Characteristics, Establishment of a Nation-wide Registration System, and Improvement of Clinical Practice -. **2020**, 66, 384-391
- 346 Exome-Wide Pan-Cancer Analysis of Germline Variants in 8,719 Individuals Finds Little Evidence of Rare Variant Associations. **2021**, 1-10 1
- 345 Effect of Rho GTPase activating protein 9 combined with preoperative ratio of platelet distribution width to platelet count on prognosis of patients with serous ovarian cancer.. **2021**, 10, 4440-4453 1
- 344 Breast cancer in West Africa: molecular analysis of BRCA genes in early-onset breast cancer patients in Burkina Faso. **2021**, 15, 65 1
- 343 DoChaP: The Domain Change Presenter.
- 342 Dissecting the heterogeneity and tumorigenesis of BRCA1 deficient mammary tumors via single cell RNA sequencing. **2021**, 11, 9967-9987 1

- 341 BRCA1 Variant Assessment Using a Simple Analytic Assay.. **2022**,
- 340 Exome Sequencing Reveals a High Prevalence ofBRCA1andBRCA2Founder Variants in a Diverse Population-Based Biobank.
- 339 Hereditary Breast Cancer: BRCA and Other Susceptibility Genes. **2020**, 23-41
- 338 BRCA1 and BRCA2. **2020**, 303-304
- 337 Identification of regulatory crosstalks between RKIP and BRCA1 tumor suppressors in healthy tissues and cancer (breast and ovarian): Therapeutic implications. **2020**, 175-209 1
- 336 Fundamental and clinical knowledge about breast cancer predisposition syndromes. **2020**, 29, 1-7
- 335 Clinicopathological analysis of early-stage breast cancer patients that meet indications for genetic testing. **2020**, 32, 163-174
- 334 Bayesian assessment of the prevalence of BRCA-associated breast cancer in Moscow. **2020**, 47, 691-701 0
- 333 360 Health Analysis (H360) - A Proposal for an Integrated Vision of Breast Cancer in Portugal. **2020**, 16, 91-98 0
- 332 Two redundant ubiquitin-dependent pathways of BRCA1 localization to DNA damage sites. **2021**, 22, e53679 4
- 331 Protection of nascent DNA at stalled replication forks is mediated by phosphorylation of RIF1 intrinsically disordered region.
- 330 Effects of BRCA gene mutation on female reproductive potential: A systematic review. **2020**, 137, 11-17 1
- 329 Primary multiple BRCA associated breast cancer and ovarian cancer (clinical case). **2020**, 248-257
- 328 Cavin3 released from caveolae interacts with BRCA1 to regulate the cellular stress response.
- 327 Genetic Screening and Counseling for High-Risk Populations. **2006**, 341-357
- 326 Diagnostic des patientes àrisque de cancer du sein. **2006**, 15-40
- 325 Einführung. **2005**, 1-32
- 324 Systematischer Vergleich der Testverfahren. **2005**, 59-139

323	Young Breast Cancer Patients Undergoing Breast-Conserving Therapy: Role of BRCA1 and BRCA2. 2008 , 483-491	
322	Hereditary Issues In Ovarian Cancer. 2007 , 169-193	
321	Inherited Genetic Changes in Prostate Cancer. 2008 , 53-70	
320	Aufklärungsgespräch beim hereditären Mammakarzinom. 2006 , 111-117	
319	Familiäre Aggregation. 2007 , 111-155	
318	Kopplungsanalysen. 2007 , 157-227	
317	Risikoberechnungen in Familien. 2007 , 279-326	
316	Basis of Tumor Imaging 1: Principles of Tumor Pathology and Biology. 2006 , 264-277	
315	Präventives Versorgungskonzept bei erblichem Brustkrebs. 2008 , 901-911	
314	In Situ Analysis of DNA Repair Processes of Tumor Suppressor BRCA1. 2009 , 2211-2214	
313	Molecular Mechanisms of Early Breast Cancer. 2021 , 59-83	
312	FANCM regulates repair pathway choice at stalled replication forks.	1
311	BRCA1 Promoter Methylation and Expression - Associations with ER+, PR+ and HER2+ Subtypes of Breast Carcinoma. 2017 , 18, 3293-3299	3
310	Mining SNPs from EST databases. 1999 , 9, 167-74	218
309	BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. 2000 , 14, 927-39	760
308	In vitro assembly of a functional human CDK7-cyclin H complex requires MAT1, a novel 36 kDa RING finger protein. 1995 , 14, 5608-17	66
307	Novel topology of a zinc-binding domain from a protein involved in regulating early Xenopus development. 1995 , 14, 5947-56	23
306	The solution structure of the RING finger domain from the acute promyelocytic leukaemia proto-oncoprotein PML. 1995 , 14, 1532-41	108

305	Molecular pathology and cancer genetic screening. 1995 , 162, 449-50	1
304	Genes and generalists: why we need professionals with added competencies. 1999 , 171, 375-9	8
303	Genetic counselling and testing for susceptibility to breast, ovarian and colon cancer: where are we today?. 1996 , 154, 149-55	2
302	Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. 1997 , 60, 313-9	142
301	Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer. 1997 , 60, 1068-78	107
300	Screening for 185delAG in the Ashkenazim. 1997 , 60, 1085-98	30
299	Recurrent germ-line BRCA1 mutations in extended African American families with early-onset breast cancer. 1997 , 60, 1233-6	58
298	BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group. 1997 , 60, 1021-30	91
297	A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. 1997 , 60, 1041-9	105
296	Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. 1997 , 60, 1059-67	185
295	Frequently occurring germ-line mutations of the BRCA1 gene in ovarian cancer families from Russia. 1997 , 60, 1239-42	78
294	Optimal strategies for mapping complex diseases in the presence of multiple loci. 1997 , 60, 1222-32	18
293	Analysis of BRCA1 and BRCA2 mutations in Hungarian families with breast or breast-ovarian cancer. 1997 , 60, 1242-6	41
292	BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2. 1997 , 60, 1031-40	96
291	Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes?. 1997 , 60, 486-95	107
290	Presymptomatic testing for BRCA1 and BRCA2: how distressing are the pre-test weeks? Rotterdam/Leiden Genetics Working Group. 1999 , 36, 906-13	57
289	High frequency of BRCA1/2 germline mutations in 42 Belgian families with a small number of symptomatic subjects. 1999 , 36, 304-8	22
288	Delivery of molecular genetic services within a health care system: time analysis of the clinical workload. The Molecular Genetic Study Group. 1995 , 56, 760-8	13

287	Gene-environment interaction and public health. 1995 , 56, 821-3	19
286	BRCA1 mutations in Ashkenazi Jewish women. 1995 , 57, 189	80
285	Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer. 1995 , 57, 1-7	72
284	Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. 1995 , 56, 265-71	711
283	Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families. 1995 , 57, 1284-97	125
282	Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. 1995 , 57, 1457-62	335
281	Genetic heterogeneity of breast-ovarian cancer revisited. Breast Cancer Linkage Consortium. 1995 , 57, 957-8	56
280	Genetic epidemiology and primary care. 2006 , 56, 214-21	5
279	Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study. 1996 , 58, 271-80	177
278	Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden. 1996 , 58, 441-50	91
277	Rapid detection of regionally clustered germ-line BRCA1 mutations by multiplex heteroduplex analysis. UKCCCR Familial Ovarian Cancer Study Group. 1996 , 58, 451-6	63
276	Germ-line BRCA1 mutations in selected men with prostate cancer. 1996 , 58, 881-5	36
275	Frequent occurrence of BRCA2 linkage in Icelandic breast cancer families and segregation of a common BRCA2 haplotype. 1996 , 58, 749-56	43
274	A common BRCA1 mutation in Norwegian breast and ovarian cancer families?. 1996 , 59, 486-7	29
273	Segregation of two BRCA1 mutations in a single family. 1996 , 59, 479-81	7
272	A high incidence of BRCA1 mutations in 20 breast-ovarian cancer families. 1996 , 58, 42-51	75
271	Two distinct origins of a common BRCA1 mutation in breast-ovarian cancer families: a genetic study of 15 185delAG-mutation kindreds. 1996 , 58, 1166-76	58
270	Statement of the American Society of Human Genetics on genetic testing for breast and ovarian cancer predisposition. 1994 , 55, i-iv	50

269	The MDM2 oncoprotein binds specifically to RNA through its RING finger domain. 1996 , 2, 439-51	54
268	Hereditary breast cancer. Identifying and managing BRCA1 and BRCA2 carriers. 1999 , 45, 114-24	11
267	Setting up a breast cancer family history clinic. 1999 , 81, 393-8	
266	Mutation analysis of BRCA1 gene in African-American patients with breast cancer. 2000 , 92, 29-35	17
265	BRCA1 Expression is an Important Biomarker for Chemosensitivity: Suppression of BRCA1 Increases the Apoptosis via Up-regulation of p53 and p21 During Cisplatin Treatment in Ovarian Cancer Cells. 2007 , 1, 49-59	6
264	Fluorescent oligonucleotides can serve as suitable alternatives to radiolabeled oligonucleotides. 2009 , 20, 190-4	9
263	Detection of BRCA1 and BRCA2 mutations in a selected Hawaii population. 2010 , 69, 268-71	
262	BRCA1 Protein Expression Level and CD44(+)Phenotype in Breast Cancer Patients. 2011 , 13, 155-62	8
261	Differential expression of DNA repair genes in Hispanic women with breast cancer. 2013 , 1, 54	10
260	Prevalence of BRCA1 gene mutation in breast cancer patients in Guangxi, China. 2014 , 7, 6262-9	5
259	BRCA1 Gene Mutations in Breast Cancer Patients from Kerman Province, Iran. 2012 , 5, 210-5	5
258	A Brief History of Breast Cancer: Part III - Tumour biology lays the foundation for medical oncology. 2015 , 15, e34-8	4
257	Synchronous double primary gastric and endometrial cancer: a case report and literature review. 2015 , 8, 8573-8	3
256	Pathogenesis of serous, extra-uterine Müllerian epithelial cancer and therapeutic implications. 2015 , 4, 3-13	8
255	Functional assay for BRCA1: mutagenesis of the COOH-terminal region reveals critical residues for transcription activation. 2000 , 60, 2411-8	60
254	Haplotype analysis of BRCA1 intragenic markers in Iranian patients with familial breast and ovarian cancer. 2016 , 14, 271-4	1
253	BRCA1 Mutation Leads to Deregulated Ubc9 Levels which Triggers Proliferation and Migration of Patient-Derived High Grade Serous Ovarian Cancer and Triple Negative Breast Cancer Cells. 2016 , 2, 31-38	5
252	[BRCA1: a new predictive genomic marker for chemotherapy and radiotherapy of non-small cell lung cancer]. 2012 , 15, 481-90	

- 251 Optimization of Porous Silicon Conditions for DNA-based Biosensing via Reflectometric Interference Spectroscopy. **2019**, 20, 584-591 2
- 250 THE GORDON WILSON LECTURE: CANCER GENE VARIANT (RE)CLASSIFICATION: FROM TRUTHINESS TO TRUTH. **2018**, 129, 99-120
- 249 Genomics of adult and pediatric solid tumors. **2018**, 8, 1356-1386 12
- 248 Mutations analysis of gene in patients with breast cancer in South Khorasan province, East Iran. **2019**, 33, 105
- 247 Variants of the human gene confer defects in ionizing radiation resistance and homologous recombination repair in budding yeast. **2020**, 7, 270-285
- 246 Somatic mutation profiling in -negative breast and ovarian cancer patients by multigene panel sequencing. **2020**, 10, 2919-2932 5
- 245 Exome sequencing in BRCA1-2 candidate familias: the contribution of other cancer susceptibility genes. **2021**, 11, 649435 2
- 244 Variants of Uncertain Significances in Hereditary Breast and Ovarian Cancer. **2021**, 47-64
- 243 Roles of RACK1 in centrosome regulation and carcinogenesis. **2021**, 90, 110207 1
- 242 Complex Genetic Interactions/Data Mining/Dimensionality Reduction. **2021**, 265-277
- 241 DCMP: database of cancer mutant protein domains. **2021**, 2021,
- 240 RNA m6A methylation regulators in ovarian cancer. **2021**, 21, 609 6
- 239 Convergent evolution as an indicator for selection during acute HIV-1 infection. 1, 0
- 238 A Case of Triple-Negative Breast Cancer with Germline Pathogenic Variants in Both and .. **2021**, 14, 1645-1651 0
- 237 METTL3 promotes homologous recombination repair and modulates chemotherapeutic response by regulating the EGF/Rad51 axis.
- 236 Medical knowledge and information needs among women with pathogenic variants in moderate-risk genes for hereditary breast cancer attending genetic counseling at an academic hospital in Germany-A qualitative approach. **2021**, 1
- 235 Long Non-Coding RNA Neighbor of BRCA1 Gene 2: A Crucial Regulator in Cancer Biology.. **2021**, 11, 783526
- 234 Familial Breast Cancer: Disease Related Gene Mutations and Screening Strategies for Chinese Population.. **2021**, 11, 740227

233 Risk-Based Breast Cancer Screening. **2021**, 107-128

232 Genetic Testing. **2021**, 31-46

231 History, Advancements, and Future Strategies. **2021**, 1-14

230 Germline Findings Through Precision Oncology for Ovarian Cancer. **2021**, 211-226

229 Molecular Basis of BRCA1 and BRCA2: Homologous Recombination Deficiency and Tissue-Specific Carcinogenesis. **2021**, 15-29

228 PARP Inhibitors: Mechanism of Action. **2021**, 281-292

227 Involvement of Par-4 in Breast Cancer. **2021**, 113-131

226 Preventive population genomics: The model of BRCA related cancers. **2021**, 108, 1-33

0

225 Cancer Fatalism: Attitudes Toward Screening and Care. **2022**, 301-318

1

224 Evidence for an Inherited Contribution to Sepsis Susceptibility Among a Cohort of U.S. Veterans.. **2022**, 4, e0603

223 BRCA1/2 testing for genetic susceptibility to cancer after 25 years: A scoping review and a primer on ethical implications.. **2021**, 61, 66-76

3

222 Variants of the human RAD52 gene confer defects in ionizing radiation resistance and homologous recombination repair in budding yeast. **2020**, 7, 270-285

0

221 Molecular docking analysis of the BRCA1 protein with compounds from *Justica adhatoda* L. **2020**, 16, 888-892

1

220 Cancer genetics and breast cancer.. **2022**,

2

219 New Insights Into c.815_824dup Pathogenic Variant of in Inherited Breast Cancer: A Founder Mutation of West African Origin.. **2021**, 11, 810060

218 DNA Damage Response (DDR) proteins in canine cancer as potential research targets in comparative oncology.. **2021**,

1

217 A natural product, voacamine, sensitizes paclitaxel-resistant human ovarian cancer cells. **2021**, 434, 115816

2

216 / mutation spectrum analysis in South Asia: a systematic review.. **2022**, 50, 3000605211070757

1

215	Correlation between the risk of ovarian cancer and BRCA recurrent pathogenic variants in Japan.. 2022,	0
214	CRL4-DCAF8L1 Regulates BRCA1 and BARD1 Protein Stability.. 2022, 18, 1434-1450	1
213	Novel ratio-metric features enable the identification of new driver genes across cancer types.. 2022, 12, 5	0
212	Germline sequence variants contributing to cancer susceptibility in South African breast cancer patients of African ancestry.. 2022, 12, 802	0
211	Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology.. 2022, 104, 102337	0
210	Polygenic risk scores: the future of cancer risk prediction, screening, and precision prevention. 2022,	0
209	Hereditary Breast and Ovarian Cancer: An Updated Primer for OB/GYNs.. 2022, 49, 117-147	0
208	Hereditary breast cancer –what we have learned in the last decade. 31,	1
207	In Vitro Reconstitution of BRCA1-BARD1/RAD51-Mediated Homologous DNA Pairing.. 2022, 2444, 207-225	0
206	Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants: A Comparative Modeling Analysis.. 2022,	5
205	Myriad Laws in Defense of the Genome. 2022, 1, 35-36	
204	Genetic medicine is accelerating in Japan.. 2022,	0
203	A Swedish Genome-Wide Haplotype Association Analysis Identifies a Novel Breast Cancer Susceptibility Locus in 8p21.2 and Characterizes Three Loci on Chromosomes 10, 11 and 16.. 2022, 14,	1
202	G-Quadruplex Matters in Tissue-Specific Tumorigenesis by BRCA1 Deficiency.. 2022, 13,	0
201	Case Report Series: Aggressive HR Deficient Colorectal Cancers Related to BRCA1 Pathogenic Germline Variants.. 2022, 12, 835581	0
200	Hereditary gynecologic tumors and precision cancer medicine.. 2022,	
199	Carcinogenic Potential Of Ovulation Stimulation In BRCA1/2 Gene Mutation Carriers In Assisted Reproductive Technology Programs. 2022, 11,	
198	Detection of a pathogenic Alu element insertion in PALB2 gene from targeted NGS diagnostic data.. 2022,	0

197	BRCA1/BARD1 is a nucleosome reader and writer.. 2022,	1
196	Germline Pathogenic Variants in and : Malignancies Beyond Female Breast and Ovarian Cancers.. 2022, JCO2200003	
195	Immunohistochemical Evaluation of BAP1 Expression in Breast Cancer with Known and Mutations and Comparison with Histopathological Features.. 2022, 10668969221085969	
194	In Silico and in Vitro Evaluation of Alkaloids from <i>Goniothalamus elegans</i> Ast. for Breast Cancer Treatment. 2022, 17, 1934578X2210881	
193	BRCA1: An Endocrine and Metabolic Regulator.. 2022, 13, 844575	0
192	BRCA1 and Breast Cancer: Molecular Mechanisms and Therapeutic Strategies.. 2022, 10, 813457	1
191	Spoken and Unspoken Matters Regarding the Use of Opioids in Cancer.. 2022, 15, 909-924	
190	DNA methylation in newborns conceived by assisted reproductive technology.. 2022, 13, 1896	1
189	Identification of the most common BRCA alterations through analysis of germline mutation databases: Is droplet digital PCR an additional strategy for the assessment of such alterations in breast and ovarian cancer families?. 2022, 60,	3
188	The individual and global impact of copy-number variants on complex human traits.. 2022,	1
187	Investigation of the association of three ATM polymorphisms with breast cancer in Iranian women. 2022, 27, 101567	
186	Mitotic and DNA Damage Response Proteins: Maintaining the Genome Stability and Working for the Common Good.. 2021, 9, 700162	1
185	The Interaction of NTN4 and miR-17-92 Polymorphisms on Breast Cancer Susceptibility in a Chinese Population.. 2021,	0
184	Impact of the APOBEC3A/B deletion polymorphism on risk of ovarian cancer. 2021, 11, 23463	1
183	and Metastasis: Outcome of Defective DNA Repair.. 2021, 14,	0
182	Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ® study.. 2022, 193, 83	
181	Rates of Variants of Uncertain Significance Among Patients With Breast Cancer Undergoing Genetic Testing: Regional Perspectives.. 2022, 12, 673094	
180	Case Review: Whole-Exome Sequencing Analyses Identify Carriers of a Known Likely Pathogenic Intronic Variant in Ovarian Cancer Cases Clinically Negative for Pathogenic and Variants.. 2022, 13,	2

179 Protection of nascent DNA at stalled replication forks is mediated by phosphorylation of RIF1 intrinsically disordered region.. **2022**, 11,

1

178 TE Density: a tool to investigate the biology of transposable elements.. **2022**, 13, 11

177 Notes. 179-189

176 DataSheet_1.pdf. **2019**,

175 Image_1.tif. **2019**,

174 Image_2.tif. **2019**,

173 Image_3.tif. **2019**,

172 Image_4.tif. **2019**,

171 Table_1.xlsx. **2019**,

170 Table_2.xlsx. **2019**,

169 Table_3.xlsx. **2019**,

168 Table_4.xlsx. **2019**,

167 Data_Sheet_1.PDF. **2019**,

166 Image_1.jpg. **2018**,

165 Table_1.DOCX. **2018**,

164 Image_1.TIF. **2020**,

163 Image_2.TIF. **2020**,

162 Table_1.DOCX. **2020**,

161 Table_2.DOCX. **2020**,

160 Image_1.tif. **2020**,

159 Image_2.tif. **2020**,

158 Table_1.xlsx. **2020**,

157 Data_Sheet_1.pdf. **2018**,

156 Image_1.jpg. **2020**,

155 Image_2.jpg. **2020**,

154 Image_3.tif. **2020**,

153 Image_4.jpg. **2020**,

152 Image_5.jpg. **2020**,

151 Table_1.DOCX. **2020**,

150 Table_2.DOCX. **2020**,

149 Table_3.DOCX. **2020**,

148 Table_4.DOCX. **2020**,

147 Table_5.DOCX. **2020**,

146 Table_6.DOCX. **2020**,

145 From Genotype to Phenotype: Polygenic Prediction of Complex Human Traits.. **2022**, 2467, 421-446

144 TRIM44 promotes BRCA1 functions in HR repair to induce Cisplatin Chemoresistance in Lung Adenocarcinoma by Deubiquitinating FLNA.. **2022**, 18, 2962-2979

○

- 143 The Genetic and Molecular Analyses of and Identifies Rare Variants Implicated in Hereditary Ovarian Cancer from a Genetically Unique Population.. **2022**, 14, 1
- 142 Brain metastases in patients with ovarian cancer.. **2022**, 1-7 1
- 141 Surgical management of BRCA-mutation carriers: A single institution experience.. **2022**,
- 140 Whole-Exome Sequencing of Germline Variants in Non-BRCA Families with Hereditary Breast Cancer. **2022**, 10, 1004 1
- 139 Familial risk of epithelial ovarian cancer after accounting for gynaecological surgery: a population-based study.. **2022**, 0
- 138 Rereading the genetic origin of cancer: the puzzle of all eras.
- 137 METTL3 promotes homologous recombination repair and modulates chemotherapeutic response in breast cancer by regulating the EGF/Rad51 axis.. **2022**, 11, 0
- 136 Whole-Genome Sequencing Identifies PPARGC1A as a Putative Modifier of Cancer Risk in BRCA1/2 Mutation Carriers. **2022**, 14, 2350
- 135 Precision intervention for prostate cancer: Re-evaluating who is at risk.. **2022**, 538, 215709 0
- 134 Comprehensive review on the electrochemical biosensors of different breast cancer biomarkers. **2022**, 365, 131944 3
- 133 CobbDouglas R&D production function, appropriability and opportunity: effects on R&D, technological progress and knowledge sharing. 1-18
- 132 Ovarian, Vaginal, and Vulvar Cancer. **2022**, 317-339
- 131 A Survey on Various Combination of Breast Cancer Biomarkers. **2022**,
- 130 BRCA-Mutated Pancreatic Cancer: From Discovery to Novel Treatment Paradigms. **2022**, 14, 2453 1
- 129 Development of Novel Cancer Biomarkers for Diagnosis and Prognosis. **2022**, 277-343
- 128 2. Paradigm Shift from the Experiences of Hereditary Breast Cancer. **2022**, 78, 531-534
- 127 Breast Cancer With Relevance for Heavy Metals, Mycotoxines, and Pesticides. **2022**, 357-397
- 126 The associations of healthy lifestyle index with breast cancer incidence and mortality in a population-based study. 1

125	Prospects of PARP Inhibitors in Treatment of BRCA-Mutated Pancreatic Cancer: a Literature Review. 2022 , 12, 48-55	
124	Discovery of BRCA1/BRCA2 founder variants by haplotype analysis. 2022 , 266-267, 19-27	
123	BRCA1 haploinsufficiency promotes chromosomal amplification under Fenton reaction-based carcinogenesis through ferroptosis-resistance. 2022 , 54, 102356	1
122	Current Systemic Treatments for the Hereditary Cancer Syndromes: Drug Development in Light of Genomic Defects. 2022 , 1-17	1
121	BRCA1, BRCA2, TP53, PIK3CA, PTEN and AKT1 genes mutations in Burkina Faso breast cancer patients: prevalence, spectrum and novel variant.	1
120	The current state of molecular profiling in gastrointestinal malignancies. 2022 , 17,	0
119	The Breast Cancer Protooncogenes HER2, BRCA1 and BRCA2 and Their Regulation by the iNOS/NOS2 Axis. 2022 , 11, 1195	0
118	Inhibitors of ROCK kinases induce multiple mitotic defects and synthetic lethality in BRCA2-deficient cells.	
117	The increasing importance of pathology in modern clinical trial conduct: OlympiA as a case in point. 2022 ,	
116	Host and Microbiome Interplay Shapes the Vaginal Microenvironment. 13,	0
115	Natural Compounds or Their Derivatives against Breast Cancer: A Computational Study. 2022 , 2022, 1-10	1
114	Characteristics of breast cancer patients tested for germline BRCA1/2 mutations by next-generation sequencing in Ramathibodi Hospital, Mahidol University.	
113	Surgical Management of Inherited Breast Cancer: Role of Breast-Conserving Surgery. 2022 , 14, 3245	0
112	Functions of Breast Cancer Predisposition Genes: Implications for Clinical Management. 2022 , 23, 7481	1
111	Machine learning-based screening of MCF-7 human breast cancer cells and molecular docking analysis of essential oils from Ocimum basilicum against breast cancer. 2022 , 1268, 133627	1
110	Lessons from a Symposium on Breast Cancer held in the College on 25 September 1998. 1999 , 29, 116-119	
109	BRCA1 and BRCA2 Mutations in a Study of African American Breast Cancer Patients. 2004 , 13, 1794-1799	16
108	Genetics in Clinical Cancer Care: A Promise Unfulfilled among Minority Populations. 2004 , 13, 1683-1686	7

- 107 Precise, Genotype-First Breast Cancer Prevention: Experience With Transferring Monogenic Findings From a Population Biobank to the Clinical Setting. 13,
- 106 The Identification by Exome Sequencing of Candidate Genes in BRCA-Negative Tunisian Patients at a High Risk of Hereditary Breast/Ovarian Cancer. **2022**, 13, 1296 0
- 105 Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment options. **2022**, 237, 108253 3
- 104 Genetic Mapping of a Third Li-Fraumeni Syndrome Predisposition Locus to Human Chromosome 1q23. **2005**, 65, 427-431 18
- 103 Fertility Intentions Following Testing for a BRCA1 Gene Mutation. **2004**, 13, 733-740 11
- 102 An Autosomal-Wide Scan for Linkage Disequilibrium-Based Association in Sporadic Breast Cancer Cases in Eastern Finland: Three Candidate Regions Found. **2005**, 14, 75-80 10
- 101 Recombinant human chorionic gonadotropin induces signaling pathways towards cancer prevention in the breast of BRCA1/2 mutation carriers. Publish Ahead of Print,
- 100 The False Dawn of Polygenic Risk Scores for Human Disease Prediction. **2022**, 12, 1266
- 99 Breast cancer in East Africa: Prevalence and spectrum of germline SNV /indel and CNVs in BRCA1 and BRCA2 genes among breast cancer patients in Tanzania. 0
- 98 Association between Health Insurance Type and Genetic Testing and/or Counseling for Breast and Ovarian Cancer. **2022**, 12, 1263
- 97 Prevalence of BRCA1 and BRCA2 pathogenic variants in 8627 unselected patients with breast cancer: stratification of age at diagnosis, family history and molecular subtype. 0
- 96 BRCA1/2 variants and copy number alterations status in non familial triple negative breast cancer and high grade serous ovarian cancer. **2022**, 20, 0
- 95 Extracellular vesicle contents as non-invasive biomarkers in ovarian malignancies. **2022**, 26, 347-359
- 94 Is There an Inherited Contribution to Risk for Sporadic Unilateral Vestibular Schwannoma? Evidence of Familial Clustering. Publish Ahead of Print, 0
- 93 Coupled MD simulations and NMR reveal that the intrinsically disordered domain of the breast-cancer susceptibility 1 protein (BRCA1) binds head-on to DNA double-strand ends. **2022**, 12-13, 100069 0
- 92 Modern ideas about oncological aspects of ovulation induction in assisted reproductive technology programs in carriers of BRCA1/2 gene mutations. **2022**, 22, 47 0
- 91 Histopathological characterization of carcinoma breast with BRCA1/2 sequence variation in a Tertiary Care Center in Kerala, South India. **2022**, 6, 117 0
- 90 DNA damage, metabolism, and epigenetic regulation. **2022**, 111-138 0

89	Genetic Syndromes and RT for Breast Cancer. 2022 , 373-381	o
88	Activation of recombinational repair in Ewing sarcoma cells carrying EWS-FLI1 fusion gene by chromosome translocation. 2022 , 12,	1
87	The Multi-Omic Landscape of Primary Breast Tumors and Their Metastases: Expanding the Efficacy of Actionable Therapeutic Targets. 2022 , 13, 1555	1
86	Carbon Nanostructure-Based DNA Sensor Used for Quickly Detecting Breast Cancer-Associated Genes. 2022 , 17,	o
85	BRCA1 transports the DNA damage signal for CDDP -induced centrosome amplification through the centrosomal Aurora A.	o
84	BRCA1 overexpression attenuates breast cancer cell growth and migration by regulating the pyruvate kinase M2-mediated Warburg effect via the PI3K/AKT signaling pathway. 10, e14052	o
83	Vesicle amine transport-1 regulates hepatocellular carcinoma progression by EGF-induced STAT3 signalling.	o
82	A bibliometric analysis of the top 100 most cited papers and research trends in breast cancer related BRCA1 and BRCA2 genes. 2022 , 101, e30576	o
81	<i></i>BRCA</i>-associated ovarian cancer: a review of the current literature. 2022 , 12, 56-62	o
80	Interpretation of the role of germline and somatic non-coding mutations in cancer: expression and chromatin conformation informed analysis. 2022 , 14,	o
79	Occurrence of variants of unknown clinical significance in genetic testing for hereditary breast and ovarian cancer syndrome and Lynch syndrome - A Literature review and analytical observational retrospective cohort study.	o
78	Controversies and Open Questions in Management of Cancer-Free Carriers of Germline Pathogenic Variants in BRCA1/BRCA2. 2022 , 14, 4592	o
77	Analysis of rare disruptive germline mutations in 2,135 enriched BRCA-negative breast cancers excludes additional high-impact susceptibility genes. 2022 ,	o
76	Spectrophotometric Detection of the BRCA1 Gene via Exponential Isothermal Amplification and Hybridization Chain Reaction of Surface-Bound Probes. 2022 , 38, 12050-12057	o
75	Differential requirement for BRCA1-BARD1 E3 ubiquitin ligase activity in DNA damage repair and meiosis in the <i>Caenorhabditis elegans</i> germ line.	o
74	DDX17 is required for efficient DSB repair at DNA:RNA hybrid deficient loci.	1
73	Risk Assessment and Prevention Strategies for Hereditary Gynecological Cancers. 2022 , 87-113	o
72	Breast MRI: Techniques and Indications. 2022 , 165-214	o

71	BRCA1?DNA?????????. 2022,	0
70	Interdisciplinary risk counseling for hereditary breast and ovarian cancer: real-world data from a specialized center.	1
69	BMI -1 promotes breast cancer proliferation and metastasis through different mechanisms in different subtypes.	0
68	Uptake of BRCA1/BRCA2 predictive genetic testing in an Irish population is low: a missed opportunity.	0
67	BRCA Biological Functions.	0
66	Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors. 2022, 29,	0
65	PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology. 2022,	1
64	Hereditary Cancer Syndromes: Risk Assessment and Genetic Counseling. 1-28	0
63	The intricate interplay between HIFs, ROS, and the ubiquitin system in the tumor hypoxic microenvironment. 2022, 108303	0
62	Familial history and prevalence of BRCA1, BRCA2 and TP53 pathogenic variants in HBOC Brazilian patients from a public healthcare service. 2022, 12,	0
61	Genes and cancer: Genetic counselling and clinical management. 2023, 521-559.e6	0
60	A spectrum of BRCA1 and BRCA2 germline deleterious variants in ovarian cancer in Russia.	0
59	Germline pathogenic variants associated with ovarian cancer: A historical overview. 2022, 44, 101105	0
58	BRCA1 mediates protein homeostasis through ubiquitination of PERK and IRE1. 2022, 105626	0
57	Non-directive Genetic Counselling [Respect for Autonomy or Unprofessional Practice?]. 2011, 40, 36-42	0
56	PARP Inhibitors as a Novel Treatment Strategy for Patients with BRCA-Mutated Metastatic Breast Cancer. 68-76	0
55	Exceptional behavior of breast cancer-associated type 1 gene in breast invasive carcinoma. 2022, 18, 1743	0
54	Studies on ultrasound-mediated insertion-deletion polymorphisms of DNA and underlying mechanisms based on Ames tester strains. 2023, 92, 106270	0

- 53 Recent advances in biosensors and sequencing technologies for the detection of mutations. **2023**, 185, 108306 ○
- 52 Testing for Inherited Susceptibility to Breast Cancer. **2023**, 37, 17-31 ○
- 51 BRCA1 deficiency in triple-negative breast cancer: Protein stability as a basis for therapy. **2023**, 158, 114090 ○
- 50 Triple-Negative/Basal-Like Breast Carcinomas. **2022**, 445-462 ○
- 49 Hallmarks of cancer: The insulin-like growth factors perspective. 12, ○
- 48 Analyzing the effects of BRCA1/2 variants on mRNA splicing by minigene assay. ○
- 47 Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia. **2022**, 10, 3008 ○
- 46 Metastatic colorectal cancer as the primary phenotype in a hereditary breast and ovarian cancer patient with Germline BRCA1 mutation: a case report. **2022**, 15, ○
- 45 Gastric Cancer Risk and Pathogenesis in BRCA1 and BRCA2 Carriers. **2022**, 14, 5953 1
- 44 Discovery of synthetic lethal interactions from large-scale pan-cancer perturbation screens. **2022**, 13, ○
- 43 Evolution of breast cancer incidence in young women in a French registry from 1990 to 2018: Towards a change in screening strategy?. **2022**, 24, ○
- 42 A global perspective on the ethnic-specific BRCA variation and its implication in clinical application. **2022**, ○
- 41 Environmental impact on carcinogenesis under BRCA1 haploinsufficiency. **2023**, 45, ○
- 40 Discovery of BRCA Mutations: Historical Perspective of Its Scientific, Clinical and Social Impact. ○
- 39 Regulation of DNA damage response by trimeric G-proteins. **2023**, 105973 1
- 38 Immunogenetic Profiles and Associations of Breast, Cervical, Ovarian, and Uterine Cancers. **2023**, 22, 117693512211485 1
- 37 Genetic Testing in the Latinx community: Impact of acculturation and provider relationships. **2023**, 169, 125-130 ○
- 36 iKNOW - a paradigmatic approach to support personalized counseling with digital health (Preprint). ○

- 35 Biosensors for cancer biomarker detection. **2023**, 297-336 ○
- 34 Genetically Engineered Mouse Models for Hereditary Cancer Syndromes. ○
- 33 Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control. **2023**, ○
- 32 Whole exome sequencing and replication for breast cancer among Hispanic/Latino women identifies FANCM as a susceptibility gene for estrogen-receptor-negative breast cancer. ○
- 31 MR imaging phenotypes and features associated with pathogenic mutation to predict recurrence or metastasis in breast cancer. **2023**, 23, ○
- 30 Occurrence of variants of unknown clinical significance in genetic testing for hereditary breast and ovarian cancer syndrome and Lynch syndrome: a literature review and analytical observational retrospective cohort study. **2023**, 16, ○
- 29 Quality of Life is Essential: Implications for Diagnosis and Treatment for BRCA1/2 Germline Mutations. ○
- 28 Differential requirement for BRCA1-BARD1 E3 ubiquitin ligase activity in DNA damage repair and meiosis in the *Caenorhabditis elegans* germ line. **2023**, 19, e1010457 ○
- 27 A comprehensive survey on spectrum of BRCA1 and BRCA2 pathogenic variants in breast and ovarian cancer. **2023**, 285-298 ○
- 26 Molecular Genetic Characteristics of FANCI, a Proposed New Ovarian Cancer Predisposing Gene. **2023**, 14, 277 ○
- 25 Breast Cancer Disease Exploitation to Recure a Healthy Lifestyle. **2022**, 2617-2635 ○
- 24 High-Risk Pedigree Study Identifies LRBA (rs62346982) as a Likely Predisposition Variant for Prostate Cancer. **2023**, 15, 2085 ○
- 23 Inflammatory cytokine-enriched microenvironment plays key roles in the development of breast cancers. 1
- 22 The Role of Cow Milk Consumption in Breast Cancer Initiation and Progression. **2023**, 12, 122-140 ○
- 21 A fast linkage method for population GWAS cohorts with related individuals. **2023**, 47, 231-248 ○
- 20 Lessons from other fields of medicine, Part 1: Breast cancer. **2023**, 101-118 ○
- 19 Hereditary Breast Cancer and Pathogenic Germline Variants. **2023**, 45-59 ○
- 18 Cost-Effectiveness of Genetic Testing Strategies for Breast Cancer. **2023**, 113-126 ○

- 17 Genetic analyses of DNA repair pathway associated genes implicate new candidate cancer predisposing genes in ancestrally defined ovarian cancer cases. 13,
- 16 In Silico-Based Structural Evaluation to Categorize the Pathogenicity of Mutations Identified in the RAD Class of Proteins. **2023**, 8, 10266-10277
- 15 Matching BRCA and prostate cancer in a public health system: Report of the Italian Society for Uro-Oncology (SIUrO) consensus project. **2023**, 184, 103959
- 14 A rare FGF5 candidate variant (rs112475347) for predisposition to nonsquamous, nonsmall-cell lung cancer.
- 13 Family History and the Risk of Breast and Gastric Cancer. **2023**, 3-14
- 12 A novel BRCA1 splicing variant detected in an early onset triple-negative breast cancer patient additionally carrying a pathogenic variant in ATM: A case report. 13,
- 11 Overexpression of tripartite motif-containing 47 (TRIM47) confers sensitivity to PARP inhibition via ubiquitylation of BRCA1 in triple negative breast cancer cells. **2023**, 12,
- 10 BRCA1-BARD1 combines multiple chromatin recognition modules to bridge nascent nucleosomes.
- 9 DNA damage repair and cancer immunotherapy.
- 8 Gene-specific machine learning for pathogenicity prediction of rare BRCA1 and BRCA2 missense variants.
- 7 Somatic Super-Enhancer Epigenetic Signature for Overall Survival Prediction in Patients with Breast Invasive Carcinoma. **2023**, 17, 117793222311627
- 6 Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study.
- 5 Deregulated Metabolic Pathways in Ovarian Cancer: Cause and Consequence. **2023**, 13, 560
- 4 Radiological Features of B3 Lesions in Mutation Carrier Patients: A Single-Center Retrospective Analysis. **2023**, 13, 4994
- 3 The association between age at breast cancer diagnosis and prevalence of pathogenic variants.
- 2 Paradigmatic Approach to Support Personalized Counseling With Digital Health (iKNOW) (Preprint).
- 1 MALE BREAST CANCER. **1998**, 52, 571-576